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Abstract 
Introduction: 
Opioid poisoning has been rapidly increasing in the past decade, and has been driven in large 
part due to increases in opioid prescribing.  This has been accompanied by intervention efforts 
aimed at preventing and reversing opioid poisoning through naloxone prescription programs.  
Current literature have not quantified the economic burden of opioid poisoning.  Understanding 
this information can help inform these efforts and bring light to this growing problem.  In 
addition understanding various determinants of increased costs can help to identify the types of 
populations more likely to have greater costs. 
Main Objectives: 
The objectives are 1) to quantify the economic burden of opioid poisoning, 2) to evaluate 
differences in costs, LOS, and in-hospital mortality depending on opioid type, 3) to identify 
opioids most likely to result in hospitalization for opioid-related ED visits and 4) to determine 
differences in the odds of admission to various hospital admission categories with respect to 
opioid type. 
Methods: 
A cost-of-illness approach was used to estimate the economic burden of opioid poisoning.  
Direct costs and prevalence estimates were obtained from nationally representative databases.  
Other sources of direct costs were obtained from the literature.  Indirect costs were measured 
using the human capital method.  Differences in costs, LOS, and in-hospital mortality were 
measured through generalized linear models using the National Inpatient Sample in 2009 from 
the Healthcare Cost and Utilization Project.  The Drug Abuse Warning Network database was 
 xviii 
used to evaluate opioids most likely to result in hospitalization and to evaluate the likelihood of 
different opioids to cause admission into different types of hospital settings.    
Results: 
Opioid poisoning resulted in an economic burden approximately $20.4 billion dollars in 2009.  
Productivity losses were associated with 89% of this total.  Direct medical costs were associated 
with $2.2 billion.  Methadone was associated with the greatest inpatient costs and LOS, while 
heroin was associated with a greater likelihood of in-patient mortality compared to prescription 
opioids.   Heroin, methadone, and morphine were associated with the greatest odds of 
hospitalization.  Among admitted patients, methadone, morphine, and fentanyl were each 
associated with the greatest odds of ICU admission compared with other opioids. 
Conclusions: 
Opioid poisoning results in a significant economic burden to society.  Costs, length of stay, in-
patient mortality and the odds of hospitalization and admission type depend on the type of opioid 
involved.  The results from this study can be used to inform policy efforts in providing 
interventions to reduce opioid poisoning and help focus efforts on populations at highest risk for 
increased costs. 
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Chapter I: 
 
Section 1.1: Introduction 
 
 Increases in opioid prescribing have ushered in a period of increased misuse and abuse of 
opioid analgesics.  This has also been accompanied by increases in opioid-related emergency 
(ED) visits and associated mortality that has significantly increased over the past decade.  As 
opioid analgesics have become more accessible, the opportunity for adverse drug events 
associated with these agents has grown.  Local efforts to prevent opioid poisoning and to reduce 
opioid poisoning related mortality have been implemented across the country.  In such efforts, 
education is provided to patients and caregivers along with prescribed naloxone that friends or 
caregivers can use should an episode of opioid poisoning occur.  Providing a national estimate 
for opioid poisoning can help to inform efforts in providing these initiatives and can aid in 
demonstrating the value of these programs.   
Previous studies have quantified the economic burden of opioid analgesic misuse and 
abuse, but have not focused on opioid poisoning specifically.  These studies have also not 
presented data in such a way that the costs associated with each episode of poisoning can be 
estimated.  This study fills the gap in the literature by providing such estimates using nationally 
representative data.  Secondly, differences in inpatient hospital costs, length of stay, and in-
hospital mortality were evaluated between broad opioid categories (heroin, methadone, non-
methadone opioid analgesics).  Finally, because of the high costs of hospitalization, specific 
opioids were evaluated for their likelihood to result in hospitalization among those who present 
to the ED as a result of opioid use.  As differences exist in costs with regards to the type of 
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hospitalization, this outcome is also evaluated among admitted patients with respect to specific 
opioids. 
 The specific aims, hypotheses, introduction, and background are provided in this chapter.  
Chapter 2 provides a literature review regarding previous studies that have evaluated the costs of 
opioid misuse and abuse, along with the relevant conceptual frameworks that serve as a basis for 
this analysis.  Chapters 3, 4, and 5 provide the methods, results and discussion for Specific Aims 
I, II, and III, respectively.  Finally Chapter 6 contains the final conclusions given the findings for 
each of the specific aims. 
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Section 1.2: Specific Aims 
Specific Aim I: 
A:  Estimate the total yearly direct and indirect costs of opioid poisoning in the United 
States for heroin and prescription opioids. 
B:  Estimate the cost per poisoning event in the United States for heroin and 
prescription opioids. 
C:  Estimate the total direct and indirect costs for opioid poisoning caused by specific 
prescription opioids in the United States. 
 
Specific Aim II: 
A: Describe patient and hospital characteristics for inpatient stays involving heroin, 
methadone, and non-methadone opioid analgesics. 
B: Evaluate differences in costs, length of stay and death between hospital stays for 
poisonings involving heroin, methadone, and non-methadone opioid analgesics. 
 
Specific Aim III: 
A: Describe patient characteristics among emergent opioid-related emergency 
department visits. 
B:  Identify opioids that are most likely to result in hospitalization among emergent 
opioid-related ED visits. 
C: Among admitted patients, evaluate differences in ICU admission, 
psychiatric/detoxification admission, and transfers compared to other admissions 
for all opioids. 
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Section 1.3: Hypotheses 
These hypotheses are specific to Specific Aim IIA.  Because of the potential differences in 
pharmacological properties between heroin and opioid analgesics and potential differences in 
demographic and behavioral characteristics between these populations, it was of interest to 
formally test differences in costs, length of stay, and in-hospital mortality between these agents.   
 
1. Costs: 
a. Costs associated with inpatient treatment of opioid poisoning are highest for 
methadone compared with heroin or non-methadone opioid analgesics. 
b. Non-methadone opioid analgesics result in higher inpatient treatment costs than 
heroin. 
2. Length of stay: 
a. The length of stay associated with inpatient treatment of opioid poisoning is 
highest for methadone compared with heroin or non-methadone opioid analgesics. 
b. Non-methadone opioid analgesics result in higher hospital length of stay than 
heroin. 
3. In-hospital mortality: 
a. In-hospital mortality is more likely for methadone compared with heroin or non-
methadone opioid analgesics. 
b. Non-methadone opioid analgesics result in a higher likelihood of in-hospital 
mortality compared with heroin.   
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Section 1.4: Background 
Pharmacology 
 Opioids are a class of biologically active substances that primarily affect the central and 
peripheral nervous systems through the binding of opioid receptors.  Different types of opioid 
receptors exist in the body and are responsible for attenuating the perception of pain along with a 
host of other effects on the body, depending on the types of receptors involved.  The three 
classical opioid receptors are the mu, kappa, and delta receptors. 1 Though all three are 
responsible for the analgesic effects, most of the clinically used opioids are selective for the mu 
receptor. 1  In sufficiently high doses, however, these opioids can interact with other receptor 
subtypes.  The mu receptor is also responsible for other effects on the body, such as euphoria, 
physical dependence, miosis, decreased gastrointestinal motility, and respiratory depression. 
 Opioids have distinct pharmacokinetic and pharmacodynamic profiles.  The prototypical 
opioid analgesic is morphine, originally derived from the opium poppyseed plant.  As the 
prototypical agent, the potency of other opioids is measured relative to the potency of morphine.  
For example, fentanyl is one of the most potent opioid analgesics clinically used with a relative 
potency of 80. 1  Other opioids such as hydrocodone and codeine are less potent than morphine, 
with potencies of 0.6 and 0.2, respectively. 2  These opioids may also differ also in their 
elimination half life, which can depend on the intrinsic properties of the opioid and on the 
formulation.  Opioids with extended half lives are considered “long-acting” opioid analgesics, as 
opposed to the “short-acting” opioids.  The potencies and duration of action for these agents can 
have clinical implications on the appropriate use of these drugs in various populations, the abuse 
potential, and the development of adverse effects. 
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Treatment of Pain 
 Opioid analgesics are an indispensable treatment modality for the treatment of pain.  
These agents can be used to treat acute pain, chronic musculoskeletal pain, and cancer-related 
pain.  The prevalence of chronic pain among adults has been found to vary between 2% to 40%.3  
In the United States, it has been estimated that approximately 31% of the population have 
chronic pain that persists for 6 months or more. 4  Among patients starting long-term opioid 
therapy for chronic non-cancer pain, back pain and extremity pain are the most common pain 
diagnoses (38% and 30%, respectively). 5  Other less common pain diagnoses include 
osteoarthritis, neck pain, abdominal pain, headache, and menstrual pain. 5  The most commonly 
prescribed opioid analgesics in chronic non-cancer related pain are hydrocodone and oxycodone 
(46% and 25%, respectively). 5   
The goals for the treatment of chronic pain include management of the symptoms of pain 
and improved physical and/or psychosocial function. 6 Despite the wide use of opioids in chronic 
non-cancer related pain, the evidence for the effectiveness and safety of these agents in this 
setting is less compelling.  Evidence from short-term (≤12 weeks) clinical trials suggests that 
opioids are moderately effective for pain relief and only slightly effective for improved 
functional outcomes. 7  The evidence for the long-term use (> 6 months) of opioids in chronic 
noncancer pain is sparse. 7  When evaluating the use of opioids specifically for chronic low back 
pain, the evidence is even less supportive.  A recent systematic review concluded that opioids are 
no more effective than non-steroidal anti-inflammatory drugs (a.k.a., NSAIDs) for the treatment 
of chronic low back pain and that their use confers a greater incidence of adverse effects. 8    
 The role for opioids in cancer-related pain is clearer.  Opioid analgesics are a mainstay in 
the treatment of mild to moderate cancer-related pain in non-palliative and palliative settings.  
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Guidelines incorporate the rational use of opioids for this population in treating pain.  For 
example, the World Health Organization advocates a three-step approach to addressing cancer 
pain, starting with non-opioids as an initial step, mild opioids such as codeine with or without 
non-opioids for mild symptoms that continue to persist, and then strong opioids for moderate to 
severe pain. 9  
 Uncontrolled pain results in significant morbidity, healthcare costs, and lower quality of 
life. 10, 11  Though pain is one of the most common reasons patients see physicians, it has been 
historically undertreated.  This was thought to be due to inadequate education, legal and 
regulatory pressures, concerns regarding side-effects, physicians’ perceptions regarding the 
validity of patient’s complains of pain, among other reasons. 12  Other frameworks suggest that 
the undertreatment of pain results from the subjectivity of pain, a poorly understood causal basis 
of pain, and the perception of pain as only a symptom rather than a disease. 12 Nevertheless, 
improvements have been made, with increased recognition for the need for optimal pain 
management.  In January 1, 2001, Congress passed into law a provision that declared it the start 
of the Decade of Pain Control and Research. 13  This has helped in efforts to bring greater 
awareness to the need for pain control and in developing programs that address the treatment of 
pain.  Consequently, changes in practice guidelines have advocated for adequate pain control 
while recognizing the potential for addiction, misuse and abuse.  This presents physicians with 
the challenge of adequately treating pain while ensuring that they avoid the risk for subsequent 
misuse and abuse of the opioids.   
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Definitions of Misuse and Abuse 
 It is important to understand the contexts under which opioid poisoning may occur.  
Misuse, abuse, and dependence are terms often used that describe behaviors related to opioid use 
disorders.  In addition, opioid poisoning may be due to iatrogenic causes, such as prescribing an 
inappropriately high dose or other medications that may interact with the opioid analgesic.  
Underlying substance dependence or addiction may have an effect on drug-seeking behaviors 
that contribute to opioid misuse or abuse.  The terms “dependence” and “addiction” have been 
used interchangeably in the literature, and for the purpose of this dissertation, are synonymous.  
Definitions are summarized in Figure 1.1.  Dependence is defined by the Diagnostic Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) as “a maladaptive pattern of substance 
use leading to clinically significant impairment or distress” within a 12-month period with signs 
of tolerance, withdrawal, drug-seeking behaviors, and other factors that represent an impediment 
of social functioning. 14  The DSM-IV defines substance abuse as “a maladaptive pattern of 
substance use leading to clinically significant impairment or distress” within a 12-month period 
with specified substance-use related behaviors that adversely impact different types of measures 
of day-to-day functioning that is not preceded by dependence. 15  This definition treats substance 
abuse as a separate disorder from substance dependence.  However, the distinction between the 
two has been called into question by several studies and developing DSM-V criteria call for 
removing the distinction between abuse and dependence when defining opioid use disorders. 16  It 
is important to note that the DSM-IV criteria define these disorders in terms of long-term, 
behavioral patterns and can be difficult to apply on an episodic basis.  For example, an individual 
that consumes the drug one time for the purposes of getting high (i.e., non-medical use, or abuse) 
would not meet the psychiatric definition of a substance abuser.   
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Other definitions have been used to describe aberrant drug use behaviors on an episodic 
basis.  Prescription drug misuse is defined by the National Institute on Drug Abuse (NIDA) as 
“taking a medication in a manner other than that prescribed or for a different condition than that 
for which the medication is prescribed” and drug abuse as “the intentional misuse of a 
medication outside of the normally accepted standards of use.” 17  Using this definition, 
prescription drug abuse can be considered a subset of prescription drug misuse.  Misuse has also 
been defined as the “use of a medication (for a medical purpose) other than as directed or as 
indicated, whether willful or unintentional, and whether harm results or not” and abuse as “any 
use of an illegal drug” or “the intentional self-administration of a medication for a nonmedical 
purpose such as altering one’s state of consciousness.” 18  Though these definitions are more 
amenable for characterizing illicit drug use on an episodic basis, they require detailed 
information regarding the circumstances of the use of the drug to correctly distinguish between 
misuse and abuse.   
 
Use of Opioid Analgesics 
 The increased recognition for the adequate treatment of pain has ushered in a period of 
rapid increases in utilization. From 1992 to 2001, the use of opioids increased from 43 per 1,000 
patient visits to 59 per 1,000 patient visits. 19  From 1995 to 2004, prescribing for various opioids 
increased by as much as close to 3-fold over the time period. 20  Though this increase reflects 
increased access to opioid analgesics in the treatment of pain, it has not been without harm as 
increases in misuse and abuse of these agents have been noted.  From 1995 to 2004, self-reported 
non-medical use and drug-related emergency department visits for these drugs increased by 6.4- 
and 5.6-fold, respectively, for oxycodone. 20  Increases in opioid poisoning mortality have also 
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been documented in the past decade.  Evidence exists that sales, overdose death rates, and 
substance abuse treatment admissions increased in parallel from 1999 to 2008. 21  In the past 
decade, opioid poisoning mortality has increased by as much as 3-fold. 22  Root causes for opioid 
poisoning mortality have been found in part to be due to physician error, knowledge deficits, 
patient non-adherence, and unanticipated medical and mental health comorbidities.23 
 
Use of Heroin 
 It has been estimated that 620,000 Americans used heroin at any point in 2011.  This is in 
contrast with non-medical prescription opioid use (i.e., prescription opioid abuse) in the same 
year, which was estimated to be 11,143,000. 24  The disparate use of heroin compared to 
prescription opioid analgesics also translates to fewer deaths compared to the latter.  Heroin 
related deaths have remained steady from 1999 through 2007, with approximately 2,000 deaths 
in 2007, compared to just under 12,000 deaths for prescription opioids in the same year.25 
 Heroin users represent a distinct population compared to misusers and abusers of 
prescription opioid analgesics.  For example, a relatively large percentage of heroin users have 
HIV/AIDS (up to 3.4%) or hepatitis (up to 27.5%) and are 2.8 and 6.4 times as likely as nonusers 
to have these conditions, respectively. 26  This is due to not only riskier behaviors that these users 
engage in but can be attributed to the common method of administering heroin via injection.  
Furthermore, the use of heroin is limited to only those who use the drug non-medically (and can 
be solely classified as a street drug), while prescription opioid use can occur among medical and 
non-medical users.   
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Figure 1.1: Misuse, Abuse and Dependence Definitions 
Definition Source Definition 
NIDA
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Misuse:   “Taking a medication in a manner other 
than that prescribed or for a different 
condition than that for which the 
medication is prescribed.” 
 
Abuse: “The intentional misuse of a medication 
outside of the normally accepted 
standards of use.” 
Katz et al. 
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Misuse:  “Use of a medication (for a medical 
purpose) other than as directed or as 
indicated, whether willful or 
unintentional, and whether harm results 
or not.” 
 
Abuse: “Any use of an illegal drug” or “the 
intentional self-administration of a 
medication for a nonmedical purpose 
such as altering one’s state of 
consciousness.” 
DSM-IV
15
 
 
Dependence: “a maladaptive pattern of substance use 
leading to clinically significant 
impairment or distress” within a 12-
month period with signs of tolerance, 
withdrawal, drug-seeking behaviors, and 
other factors that represent an 
impediment of social functioning.” 
 
Abuse: “a maladaptive pattern of substance use 
leading to clinically significant 
impairment or distress” within a 12-
month period with specified substance-
use related behaviors that adversely 
impact different types of measures of 
day-to-day functioning that is not 
preceded by dependence.” 
 
 
 
Presentation and Treatment of Opioid Poisoning 
The presence of hypopnea or apnea, miosis, and stupor, in combination with an 
assessment of patient history can lead to a diagnosis of opioid overdose. 27  Though the classic 
 
Abuse 
       Dependence 
Misuse Abuse 
Misuse Abuse 
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toxidrome may include apnea, stupor, and miosis, the clinical presentation of opioid poisoning 
may involve of a variety of other findings (Table 1.1).  These three types of symptoms may not 
be consistently present in all cases. Respiratory depression (defined as 12 breaths per minute or 
less) can be potentially life threatening if not treated.  Decreased respiratory rate has been shown 
to be most predictive of opioid poisoning, and results in decreased oxygen saturation and 
subsequent coma and death. 28  Most cases of opioid poisoning can be managed in the emergency 
department, with more severe or complicated cases requiring inpatient admission.  Patients with 
apnea may require pharmacologic or mechanical stimuli for respiration. 27  For patients with 
stupor and who have respiratory depression, ventilation is provided.  Pharmacologic treatment 
consists of naloxone, a competitive mu receptor opioid antagonist, to reverse the CNS depressant 
effects of the offending opioid.  It is usually administered in the hospital setting, but can be given 
by emergency medical service personnel in some settings.  Subcutaneous, intramuscular, and 
intravenous formulations exist, but intranasal administration has been described as generally 
effective and safe in the literature.  In most cases, the administration of naloxone can completely 
reverse all symptoms, but complications such as persistent hypoxemia, pulmonary edema, 
compartment syndrome, and rhabdomyolysis may occur.  Some patients may require multiple 
dosing or continuous infusions of naloxone, especially in cases where symptoms are persistent 
and/or a long acting drug was administered.  Certain populations, such as children and the 
elderly, may have prolonged toxic effects and unexpectedly severe poisoning, necessitating 
closer monitoring.27 
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Table 1.1: Clinical Presentation of Opioid Poisoning27 
1. Respiratory depression 
2. Miosis 
3. Stupor 
4. Hepatic injury from acetaminophen or hypoxemia 
5. Myoglobinuric renal failure 
6. Rhabdomyolysis 
7. Absent or hypoactive bowel sounds 
8. Compartment syndrome 
9. Hypothermia 
10. Possible presence of one or more fentanyl patches 
 
 
Opioid Poisoning as an Adverse Drug Event 
 Misuse and abuse of opioids can result in a reduced ability to function normally in 
society and can carry criminal and legal consequences.  Because misuse and abuse occur outside 
standard uses, it can increase the likelihood of opioid poisoning.   Opioid poisoning can be 
thought of as falling under several categories of drug events.  An adverse drug event (ADE) is 
defined as an “injury resulting from the use of the drug”. 29, 30  An adverse drug reaction (ADR) is 
defined as a “harm directly caused by a drug at normal doses”. 29, 31  In this respect, ADRs are 
considered a subset of ADEs.  A medication error is defined as “inappropriate use of a drug that 
may or may not result in harm” and a side effect is a “usually predictable or dose-dependent 
effect of a drug that is not the principal effect for which the drug is chosen”.29 
Opioid poisoning can be considered as an injury from the use of a drug (i.e., ADE), but 
can potentially occur at normal, therapeutic doses as well (i.e., ADR).  It may also be the effect 
of a medication error in cases where the opioid was misused or abused.  Other common ADRs 
associated with the use of OAs include nausea, vomiting, constipation, and sedation.   
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Figure 1.2: 
Relationship of Adverse Drug Events, Adverse Drug Reactions, and Medication Errors
29
 
 
 
 
Interventions for Opioid Misuse, Abuse, and Poisoning 
Regulatory action has also been established to ensure that these drugs are prescribed and 
used safely.  For example, Risk Evaluation and Mitigation Strategies (REMS) have been 
implemented for various opioid analgesics.  The requirement for REMS for drugs with known or 
suspected risks of abuse or overdose was established as part of the FDA Amendments Act of 
2007.  Since 2009, the FDA has implemented requirements for REMS from manufacturers for a 
variety of opioid products such as morphine, oxycodone, fentanyl, buprenorphine, among others.  
These strategies vary and may require a combination of the provision of a medication guide to 
patients, elements to assure safe use that can vary by drug, and an implementation plan.  The 
FDA has also recently begun to focus more efforts into requiring REMS for longer-acting and 
extended release opioids due to an increased risk of overdose and death from the use of these 
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agents.  Though REMS may reduce abuse of these drugs, empirical evidence for the 
effectiveness of REMS in reducing adverse events is lacking.   
As another example, “prescription monitoring programs” exist at the state level and 
house databases that contain prescriber and patient-level prescription data on drugs of abuse.  
These data are used in different ways depending on the state.  In most states, information is 
provided to pharmacy and other healthcare professionals and in some, can be provided to law 
enforcement or Medicaid programs.   These programs make this information available to 
healthcare professionals so that proper preventive and treatment efforts can be made to those that 
are identified as drug abusers and data show that these programs are effective in altering 
prescriber behavior. 32   
Though prescription drug monitoring programs and REMS are intended to promote the 
safe use of drugs and to deter abuse, other initiatives have been implemented that address opioid 
poisoning directly.  These programs, akin to syringe exchange programs, supply naloxone as an 
outpatient prescription to be administered by a friend or family member to patients who are 
known abusers or at high risk of abuse.  As cases of opioid overdoses have increased over the 
past decade, an increase in the number of such programs has been noted. 33  Several challenges to 
these programs have been cited including costs, training, and medical liability. 34  Despite these 
challenges, access to naloxone has the potential to save lives and reduce healthcare costs.   
  
  
 
 
 
 16 
Section 1.5: Rationale 
 
Rates for prescription opioid misuse and abuse have been rapidly rising over the past 
decade and have been attributed in large part to rising rates of opioid prescribing. 20  Accordingly, 
rates of prescription opioid poisoning and related mortality have risen by as much as 3-fold since 
1999, far outpacing that of illicit drugs such as cocaine and heroin 22  A growing number of 
initiatives across the nation have sought to prevent and reverse opioid poisoning through 
education and increasing access to prescription naloxone 33  
Though costs associated with misuse and abuse of prescription opioids have been well 
documented in the literature, most have not focused on costs specifically related to opioid 
poisoning. 35-39  Furthermore, previous studies have only evaluated prescription opioids and do 
not include heroin in their analysis.  As initiatives, such as naloxone prescription programs, are 
targeted towards injection drug users with a growing focus on prescription opioid abusers,, 
evaluating the costs of both heroin and prescription opioid poisoning is worth considering.   
Evaluating factors related to hospitalization and increased costs relating to hospitalization 
are important as inpatient costs are also likely to represent the largest component of direct 
medical costs in opioid poisoning.   In 2010, inpatient hospital care represented approximately 
33% of the $2.2 trillion in national health expenditures in the United States. 40  Indeed, hospital 
care is an expensive component of direct medical costs and evaluating factors that increase 
inpatient care costs or increase the likelihood of inpatient care can further elucidate which types 
of patients are more likely to be costly when experiencing opioid poisoning. 
Therefore, in addition to quantifying the costs of opioid poisoning to society this 
dissertation also focuses on evaluating determinants of increased costs in terms of differences in 
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costs, length of stay, and mortality among opioid types after admission to the hospital.  Patient 
and hospital characteristics are also described to characterize those patients who are admitted to 
the hospital for opioid poisoning.  Also explored in this dissertation are differences in the 
hospitalization between opioid types and in different categories of hospital care, such as the 
intensive care unit (ICU).  This was done to  understand the severity in the varying presentations 
of opioid-related ED visits and the nature of hospitalization for these types of cases.  
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Chapter II: 
 
Literature Review and Conceptual Framework 
Section 2.1: Systematic Literature Review on the Economic Burden of Opioid Poisoning 
 A systematic literature review was conducted in June 2012.  MEDLINE, CINAHL, 
ECONLIT, and IPA were searched for the following terms: (“opiate” OR “opioid” OR “opiates” 
OR “opioids”) AND (“cost” OR “costs”) AND ("misuse" OR "abuse" OR "poisoning" OR 
"overdose" OR “intoxication” OR “dependence”).  Titles and abstracts were first screened for 
inclusion criteria and exclusion criteria.  After applying the exclusion criteria, article reference 
lists from included studies and review articles were evaluated for eligibility for inclusion in the 
literature review.  The inclusion and exclusion criteria that were applied are defined as the 
following: 
Inclusion criteria: 
1. Evaluates costs attributed to opioid misuse, abuse, and/or poisoning 
Exclusion criteria: 
1. Does not evaluate the costs of prescription opioid use 
2. Evaluates cost-effectiveness of opioid analgesics 
3. Studies not conducted in the United States 
4. Only evaluates costs associated with treatment dependence 
The search over all databases yielded 496 articles.  In addition, review articles were reviewed 
to search for other relevant articles that may have been missed in the literature search. 41-47  After 
eliminating duplicates and applying inclusion and exclusion criteria, a total of five original 
research articles were found.
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Table 2.1: Included Articles from Literature Review and Summary of Findings 
Author Opioid Use Data Sources Costs Findings 
White et al.  35 (2005) “Abuse” Administrative claims 
data 
Direct Abusers vs. Not 
($15,884 versus $1,830, 
P < 0.01)* 
McAdam-Marx et al.39 “Abuse and misuse” Medicaid data Direct Poisoning vs. Not 
$16,952 versus $7,066; 
P < .001)* 
Birnbaum et al.  36 (2006) “Prescription opioid 
abuse” 
NSDUH 
TEDS 
DAWN 
Private claims data 
Secondary data 
Direct and indirect $8.6 billion annually 
Hansen et al. 38 (2011) “Nonmedical use” NSDUH 
NVSS Mortality File 
Other secondary data 
sources 
Direct and indirect $50 billion annually 
Birnbaum et al.  37 (2011) “Abuse, dependence and 
misuse” 
Private claims data 
Florida Medicaid 
NSDUH report 
Other secondary data 
sources 
Direct and indirect $55.7 billion annually 
*per patient, per year, total aggregated costs;  NSDUH = National Survey on Drug Use and Health; TEDS = Treatment Episode Data 
Set; DAWN = Drug Abuse Warning Network 
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Summary of Literature 
White et al. 35 (2005) 
 White et al. 35 evaluated the payer burden of opioid abuse using data from a large 
administrative claims database containing data on medical claims and prescription claims from 
approximately 2 million insured members from 16 large employers during the years 1998 
through 2002.  Abusers and non-abusers were compared during a 6 month post-index period 
during this time period.   Opioid abusers were defined as those having an ICD-9-CM code for 
opioid dependence, combinations of opioid abuse with other, opioid abuse, and poisoning by 
opiates excluding heroin.  Non-abusers were drawn from the same overall population and 
matched in a 3:1 ratio to abusers based on gender, age, employment status, and census 
geographic region.  Non-abusers were defined as those who did not have an ICD-9-CM 
diagnosis of opioid dependence, opioid abuse or poisoning.     
Medical utilization was categorized both by place of service and type of medical service.  
Places of service included outpatient physician visits, outpatient mental health visits, hospital 
inpatient stays, emergency room visits, mental health inpatient stays, and another category for 
“other” places of service.  Medical services included motor vehicle traffic accidents, trauma, 
outpatient substance abuse treatment, inpatient substance abuse treatment, and mental disorders.  
  Abusers were found to have significantly greater utilization in each of the places of 
service and greater consumption of each of the medical service categories.  Pain and non-pain 
comorbidities were also compared between abusers and non-abusers.  A larger percentage of 
opioid abusers were found to have various pain diagnoses compared to non-abusers.  Similarly, 
abusers had a greater percentage of various comorbidities compared to non-abusers.  Such 
comorbidities included non-opioid poisoning, hepatitis, pancreatitis, psychiatric diagnoses, liver 
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disease, HIV/AIDS and other STDs, among other diagnoses.  The total average aggregated per-
patient direct healthcare costs were found to be $15,884 for opioid abusers and $1,830 for non-
abusers (p < 0.01), representing a difference of $14,054 per patient.  Hospital inpatient costs 
represented the greatest percentage of costs (48%), followed by physician visit/outpatient costs 
(34%), drug costs (13%) and “other” costs (5%, including other places of service and emergency 
department costs).   The differences in cost do not take into account differences in comorbidities.  
In a sensitivity analysis, a multivariate regression was performed comparing opioid abusers to 
matched patients diagnosed with depression.  Depression was chosen because it is common and 
diagnosed consistently, managed by primary care doctors and specialists, and is costly to payers.  
The investigators controlled for age, sex and comorbidities.  In this analysis, the incremental cost 
of treating opioid abuse patients compared to depressed patients was $3,040 after controlling for 
comorbidities.   
The goal of this study was to measure how much extra it costs to treat abusers vs. non-
abusers.  As such, it represented all types of healthcare expenditures..  Although the study 
accomplishes this goal, the primary analysis does not attribute the total differences in costs to 
opioid abuse since it did not control for comorbidities.  In the sensitivity analysis, the authors 
were able to compare the incremental cost of opioid abusers to patients who were depressed after 
controlling for various comorbidities, but did not specifically measure the incremental costs 
directly attributable to the abuse treatment-related services (i.e., poisoning, detoxification) in a 
general population.  
The authors also applied a liberal interpretation of opioid abuse by including patients who 
had diagnoses for dependence and poisoning.  Different definitions exist for “abuse”, including 
that given by NIDA, Katz, et al., and the Diagnostic Statistical Manual-IV (DSM-IV) as used in 
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psychiatry. 14, 15, 17  The DSM-IV distinguishes dependence as a separate condition from opioid 
abuse, and other definitions distinguish between misuse (i.e., unintentional use of a drug outside 
normal use, or for a medical purpose) and abuse (i.e., intentional misuse, or for a non-medical 
purpose).  Whether patients had the intent to use the drug for recreational purposes or if the 
patient was simply overmedicating to adequately control pain was not considered.  Poisoning is 
not necessarily exclusive to the abuse of the drug, but can be related to misuse as well.   
This study did not distinguish between poisoning costs and other costs associated with abuse.  
It does, however, distinguish between “inpatient” costs and other costs.  Inpatient costs can 
include patients who need to be monitored and hospitalized for dependence and abuse behaviors 
rather than for diagnoses directly related to poisoning.  This study also used data from private 
employers and is not generalizable to the national population.  Other populations with a lower 
socioeconomic status (i.e., Medicaid patients) may be predisposed to higher costs. 48-54  Finally, 
only direct costs were considered; indirect costs were not included in the analysis.   
 
McAdam-Marx et al. 39 (2010) 
 McAdam-Marx et al. 39 performed a similar analysis in the Medicaid population.  The 
data was taken from the Medicaid Analytic eXtract (MAX) files representing data from all 50 
states and the District of Columbia.  Patients were identified using the same ICD-9-CM codes 
used by White et al. 8 in the previous analysis.  The index date was defined as the date of the first 
abuse-related diagnosis in 2002, after which a 12-month evaluation period followed.  Non-opioid 
abusers were sampled from the same general population and were matched in a 3:1 ratio to 
opioid abusers based on age, gender, and state of residence.  These control patients were defined 
as those who did not have a diagnosis of opioid abuse.  All patients included in the study had to 
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have at least 12 months of continuous eligibility from January 1, 2002 through December 31, 
2003.  During the evaluation period, costs pertaining to prescription drug use and location of care 
were obtained.  Pain and non-pain-related comorbidities were tracked as outcomes during the 
period.  After costs were obtained, multivariate regression analyses were performed to control 
for patient demographics and differences in comorbidities.   
 It was estimated that the prevalence of opioid abuse and/or dependence was 8.7 per 1,000 
Medicaid patients.  Costs for opioid abuse/dependence patients were significantly higher than the 
matched control group, at $14,537 and $8,663, respectively, with a difference of $5,874.  
Patients with an opioid poisoning diagnosis had an overall excess cost of $9,886 over the entire 
year ($16,952 vs. $7,066).  In the regression model, abuse patients were found to have a 
significantly greater total adjusted cost ($23,556 vs. $8,436).  The most common comorbidities 
were psychiatric disorders (49%), pain-related diagnoses (49%) and substance abuse (45%).  A 
higher proportion of abusers had HIV/AIDS compared to non-abusers.  The relative risks for 
having particular comorbidities relative to matched controls were highest for those having 
experienced other non-opioid poisonings (7.7) and  hepatitis A, B, or C (7.2). Odds ratios were 
highest for substance abuse (9.4), hepatitis A, B or C (8.8) and poisonings (8.5).   In this 
analysis, different types of comorbidities that tend to be associated with substance abuse were 
controlled for, including psychiatric diagnoses, HIV/AIDS, various skin infections, liver disease, 
hepatitis, and other STDs.    
 Several limitations existed with this analysis.  Results from this study cannot be 
generalized to the total population.  Those from Medicaid come from a lower socioeconomic 
status compared to patients under private insurance plans.  Another consideration is that no pre-
index period requirement was placed on the sample.  Patients may thus have been diagnosed with 
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an opioid use disorder or opioid poisoning prior to the given index date.  Unlike in White et al., 
this study stratifies costs by diagnosis type.  Thus, the cost 1-year after diagnosis of opioid 
poisoning was obtained.   However, it cannot be determined from this analysis how much of 
these costs are directly attributed to the opioid poisoning event and no further information 
regarding specific resource utilization after this event was obtained.  This is because annual 
yearly costs were measured as the total incremental costs for the entire year with no specification 
for the source of the increased costs.  Furthermore, the figure obtained does not adjust costs 
related to opioid poisoning specifically, and only adjusted costs for comorbidities when 
evaluating all opioid abuse diagnoses together.. 
 
Birnbaum et al. 36 (2006) 
The previous two studies focused on evaluating the per-patient cost of opioid abuse.  The 
next studies focus on obtaining an overall annual estimate of opioid abuse in the United States.  
In the first such study, Birnbaum et al. 36 estimated the costs of prescription opioid abuse in an 
employed population and used two methods to obtain the estimate: 1) a “quantity” method (i.e., a 
bottom-up approach) whereby survey-derived prevalence estimates of reported opioid abuse are 
multiplied by the per-patient cost of abuse, and 2) an “apportionment” method (i.e., top-down 
approach) that starts with the overall drug abuse costs and apportions the total cost to opioid 
abusers based on the percent of opioid abusers among all drug abuse.  Included in the total 
estimate were healthcare costs, criminal justice costs, and workplace costs.   
Healthcare costs included treatment costs for substance abuse and excess medical costs 
excluding substance abuse treatment costs to avoid double counting.  Treatment costs were 
estimated using the apportionment method using data from the Office of National Drug Control 
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Policy (ONDCP) in 2001 for the costs and the Treatment Episode Data Sets (TEDS) for the ratio 
of opioid abusers to total drug abusers.  Excess medical costs were estimated using a privately 
insured administrative claims database.  Opioid abusers were compared to non-abusers using a 
log-linear regression controlling for patient demographics, employment status, geographical 
location, insurance plan type, and the presence of particular pain-related comorbidities.  Once the 
differences in costs were obtained through the regression, the quantity method was used by 
multiplying this per-patient difference by prevalence estimates of opioid abuse obtained from the 
National Survey of Drug Use and Health (NSDUH).   
Criminal justice costs included costs related to police protection, legal and adjudication 
costs, and costs related to correctional facilities.  The apportionment method was applied using 
several datasets and other publicly available data.  Workplace costs included those from 
premature death, reduced wages and/or employment, and incarceration.  Data for premature 
death were estimated using data obtained from the Drug Abuse Warning Network (DAWN).  
Associated costs using the human capital method were taken from data from the Current 
Population Survey and national Vital Statistics life tables data. The number of inmates for 
prescription opioid abuse offenses was multiplied by the gender-specific average earnings and 
employment rates.   
Treatment costs and excess medical costs were summed to $126 million and $2.48 
billion, respectively, with a total of $2.6 billion for healthcare costs.  Criminal justice costs were 
estimated to be $1.4 billion.  Premature death was estimated at $865 million, reduced wages at 
$3.0 billion and incarceration at $658 million for a total of $4.5 billion in total workplace costs.  
The total societal costs were estimated at $8.6 billion.  All reported costs are reported in 2001 
U.S. dollars. 
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 Several limitations existed with this analysis.  Treatment costs were not measured 
directly.  Instead, a “top-down” approach (i.e., apportionment method) was used, and did not 
allow for direct measurement of treatment costs.  This relies heavily on various assumptions and 
several calculations from multiple datasets to obtain a final estimate.  Because of this, specific 
resources used (i.e., outpatient, inpatient, etc.) were not able to be measured and costs could not 
be attributed to specific reasons for utilization, whether for opioid dependence, poisoning, 
withdrawal, or other abuse-related diagnoses.  Excess medical costs were measured between 
patient who were opioid abusers compared to those who were not.  When this method was 
employed by White et al. 35, patients were matched based on certain characteristics.  In this case, 
they were not.  Another limitation is that these excess costs were not necessarily directly 
attributable to opioid abuse.  Only pain-related diagnoses were controlled for in the analyses.  
This analysis does not establish whether or not comorbidities such as bloodborne pathogens and 
psychiatric comorbidities were directly related to the opioid abuse.  Therefore, some of the 
excess medical cost per-patient may be overstated when attributing these costs to opioid abuse.  
Patients that engage in drug abuse may engage in behaviors that are riskier in general and may be 
more susceptible to particular comorbidities that are not directly a result of the actual drug use.  
While the final figure for direct medical costs would be helpful in determining how much this 
population costs to payers, it would be less useful for informing interventions designed to 
address specific components of opioid abuse such as opioid poisoning.  
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Birnbaum et al.  37 (2011) 
 In the most comprehensive analysis to date, Birnbaum et al. 37 conducted a subsequent 
analysis, updating previous estimates36 by including caregiver burden, additional criminal justice 
and lost productivity costs, and a more comprehensive dataset to measure the prevalence of 
opioid mortality.  Similar to the previous analysis by Birnbaum et al. 36, total costs consisted of 
three components: health care, criminal justice, and lost workplace productivity costs.   
 Healthcare costs were derived from excess medical and drug use, substance abuse 
treatment, prevention, and research.  Excess medical and drug costs were measured using a 
privately insured administrative claims database and the Florida Medicaid database.  The 
privately insured database contained information not only on opioid abusers, but that of 
caregivers in the same insurance plan as well.  Three groups were used to evaluate costs: 1) the 
Florida Medicaid sample, 2) privately insured opioid abusers, and 3) caregivers of the privately 
insured abusers.  Each group was matched 1:1 to controls on age, gender, geographic location, 
employment status (for privately insured), and race (Medicaid only).  Controls for the opioid 
abusers were those that did not have a diagnosis of opioid abuse (irrespective of opioid use) and 
controls for caregivers were those who were not considered caregivers for opioid abuse patients.  
It was not clear how controls for caregivers were selected. The per-patient costs for each of the 
three groups was then multiplied by the prevalence of reported opioid abuse as reported through 
the NSDUH.  Treatment, prevention, and research costs were calculated using the apportionment 
method (i.e., top-down approach) using overall costs for substance abuse for each of the 
categories and then subsequently multiplying by the ratio of opioids to overall drug abuse.   
 Criminal justice costs were calculated using the apportionment method and considered 
spending related to opioid abuse on police protection, legal and adjudication costs, correctional 
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facilities, and property lost due to crime.  Data were obtained from the Criminal Justice 
Expenditures and Employment Extract Program (CJEEP) and was multiplied by the proportion 
related to opioid abuse for arrests or incarcerations.  
 Lost workplace productivity costs included absenteeism, presenteeism (i.e., reduction in 
productivity while working), incarceration, and premature death costs and were calculated using 
the human capital method.  Per-patient absenteeism and disability costs were calculated using 
data from a privately insured administrative claims database and multiplied by the number of 
employees with opioid abuse.  Presenteeism costs were measured using a ratio of total medical, 
drug, absenteeism, and disability costs.  Lost productivity from incarceration was estimated 
using the per-inmate cost of incarceration and multiplied by the number of inmates incarcerated 
for crimes due to opioid abuse.  Premature death was calculated using data from DAWN and 
multiplying by the average lifetime earnings by age and gender. 
 The total economic burden was calculated to be $55.7 billion in 2006 dollars.  Healthcare 
costs consisted of approximately 45% of the total amount, or $25 billion.  Of this amount, excess 
medical costs comprised 94.9% or $23.7 billion, with the rest consisting of substance abuse 
treatment and prevention/research.  Costs for opioid abuse patients consisted of 92% of the 
excess medical costs, with the remaining attributed to caregiver costs.   The Medicaid population 
consisted of one-third of all excess medical and drug costs and Medicare patients and caregivers 
accounted for about 5% of all excess costs.  
 Criminal justice costs accounted for approximately $5.1 billion.  The greatest share of 
costs was represented by correctional facilities (44.1% of all criminal justice costs), followed by 
police protection (29.7%), legal and adjudication (14.1%) and property lost due to crime 
(12.2%).  The largest of the three components of total costs was due to lost workplace 
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productivity, representing 46% of the total, or $25.6 billion.  Of this, premature death contributed 
the largest percentage, or 43.8% or $11.2 billion.  This was followed by lost 
wages/unemployment (31.0%), excess disability and medically related absenteeism (10.2%), 
presenteeism (8.0%) and incarceration (6.9%).   
This is the first the study evaluating costs related to opioid abuse incorporating both 
private and public payer datasets.  This analysis updated previous estimates and resulted in a 
substantially larger estimated economic burden than the first study by Birnbaum et al. 36  In the 
former study, excess medical costs amounted to approximately $2.5 billion.  In this study, excess 
medical costs were estimated to be $23.7 billion.  A small part of this discrepancy can be 
explained by the inclusion of caregiver burden in the most recent study, but excess caregiver 
costs accounted for only 8% of the total excess medical and drug costs.  Excess medical and drug 
costs were included the Medicaid population in the most recent study, whereas in the previous 
study, this was not included.  Medicaid patients and caregivers accounted for one-third of total 
excess medical and drug costs in the most recent analysis, contributing to the increased costs.  
Finally, per patient costs in the former study adjusted for demographics and a select number of 
pain-related comorbidities, but did not completely isolate the costs attributed to opioid abuse as 
total healthcare costs also reflected that of comorbidities that are not necessarily related to opioid 
abuse.  In this study, comorbidities were measured using the Charlson Comorbidity Index, but 
the analysis did not adjusted for this.  Controls had lower comorbidities compared to opioid 
abuse patients.  Thus, these estimates may overstate the excess medical and drug costs per person 
that can be directly attributed to prescription opioid abuse.    
Criminal justice costs in the most recent study were also larger compared to the previous 
study.  This was explained by the inclusion of more criminal justice costs, such as lost properties 
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and correctional facilities.  Costs related to lost workplace costs were also significantly higher in 
this study.  In the previous study, workplace costs totaled at $4.5 billion, compared to $25.6 
billion in this study.  A large portion of this discrepancy is attributed to premature death.  In both 
studies, DAWN data were used to capture prescription opioid-related deaths.  However, opioid-
related deaths have been shown to substantially increase during the time between the two studies.  
Furthermore, the data from DAWN used in the previous study did not at the time contain 
detailed demographic information by drug type, and an assumption was made that the number of 
deaths associated with drugs was proportional to the prevalence of nonmedical use of opioids 
obtained through NSDUH.  Later editions of DAWN data contain this detailed information and 
can be used to provide a more accurate estimate of opioid-related deaths.  Finally, presenteeism 
costs were also included in the final estimate of the recent study and were not accounted for in 
the previous study. 
Several limitations exist with this analysis.  Excess medical costs in this analysis may 
represent costs related to comorbidities or other healthcare utilization not directly related to 
opioid abuse.  No adjustment was made to allow for differences in comorbidities between the 
two groups.  To state that these excess medical and drug costs were attributable to opioid abuse 
implies causation, which is not established in this study.  Like previous studies, this information 
can be useful to determine how much extra an average opioid abuser can cost, but does not 
measure the marginal cost of treating opioid abuse patients for abuse-related healthcare 
utilization.  Thus, it can be less useful to inform interventions that address opioid abuse 
specifically.  For example, interventions that may be aimed at reducing opioid abuse may not be 
directed towards reducing associated comorbidities.  This may be the case among current 
abusers, where abuse interventions will not reduce pre-existing comorbid disorders such as 
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HIV/AIDS. Data are also lacking in this study on the types of resource utilization. Costs were 
neither stratified by the type of diagnosis, nor by drug type.  It was not clear whether increased 
costs were due to poisoning events, acute substance abuse treatment and monitoring, or 
associated comorbidities.   
 
Hansen et al. 38 (2011) 
 Hansen et al. 38 conducted a study evaluating the economic burden of the nonmedical use 
of opioids.  The components he included were abuse treatment costs, medical complications, 
productivity losses, and criminal justice costs.  All costs were apportioned to specific opioid 
analgesics.  Substance abuse treatment costs included general hospital/inpatient costs, general 
hospital/outpatient costs, and costs incurred in substance abuse facilities and from physicians and 
other healthcare professionals.  All costs were measured using a top-down approach.  First, 
estimates were obtained from a report from the Substance Abuse and Mental Health Services 
Administration (SAMHSA) which evaluated national expenditures for substance abuse 
treatment.  Subsequently pooled data from 2004 to 2006 were used to obtain the proportion of all 
opioid nonmedical use versus all drugs of misuse.  Medical complications included the costs 
associated with HIV/AIDS, chronic hepatitis C, and neonatal care.  Total HIV/AIDS and 
hepatitis C prevalence estimates were obtained and were apportioned to opioids based on the 
percent of HIV/AIDS cases attributable to intravenous drug abuse.  These prevalence estimates 
were then multiplied by costs associated with HIV/AIDS or hepatitis C, respectively.  Prevalence 
estimates for opioid withdrawal syndrome among newborns were obtained through the 
Healthcare Cost and Utilization Project Kids’ Inpatient Database (HCUP KID).  The cost of 
hospitalization was obtained using a fixed cost-to-charge ratio of 66%.  
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 Criminal justice costs were based on costs of police services, the legal system, and 
incarceration based on data from the Bureau of Justice Statistics.  These expenditures were 
stratified based on drug law violations.  These costs were apportioned to specific opioids based 
on the percentages of all drug seizures.  Costs to crime victims were also considered by using 
total costs of drug-related crime to victims.   
 Treatment costs for drug abuse were estimated at $11.5 billion in 2006 dollars.  This was 
apportioned to prescription opioids for a total of $2.2 billion, or approximately 19%. In 
Birnbaum’s first study, total treatment costs were apportioned to prescription opioid based on a 
ratio of treatment admissions for opioids to treatment admissions for all drugs of abuse and was 
not based on the ratio of reported opioid abuse to all drug abuse.  In the second study, Birnbaum 
et al. 37 used a similar approach to Hansen et al. by apportioning the total treatment costs based 
on the ratio of reported opioid abuse to all drug abuse.  
 The authors apportioned total substance abuse costs to opioids based on the prevalence of 
all opioid nonmedical use to all misuse of drugs.  This assumes that the intensity of healthcare 
services is constant across all drug misuse. For neonatal care, a fixed cost-to-charge ratio was 
used, and may not represent the true average cost since this varies according to hospital.  
 Although HIV/AIDS and hepatitis C are important considerations, these comorbidities 
can be a direct result of substance abuse only through contaminated paraphernalia used among 
injection drug users.  Prescription opioid analgesics are largely available in oral formulations in 
tablet or capsule form.  Although these formulations can be put into a liquid solution or 
suspension, many drug abusers can also use them orally.  Furthermore, the methods employed by 
the authors make the inherent assumption that all cases of HIV/AIDS attributable to IV drug 
abuse are also attributable to prescription opioid analgesic drug abuse.  This may be the case 
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with illicit opioids such as heroin, along with other non-opioid drugs of abuse such as cocaine or 
methamphetamine, but not with orally administered drugs.  The extent to which these 
comorbidities can be attributed to prescription opioid abuse may be overstated.  
 
Gaps in the Literature 
 One of the key components of previous analyses was that heroin was excluded.  This was 
understandable since heroin is classified as a Schedule I drug and has no approved medical use in 
the United States.  Since the intention of this analysis is to inform programs directed at the 
prevention and/or reversal of opioid poisoning in the United States, heroin poisoning will be an 
important component in this analysis since these programs are directed not only at injection drug 
users but also at prescription opioid abusers.   
 Another common feature of previous studies is that they all evaluate opioid abuse from a 
broad perspective.  One study categorized healthcare utilization based on the location of service 
longitudinally, but did not provide specific reasons for utilization (i.e., poisoning, comorbidities, 
or other complications). With the exception of the study by McAdam-Marx et al. 39, these studies 
did not focus on evaluating costs of opioid poisoning, which is a narrower scope than what has 
been studied.  Although McAdam-Marx evaluated the yearly costs after an opioid poisoning 
diagnosis, they did not calculate marginal costs associated with opioid poisoning nor did they 
provide indirect costs with opioid poisoning.  Furthermore, the use of Medicaid data limited 
generalizability.  
 Another gap in the literature is that none have specifically attached these costs to specific 
opioids.  Although the increases in opioid abuse have been seen in almost all common opioid 
types, the market share of each of these types differ.  Additionally, opioids differ in their 
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pharmacological characteristics and mode of administration, which can render some opioids to 
be more likely to cause symptoms of opioid poisoning.  It may be of interest when informing 
harm reduction programs to evaluate specific costs associated by opioid type as intervention 
efforts can focus on opioids most highly abused or most highly implicated in opioid poisoning.  
 Finally, sensitivity analyses were limited in the previous studies.  Some sensitivity 
analyses were conducted primarily by changing the scenarios.  However, each data input requires 
an assumption and error is introduced each time a variable is introduced from different datasets 
that sample from different populations.  None of these studies employed a probabilistic 
sensitivity analysis, whereby variables are allowed to vary simultaneously based on predefined 
distributions.   
 
Section 2.2: Conceptual Frameworks 
 
Cost of Illness Studies  
 Opioid poisoning represents one component of costs associated with opioid misuse and 
abuse of opioids.  It is an acute condition, and can be rapidly reversed upon expedient medical 
care.  It is also important to note that opioid poisoning does not occur exclusively among those 
with a diagnosed substance use disorder, but can occur among medical users of the drug who use 
it for pain control.  
 An opioid poisoning event can be deconstructed into various events.  At the highest level, 
we can consider all those in the “at-risk” population, which may include, but not limited to, those 
with prior substance use disorders and/or those who are prescribed opioid analgesics.  Evaluating 
this requires a comprehensive dataset with the ability to track individual patients longitudinally 
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while evaluating prior histories.  Once an individual has an opioid poisoning event, costs can be 
incurred through transport to the health system by ambulance, where the patient is evaluated in 
the ED.  Depending upon the presentation of the patient (i.e., drugs involved, severity, 
comorbidities), the patient may be discharged or admitted into the inpatient setting, which is 
more costly than ED visits.  Once admitted, patients can face various levels of resource 
utilization and lengths of stay, resulting in increased costs.   
 To quantify the costs associated with opioid poisoning, a cost of illness approach is used.  
This method for estimating the cost of illness was first detailed by Rice in 1966. 55   Rice 
provided a useful conceptual framework when evaluating the costs associated with an illness.  
This framework continues to serve as the basis for many cost-of-illness studies. 56  According to 
this framework, direct costs consist of those expenditures related to prevention, detection, 
treatment, rehabilitation, research, training, and capital investment in medical facilities. Although 
the evaluation of each component may not be possible given the limitations of available data, 
each should be addressed to identify limitations of the current research and areas for future 
research.  These components are addressed below: 
Prevention 
 In a recent report published by the CDC, there were 50 programs in 2010 that provided 
prescription naloxone to individuals who abuse opioids. 33  These programs vary in size and 
scope and include education and training for opioid abusers and caregivers along with the 
dispensation of prescription naloxone.  Although these programs are important when evaluating 
the cost of opioid poisoning, no information is given with regards to the costs of maintaining 
such programs.  Though information on costs is lacking, information on the number of vials 
dispensed by these programs is available. 33  Because naloxone is used for treatment rather than 
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poisoning, this is captured as a treatment cost.  However, it is a total cost in programs that are 
designed to prevent opioid poisoning and related death.   
Detection 
 Because of the nature of opioid poisoning, detection is less of a concern for costs.  Unlike 
other diseases where medical expenditures are required to detect disease (i.e., diabetes, cancer, 
hypertension, etc.), opioid poisoning occurs suddenly and acutely.  Costs may be incurred 
through the detection of opioid misuse and abuse, but are irrelevant when framed around opioid 
poisoning. 
Rehabilitation 
 Rehabilitation is an important consideration for costs.  Rehabilitation may include 
detoxification, which is primarily used for patients who develop dependence to opioids.  This 
form of rehabilitation is more relevant when evaluating costs under the broader framework of 
misuse and abuse, but can also be relevant for opioid poisoning if patients are more likely to 
undergo detoxification after the poisoning event.  Longitudinal data are necessary to evaluate 
subsequent healthcare utilization after the opioid poisoning event. 
Research 
 Research related expenditures for misuse and abuse have been reported, but none have 
focused on research in opioid poisoning.  Because research funding related to opioid poisoning 
can sometimes be captured under the umbrella of research related to opioid misuse and abuse, an 
exact number for funds dedicated solely for the purposes of opioid poisoning would be difficult 
to ascertain.   
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Treatment 
 Treatment costs include those incurred within the healthcare system (ED visits and 
inpatient stays), ambulance costs, and naloxone prescription costs.  This evaluation directly 
measures ED costs and inpatient costs through the use of ED and inpatient databases.  Naloxone 
prescription costs and ambulance costs are measured through the use of secondary datasets. 
 
Table 2.2: Components of Cost of Illness Studies55 
Prevention Naloxone prescription programs; A significant 
cost of these programs is captured by naloxone 
prescriptions, which are captured in treatment 
costs.  Education is also an important part of 
these programs, but information on the costs to 
provide this education is lacking. 
Detection Detection is less important in acute events as 
the detection of the condition occurs at the 
moment of treatment.  This is unlike chronic 
disease states where detection of disease occurs 
before treatment.   
Rehabilitation Most cases of opioid poisoning can be 
completely reversed if treated expediently.  
Rehabilitation may be required to address 
substance use disorders, but is outside the 
scope of this study.  Data are lacking for 
rehabilitation costs for the fraction of patients 
who experience severe anoxia, which would be 
expected to result in brain damage. 
Research Costs associated with research in opioid 
misuse and abuse have been reported, but none 
of have reported on current research that is 
dedicated towards opioid poisoning.   
Treatment Treatment costs include those incurred in the 
hospital setting (emergency department and 
inpatient setting), ambulance transport, and 
naloxone prescription costs. 
 
Indirect costs are those that are imposed due to the loss of output to the economy.  There 
are generally three sources of indirect costs: absenteeism, presenteeism, and premature death.  
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Absenteeism is measured by the number of absent days that are incurred as a result of the illness.  
Presenteeism refers to the reduction in productivity while working, and costs related to 
premature death are the lost future earnings of the decedent measure those.  There are two 
general methods for estimating indirect costs: the human capital method, and the friction cost 
method.  Debates in the literature have been documented regarding the validity of the human 
capital method compared to the frictional cost method. 57-59  The general principles of each and 
the motivations for their use are described here. 
The human capital method was first proposed by Burton Weisbrod60 in 1961 and 
followed by Rice and Cooper55. The human capital method ascribes value to an individual as a 
productive asset to society. Society refers to the entire population except for the individual being 
valued.  It is based on the economic theory of marginal productivity of labor and makes several 
assumptions.  These include full productivity and full employment in the market, competitive 
labor markets, negligible transaction costs and firms’ behaviors to maximize profit. 58   
There are two ways to measure the value of life for an individual under the human capital 
method.  The first considers the value of a person to others, which ascribes value based on the 
net contribution of the total output.  The second, more common approach is to value the total 
output of an individual by measuring the individual’s gross productivity. 60  The question of 
whether to use net productivity versus gross productivity has been a subject of debate.  In both 
cases, the estimate is the value of potentially lost production or earnings instead of actual lost 
earnings.  However, net productivity involves subtracting out consumption to be more consistent 
with the societal approach.  Ultimately, gross productivity prevailed since no value to years of 
life would be attributed when consumption equals productivity. 58  To calculate lost productivity, 
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the net present value (NPV) of future earnings is calculated and defined by the following 
equation at age a: 
           
  
        
     
60, 
where Yn = value of gross productivity of a person at age n; P
n
a = the probability of a person at 
age a being alive at age n; and r = discount rate.  The NPV can be calculated by age and sex, and 
should take into consideration labor force participation rates.  The human-capital method 
traditionally does not account for unpaid labor, but can be incorporated into the valuation of 
human capital using the market-value approach or the opportunity-cost approach.  The 
opportunity-cost approach values unpaid labor at the wage rate the individual would likely 
receive if in the work force, while the market-value approach uses the market price for the 
service.58 
 Critics of the human capital method claim that this method underestimates costs, as it 
does not value human life more than the economic productivity of the individual. 57  Others claim 
that costs are overestimated especially in the case of premature mortality since firms can hire 
someone who is unemployed, hire someone from another firm, or reallocate resources from 
within their own firms. 57  Critics also argue that absent time increases leisure time and adds to 
the overestimation of indirect costs, though this is complicated by the fact that the leisure time is 
spent while ill. 57  Finally, it is assumed that supply and demand conditions affecting potential 
incomes are the same throughout time as they were when these costs were estimated. 57  Despite 
some of these limitations, the human capital method is the most widely used method for valuing 
productivity costs.61 
 Another method used to evaluate indirect cost is the friction cost method. 62  The friction 
cost method assumes that if unemployment exceeds frictional unemployment, unemployed 
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individuals can replace sick persons after a “friction period”.  Firms must adapt during the 
friction period and can utilize existing labor reserves within the firm, postpone non-urgent work, 
or reallocate employees over the jobs until a new employee is hired.  In this period, three 
possibilities can occur: production falls, remains equal at extra labor input and costs, or falls in 
spite of extra labor input and costs.  Because of the lack of data on the exact magnitude of these 
losses and costs during the frictional period, labor costs of the absentee can serve as the best 
estimate of average indirect costs. 62   
 Critics of the friction cost method cite that this method does not conform to neoclassical 
economic theory, which suggests economies are characterized by full employment and can adjust 
to disturbances without cost. 57 This is countered by proponents who suggest that neoclassical 
economic theory’s assumptions are unrealistic given that unemployment is always existent. 57  
Critics also question the ability of workers to make up lost work in short-term absences. 57  
Nevertheless, the friction cost method and the human capital method are not expected to differ 
for short-term absences. 57  Valuation of the opportunity cost of labor beyond the friction period 
as zero is argued as not supported by neoclassical economic theory nor by empirical evidence.57 
 Although no consensus is given in the literature regarding which method for valuing 
productivity costs is superior, the human capital method remains the most widely and frequently 
used method for valuing these costs.  Because of its broad use in the literature and its ease of 
implementation, the human capital method was employed in this analysis. This will also allow 
for easier comparisons to other studies, which have used the human capital method to measure 
productivity costs.   
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Evaluation of Hospital Costs 
It is also of interest evaluate differences in costs, lengths of stay, and in-hospital mortality 
between patients hospitalized for opioid poisoning from three types of opioid analgesics: heroin, 
methadone, and non-methadone opioid analgesics.  Each of these agents has distinct 
pharmacokinetic (PK) parameters that may result in varying degrees of poisoning severity.  For 
example, heroin has a relatively short half life (about 8 minutes) with its metabolites having a 
half-life of approximately 22 minutes. 63  This is in contrast to methadone, which has a half-life 
of anywhere form 10 to 75 hours depending on a variety of factors. 64   Other opioid analgesics 
have half-lives that depend on the drug and the formulation, and can range from anywhere from 
2 to 16 hours. 1  Hydrocodone and oxycodone, two of the most commonly prescribed opioid 
analgesics, have half lives of 2.5-4 hours and 3-5 hours, respectively. 1, 65  Pharmacodynamic 
(PD) properties also differ among opioid types.  For example, the heroin-to-morphine ratio for 
analgesic potency is approximately 2:166, whereas commonly prescribed opioid analgesics 
oxycodone and hydrocodone have relative potencies of approximately 2:1 and 0.9:1, 
respectively. 67, 68  Other opioid analgesics have significantly higher relative potencies, such as 
fentanyl with a relative potency of about 80:1. 1   
Differences in the PK/PD characteristics in these agents may result in differences in the 
severity of opioid poisoning or the need for closer and extended monitoring.  Given these 
differences, it is expected that methadone would confer the highest costs, length of stay, and in-
hospital mortality compared to either heroin or other non-methadone opioid analgesics.  The 
differences between heroin and non-methadone opioid analgesics may be less clear because the 
relative potencies and half -lives of hydrocodone and oxycodone do not differ substantially with 
heroin.  This is also complicated by the fact that heroin is usually injected instead of being given 
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orally as with hydrocodone or oxycodone.  However, because of the generally shorter half-life of 
heroin compared to opioid analgesics, it was hypothesized that heroin would result in lower 
costs.   
The costs for hospitalization are complex and reflect both patient and hospital 
characteristics.  Patient characteristics that may be involved with increased costs include 
demographic characteristics, the condition being treated, method of reimbursement, 
comorbidities, and the severity of illness of the patient.   Hospital characteristics may include 
hospital bed size, location of the hospital, hospital ownership and teaching status.  Each of these 
potential covariates is explained below.  Because systematic differences may exist between 
patients of differing opioid types that are implicated in the poisoning event, conclusions 
regarding true differences in outcomes may be erroneous if these differences are not accounted 
for.  These characteristics are discussed in further detail below.  
Comorbidities 
 A comorbidity can be defined as “any distinct additional entity that has existed or may 
occur during the clinical course of a patient who has the index disease under study.” 69, 70 Thus, 
identification of comorbid disease requires an examination of conditions co-occuring with the 
index disease under study and the distinction of these conditions as either complications of the 
disease or true comorbidities.  For example, if a patient is admitted for myocardial infarction and 
has congestive heart failure (CHF), CHF cannot be considered a comorbidity since CHF is an 
eventual complication of myocardial infarction.  However, other conditions such as asthma or 
depression may be considered comorbidities. The greater the comorbidity burden, the greater the 
overall complexity of the patient (Figure 2.1).   
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 Those presenting with opioid poisoning may come from populations who have distinct 
comorbidity profiles.  These comorbidities increase the complexity of the patient and can thus 
increase the cost of care for these patients in the hospital setting.  Differences in the comorbidity 
profile between patients of differing implicated opioid types can confound the conclusions. It is 
Figure 2.1 Framework for Disease Complexity69 
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therefore important to adjust for these comorbidities to improve the ability to truly attribute 
differences in outcomes to the opioid types involved. 
 Several methods have been proposed to adjust for comorbidities.  Two commonly used 
methods employed in database research are the Charlson Comorbidity Index and the Elixhauser 
method.  A description of these methods is provided below. 
 The Charlson Comorbidity Index (CCI) is a weighted index that incorporates a selection 
of 19 diseases, each assigned a weight from 1 to 6 depending on the specific condition.  Each of 
these scores is then summed to produce the final weighted index.  The CCI was originally tested 
to predict 1-year mortality rates among women with breast cancer. 71  Adaptations to the CCI 
have been made to allow for linkage of the CCI to claims data via ICD-9-CM codes. 72, 73  Though 
the original CCI was validated in the breast cancer population for one-year mortality, the CCI 
has been validated in other applications as well. 74-77  Though nonetheless useful for adjusting for 
comorbidities, critics have called to attention limitations with the use of this index.  One such 
criticism is that the weights applied to some conditions are outdated and have not been updated 
to reflect advances in medical treatment. 78  Such is the case with HIV/AIDS, which has the 
highest weight possible of “6” among the different conditions.  Advances in the treatment and 
management of HIV/AIDS has significantly improved since the original weighting scheme was 
created in 1987.  Though validated to predict 1-year mortality, the weights applied are somewhat 
arbitrary in their assignment, and the “true” weight for each of these condition may differ 
depending on the disease state and population under study. 
 Another way of adjusting for comorbidities is the Elixhauser method.  The original 
Elixhauser method was specifically conceptualized as a way to adjust for comorbidities using 
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administrative inpatient datasets.  The original measures included a list of 30 conditions that 
together were shown to be associated with increased length of stay, hospital charges and 
mortality in an inpatient setting. 79  In its original form, each of these conditions could be used in 
a regression model with 30 indicator variables that represent each of these 30 conditions to adjust 
main effects. Secondary diagnoses related to each of these 30 conditions were considered 
comorbidities only if they were unrelated to the diagnosis-related group (DRG) assignment at 
discharge. The latest iteration of the Elixhauser method in use by the Healthcare Cost and 
Utilization Project (HCUP) has been modified to include a total of 29 conditions after excluding 
cardiac arrhythmias due to concerns about reliability. 80  This method does not assume a specific 
weight for each of these conditions since each of these can be entered in a regression model 
separately as a regressor.  Though advantageous in these regards, its use is limited when sample 
sizes are small as the degrees of freedom are taken up by the inclusion of all of the conditions in 
the regression model. Because Elixhauser method evaluates comorbidities in relation to specific 
DRGs, it is a more systematic method of evaluating comorbidities compared to the CCI.  It has 
also been shown to perform better than the CCI in predicting survival. 81    
 Both the CCI and Elixhauser method of adjusting for comorbidities are general 
comorbidity adjustment methods and do not incorporate other conditions which may be prevalent 
in specific subpopulations and which may be predictors of costs or other outcomes.  Because 
patients with opioid poisoning may represent a unique subpopulation with other comorbidities 
that can increase costs, it is worth exploring other important comorbidities.  A previous study by 
McAdam-Marx et al. reported a higher prevalence of particular comorbidities compared to a 
matched control in a Medicaid population. 39  The comorbidities of and their prevalence among 
abuse/dependence patients and controls are listed in Table 2.2.  With the exception of alcoholic 
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hepatitis, motor vehicle and motor vehicle accidents, all other comorbidities shown in Table 2.3 
were shown to be significant predictors of increased annual costs when considering prescription 
drugs, outpatient care, and inpatient care.  These specific opioid abuse-related comorbidities 
identified by McAdam-Marx et al. 39 are discussed in further detail below.   
Table 2.3: Identified Comorbidities with Higher Prevalence in Opioid Abuse  
 Abuse/dependence patients 
(%, n = 50,162) 
Controls 
(%, n = 150,485) 
Non-pain-related 
 Other substance abuse 
 Psychiatric disorders 
 HIV/AIDS 
 Endocarditis 
 Skin infections 
 Gastrointestinal bleed 
Cirrhosis/chronic or acute 
liver disease 
Hepatitis A,B, C 
Alcoholic hepatitis 
Other hepatitis 
Pancreatitis 
Sexually transmitted 
disease 
Herpes simplex 
Burns 
Trauma 
Motor vehicle accidents 
  
 
45.1 
49.2 
14.5 
1.1 
12.7 
8.6 
7.3 
 
17.1 
0.4 
1.4 
1.7 
8.6 
 
1.3 
1.0 
31.2 
0.6 
 
8.23 
26.1 
3.1 
0.2 
5.4 
6.3 
1.7 
 
2.4 
0.1 
0.2 
0.6 
7.6 
 
0.7 
0.5 
19.8 
0.2 
Pain-related 
Cancer 
Back/neck 
Arthritis 
Neuropathic pain 
Headache/migraine 
Any pain 
 
3.4 
27.9 
27.3 
9.8 
11.7 
50.0 
 
1.2 
1.5 
1.4 
1.2 
1.6 
1.3 
 
Nonmedical opioid use is associated with a variety of comorbidities.  Mental health 
disorders are particularly associated with nonmedical opioid use.  Up to 70% of individuals with 
an opioid use disorder have a lifetime risk of having a mood or anxiety disorder, with major 
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depression being the most prevalent diagnosis. 82  It has been reported that up to 17% and 16% of 
nonmedical users of prescription opioids have depression and anxiety, respectively. 83  
Nonmedical users of prescription opioids have a 1.2 to 4.3 and 1.2 to 3.0 times greater likelihood 
of having depression and anxiety compared non-users of opioids, respectively. 84  Conversely, 
patients with mood disorders (such as depression) or an anxiety disorder have been found to also 
have an increased likelihood of non-medical prescription opioid use. 84, 85  An association with 
these diagnoses and increased use of mental health services utilization have also been noted. 86  
The correlation between mental health disorders and non-medical opioid use has even been 
shown to differ depending on the type of prescription opioid analgesic implicated, with non-
medical Oxycontin users having a greater likelihood of having an anxiety disorder compared to 
other opioid analgesics. 84, 87   
 Differences in the prevalence of mental health diagnoses have also been found to differ 
between opioid overdose decedents and other opioid users.  In a Veterans Health Affairs (VHA) 
sample, a larger percent of opioid overdose decedents had a substance use disorder or psychiatric 
disorder when compared to non-decedent opioid users (39.5% vs. 9.8% and 66.4% vs. 33.6%, 
respectively).88 
The prevalence of pain among non-medical prescription opioid users in various 
populations has been estimated to be between 14.5% and 61.5%.84  As much as 61.5% of 
prescription opioid analgesic abusers had chronic pain and 81.8% have indicated that pain was 
the reason for initiating the use of these drugs. 84, 89  The presence of back pain and headache is a 
common occurrence in these users.  A review of patients has demonstrated that 31% and 18% 
misusers of prescription opioid analgesics experienced back pain and headaches, respectively. 84, 
90  More patients who were dependent on prescription opioids had any type of history of pain 
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(97.7% vs. 43.5%), acute pain before initiating opioid use (16.3% vs. 6.5%), chronic pain before 
starting methadone maintenance therapy (88.4% vs. 12.9%) than patients dependent on heroin 
only. 84, 91  Differences in pain-related diagnoses have also been noted among opioid overdose 
decedents.  In a VHA sample, opioid overdose decedents had a higher prevalence of chronic 
bodily pains (78.4% vs. 69.3%), headache (12.0% vs. 6.6%) and injuries/acute pain (29.6% vs. 
19.1%) when compared to all opioid users.88 
 Though the literature has focused on evaluating problematic opioid-taking behaviors in 
the non-cancer population, there have been none that focus on such behaviors among patients 
diagnosed with cancer-related pain.  Patients with cancer-related pain represent a unique subset 
of patients with specific needs regarding their care, whether they are related to treatments 
directed at the cancer or the complications of the disease (i.e., pain, infections, etc.).  Because 
cancer can greatly increase the complexity of care among these patients, it should be considered 
when controlling for costs, LOS and in-hospital mortality among opioid poisoning patients.   
 Sexually transmitted infections (STIs) are prevalent among illicit drug users.  STIs such 
as HIV or Hepatitis C are not only transmitted by injection drug users through shared needles, 
but can also be transmitted via risky sexual encounters in this population along with other STIs.  
In one survey among illicit drug users in Columbus and Dayton, Ohio, between 22 to 26% 
exchanged drugs for sex within the past 30 days and 34% reported exchanging sex for money. 92  
About 52% of respondents reported having had an STI during their lifetimes. 92  The high 
prevalence of STIs among illicit drug users merits consideration as a variable to control for when 
evaluating outcomes such as costs or LOS 
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 Herpes simplex virus (HSV) is another specific STI that has been shown to be highly 
prevalent among illicit drug users.  In a sample of non-injecting cocaine and heroin users in New 
York City, the seroprevalence of the HSV-2 strain of the virus was 60%.93  Because of the high 
prevalence of this condition among heroin users and its inclusion as a factor for increased annual 
costs in previous literature, 39 it should be considered when evaluating hospitalization costs.   
 Substance use disorders are particularly prevalent among individuals with HIV/AIDS.  
Approximately 9% of all estimated new HIV infections were represented by injection drug users 
in 2009. 94, 95, 95  Individuals involved with  injection drug use  are at particular risk for blood-born 
pathogens due to practices relating to the sharing of needles with infected individuals.  Since 
2000, injection drug use has been implicated in approximately 28% of all new cases of AIDS. 96  
Treatment of HIV and related complications is expensive.  In 2005, it was estimated that HIV 
inpatient discharges cost approximately $13,290 on average. 97  Total yearly costs were estimated 
to be $19,912 in 2006. 98  Injection drug users with HIV have been shown to have greater 
incremental hospitalization costs than injection drug users without HIV ($1,752 per year in 
2001). 99  Because HIV is a prevalent diagnosis among misusers and abusers of opioids and due 
to the high costs and morbidity associated with the disease, controlling for HIV/AIDS when 
evaluating inpatient costs, length of stay, and mortality in this population should be considered. 
 Any prior injection drug use has been identified as a risk factor for developing viral 
hepatitis. 100  The three most common forms of viral hepatitis are hepatitis A, B, and C.  Hepatitis 
B and C are primarily transmitted through bodily fluids, such as the blood.  Hepatitis A is usually 
transmitted through fecal-oral route. 101  The prevalence of hepatitis B among injection drug users 
has been estimated to be between 50.9%to 89.6% with an incidence of 0.9 to 4.8 cases per 1,000 
injection drug users. 102-105  The prevalence of hepatitis C in this population has been estimated to 
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be between 60 to 90% in 2001. 105 The prevalence of hepatitis A is lower among injection drug 
users, but is still common.  Cyclic outbreaks of hepatitis A in this population have been 
implicated in up to 30% of cases in different areas. 106-109  
 Infective endocarditis is also associated with injection drug use.  The number of 
hospitalizations for IDU-related endocarditis increased between 38% to 66% in the United States 
between 2001-2002 to 2002-2003. 110  Although mechanisms for infective endocarditis are 
unclear, reasons by which IDU results in IE include improper hygiene of the surrounding tissue, 
particulate matter in drug solutions, direct injection of bacterial loads, and drug-induced 
pulmonary hypertension with increased right-side turbulence. 111  Infective endocarditis can be 
life-threatening with high complication rates from deep infections, thromboembolic events, or 
severe sepsis.112 
 Cutaneous injection-related infections are skin infections (i.e., cellulitis, abscesses) that 
occur in up to 10% to 30% of all injection drug users. 113-115 These infections have been listed as 
being among the top reasons (along with pneumonia) for hospitalization among injection drug 
users. 99  Once hospitalized, life-threatening complications may result in deep infections into vital 
areas, necrotizing fasciitis, myositis, bacteremia, and sepsis.116 
 It is established that alcohol abuse is a co-occuring problem among opioid abusers.  
Approximately 12% to 14% of patients on chronic opioid therapy are reported to have concurrent 
alcohol use. 117, 118  Acute episodes of alcohol toxicity can induce alcoholic hepatitis especially 
among chronic users of alcohol. 119  Chronically excessive alcohol use has been linked with 
alcoholic steatohepatitis, or fatty liver disease, in up to 20% of alcoholics who undergo liver 
biopsies and severe cases are associated with a poor prognosis. 120, 121  Because alcohol 
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intoxication may occur concomitantly with opioid intoxication, it merits evaluating this as a risk 
factor for increased costs, LOS or inpatient mortality. 
 Other hepatitis may be considered especially for cases which involve concomitant 
acetaminophen toxicity.  Branded and generic versions of Vicodin and Percocet contain 
acetaminophen in combination with hydrocodone and oxycodone, respectively.  Because these 
products are combined, those that overdose on these agents are also at risk of acetaminophen 
toxicity in addition to opioid poisoning.  A cardinal feature of acetaminophen toxicity is liver 
damage.  Acute hepatitis may occur with acetaminophen and may complicate care and/or require 
further evaluation.  
 Though the mechanism of action is unclear and empirical evidence limited, opioid 
analgesics such as codeine and morphine have been suspected in acute pancreatitis. 122-125  In 
addition, acute pancreatitis may be precipitated by concomitant alcohol intoxication.  Thirty 
percent of all cases of pancreatitis in the United States are attributable to alcohol consumption.126 
Demographics 
Other factors, can contribute to the overall complexity of a patient, such as age, sex, and 
other patient factors.  These factors are discussed in further detail below.   
Age 
 Because patient demographics are known to differ between opioid types and are 
associated with differences in costs, these characteristics have to be adjusted for in the model and 
explored as potential explanatory variables in increasing hospitalization costs in this population.  
Those that experience prescription opioid poisoning are more likely to be older than those who 
overdose on heroin.  Patients of increased age are likely to have poorer health than younger 
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individuals.  Additionally, differences in the physiology of older individuals may affect how 
disease is presented PK/PD effects of drugs may be altered in older individuals. 127, 128  It has been 
shown that older adults 2.8 to 8.7 times as likely to experience respiratory depression compared 
to younger adults, with those greater than 60 years of age having the greatest risks of respiratory 
depression. 129  The effect of age on health has translated to increased costs among opioid 
abusers, with those 65 years and older having up to 235% greater costs than those aged 12 to 18.  
39 
Sex 
 Sex should also be explored as a potential confounder of increased hospitalization costs 
in this population if gender is associated with increased costs and independently associated with 
opioid type.  For example, the mortality rate in 2008 for males was higher (5.9 vs. 3.7 per 
100,000 population) despite having an equal rate of emergency department visits for the 
nonmedical use of opioid analgesics. 21, 130 It has been documented in the literature that females 
tend to have greater overall healthcare utilization and/or overall costs in a variety of settings. 39, 
131, 132  If women seek more preventive care and services related to abuse and non-abuse related 
services, then they may be less likely to have severer presentations.  Males may also be more 
likely to engage in riskier or more intense abuse-related behaviors that may result in worse 
presentations than females.  If these hold true, then males may incur higher hospitalization costs 
than females.  Conversely, an increase in the likelihood to seek medical care may result in 
greater and potentially more intense opioid use than men. Furthermore, women are more likely to 
report the presence of pain, higher severity, higher frequency, and longer duration of pain 
compared to men. 133 Another consideration is the physiological differences between males and 
females that could result in differences in opioid pharmacodynamics and pharmacokinetics.  For 
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example, morphine is known to be more potent and have a slower onset and offset in women 
compared to men and women may require greater dosages of morphine to obtain the same 
therapeutic effect as males. 134  Females may also be more susceptible to opioid side effects such 
as nausea and vomiting compared to men. 129  In these cases, females may have higher 
hospitalization costs than males.  Although the direction of the effect may be unclear, differences 
in medical utilization, psychosocial behaviors and physiology may play a role in differences in 
the costs for treating patients hospitalized with opioid poisoning. 
Race 
 Race may also play a role in increased hospitalization costs.  In fact, differences in race 
have been documented with blacks having increased costs compared to whites. 39  Some evidence 
suggests that whites may be more likely to experience side effects such as nausea and vomiting 
with the administration of opioid analgesics. 129  The direction of this effect has also been 
demonstrated when evaluating mortality.  Among those with opioid users chronic pain and 
substance use disorders, whites were observed to have a greater risk of opioid overdose death 
compared to blacks. 88  Differences between white and African-American children have been 
observed, with the former exhibiting higher clearance of morphine due to genetic variations. 135  
Race may also be used to explain socioeconomic status where other measures fail to capture the 
construct. 136  
Socioeconomic Status 
 Socioeconomic status can be thought of as a measure of three constructs: economic 
status, social status, and work status.  These three constructs can be operationalized through 
income, education, and occupation, respectively. 137  Lower socioeconomic status has been linked 
to greater severity of disease at admission and/or longer length of stay in the inpatient setting, 
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although findings are mixed. 48-54  Furthermore, some evidence suggests that illicit prescription 
opioid users may have a higher socioeconomic status than heroin users. 138   
Patient-level socioeconomic variables are not always available in datasets.  One way to 
control for socioeconomic characteristics in the absence of these variables is to use a proxy. 
Median household income is one such proxy that can be used in for socioeconomic status, with 
particular caveats. 139  Caution should be exercised when interpreting the effect of area-level 
income as a proxy for household income as there is large variability between these two measures. 
140   
Geographic Area 
Some evidence suggests that non-medical users of opioids and other drugs of abuse in 
rural location have poorer self-rated health, lower perceived importance of seeking medical 
treatment and may have greater psychological and alcohol use burden compared to those in an 
urban setting. 141  This may imply greater inpatient costs for these patients due to generally worse 
health.   
Payer Type 
 Differences in the payer type may also result in differences in outcomes.  Having 
Medicaid and being uninsured are associated with the highest adjusted costs and odds of in-
patient mortality for major surgical operations. 142, 143 These differences may reflect differences in 
access to healthcare, generally poorer health, and differences in discharge practices. 142  This 
effect may depend on the types of conditions treated, however.  For example, one retrospective 
study involving motor vehicle accidents found no effect. 144  Because of the potential differences 
in costs depending on payer type and because heroin users are likely to have different payer 
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types associated with them compared to prescription opioid users, it is important to account for 
these differences when assessing patient level hospital costs. 
 
Hospital characteristics 
 Hospital costs can vary significantly by hospital and reflect a combination of inputs 
related to labor, capital, and supplies and have been shown to vary according to vary according 
to different characteristics. 145  Consideration of these characteristics is important when 
evaluating inpatient costs, as hospital level differences at each of these hospitals according to 
these characteristics may also influence cost.  Each of these different components is discussed 
here. 
 Average costs per admission have been shown to be higher for urban hospitals compared 
to rural hospitals. 145, 146  For-profit hospitals have been shown to have higher average 
administrative cost per adjusted admission compared to not-for-profit and government hospitals. 
145, 147  In a meta-analysis of hospital ownership, results were mixed, with wide variations with 
regards to the direction of the effect.  Some studies showing lower costs associated with for-
profit hospitals and some showing higher costs compared to non-profit hospitals, while 
differences between non-profit and government hospitals were not as notable. 148  Teaching 
facilities have been shown to have greater costs than non-teaching facilities, which may reflect 
the added costs of medical education within the institution. 146, 149  Finally, variations in costs 
according to hospital region (i.e., northeast, midwest, south, west) have been noted.150 
 Bed size can be important in predicting hospital costs per patients.  In theory, larger 
hospitals should have lower costs per patient due to economies of scale. 151  However, empirical 
evidence supporting this theory is mixed, with some studies supporting this theory152, 153 while 
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other studies have demonstrated diseconomies of scale. 154-156  Because of the potential for 
hospital size to influence hospital costs, hospital size should be adjusted for when evaluating 
hospital costs.   
 The importance of these hospital characteristics in calculating costs have led the Centers 
for Medicare and Medicaid Services (CMS) to adjust inpatient reimbursement accordingly.  
Inpatient reimbursement is based on an inpatient prospective payment system based on a 
Diagnosis Related Group (DRG) assigned for the particular inpatient admission, with each 
unique DRG associated with a specific reimbursement rate.  CMS accordingly pays a higher 
reimbursement to higher wage areas, teaching hospitals, and hospitals that treat a large 
percentage of low-income patients (i.e., Medicaid and Medicare).157 
 Although these characteristics are discussed here with regards to cost, they can be 
extended to other processes or outcomes such as length of stay or mortality.  Increases in cost 
can sometimes in large part be explained by increases in average length of stay and it has been 
shown the average length of stay is a significant driver of hospital costs. 156  The relationship 
between hospital costs and mortality is less clear.  Although hospital mortality rate has been 
shown to have an inverse relationship with costs156, other evidence has demonstrated parallel 
relationships with both mortality rates and costs. 158, 159  Due to the relationships between average 
costs, average length of stay, and hospital mortality rates, these hospital characteristics should be 
given consideration when evaluating each of these types of outcomes.  
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Section 2.3: Summary 
 
 Prescription opioid misuse and abuse have been increasing in the past decade, and is 
associated with significant costs to society.  Related opioid poisoning has also been increasing 
and has been responsible for an increasing number of deaths.  Naloxone prescription programs 
have been implemented to reduce the incidence of opioid poisoning related mortality, but have 
primarily focused on injection drug use.  Some efforts have broadened the focus to include 
prescription opioid abusers as well.  Current literature does not provide the data necessary to 
quantify costs associated with opioid poisoning.   
When evaluating costs associated with opioid poisoning, a cost-of-illness approach can 
be used.  Costs should be as broad as possible given the data available, and may include a variety 
of costs associated with the treatment and prevention of disease.  This approach can be used to 
quantify the direct and indirect (i.e., productivity) costs per year associated with opioid 
poisoning.  The human capital method is the most frequently used method of ascribing value to 
lost human life, though alternatives exist.  Quantifying the economic burden of opioid poisoning 
can inform efforts to intervene with opioid poisoning. 
Variations in pharmacologic profiles exist with different opioids.  In addition, different 
populations may use these agents.  Opioids may differ in their propensity to cause hospitalization 
for opioid poisoning.  They may also be different in terms of costs associated with the treatment 
opioid poisoning.  When evaluating hospital costs, however, it is important to consider a variety 
of factors that may influence costs.  These include patient characteristics such as age, sex, 
socioeconomic status, insurance status, race, comorbidities, among other characteristics.  
Hospital characteristics should also be considered as these are known to influence costs.  An 
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examination of these costs can aid in determining which types of patient populations are most 
costly to treat with respect to opioid poisoning.   
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Chapter III: 
 
Methods, Results and Discussion for Specific Aim I: 
Quantifying the Economic Burden of Opioid Poisoning 
 
Section 3.1: Methods 
Databases  
This analysis used the 2009 Healthcare Utilization Project (HCUP) National Inpatient 
Sample (NIS) and the National Emergency Department Sample (NEDS) to produce national 
weighted direct medical costs and indirect costs for the treatment of opioid overdose in the 
United States for community hospitals.  The HCUP databases are nationally representative 
datasets that are based on a 20% sample of hospitals that submit data to HCUP. 
For indirect costs due to premature mortality, the 2009 Multiple Cause-of-Death file from 
the National Vital Statistics System (NVSS) was used to estimate mortality to obtain an estimate 
the lifetime costs of mortality secondary to opioid poisoning.   
Weighted prevalence estimates for prescription opioid poisoning were estimated using 
2009 Drug Abuse Warning Network (DAWN) data in the base case scenario.  A more detailed 
description of the DAWN dataset is provided in Chapter V.  Briefly, DAWN is a network of EDs 
from which cases of drug-related visits are identified. Cases in DAWN can be categorized into 8 
types of cases, including suicide attempt, seeking detoxification, alcohol only (for ages < 21), 
adverse reaction, overmedication, malicious poisoning, accidental ingestion, and other 160.  In this 
analysis, opioid poisoning cases are defined to be cases classified in DAWN as suicide attempt, 
overmedication, malicious poisoning, or a category labeled “other”.  To limit cases that may be 
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likely to present with reasons other than for poisoning (i.e., withdrawal, need for detoxification, 
psychiatric diagnoses), those who were referred to detoxification, admitted to a chemical 
dependency/detoxification setting, or psychiatric unit were excluded.  The category representing 
adverse reactions was excluded since these patients may present with other symptoms that are 
not necessarily related to opioid poisoning.  Because it is unknown what percent of “adverse 
reactions” is likely to constitute opioid poisoning, these cases were excluded in the base case 
analysis.  Cases classified as “adverse reactions” were subsequently included in sensitivity 
analyses.  The DAWN dataset was also used to estimate the prevalence of specific opioids to 
estimate opioid-specific costs.   
Direct Costs Estimation 
A bottom up approach was used to estimate total direct treatment costs associated with 
opioid poisoning.  To use this approach, the estimated mean treatment costs were estimated using 
the NEDS and NIS databases.   Ambulance transport and prescription naloxone costs were later 
added to the total amount to arrive at an estimate of total direct costs.  All cases of opioid 
poisoning were identified using ICD-9-CM codes. These codes and their accompanying 
descriptions are described in Table 3.1 below: 
Table 3.1: Opioid Poisoning ICD-9-CM Codes 
 
Description 
E850.0 Accidental poisoning by heroin 
E850.1 Accidental poisoning by methadone 
E850.2 Accidental poisoning by other opiates and related narcotics 
965.0 Poisoning by opium (alkaloids), unspecified 
965.01 Poisoning by heroin 
965.02 Poisoning by methadone 
965.09 Poisoning by other opiates 
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Costs for emergency department (ED) visits that did not result in hospitalization (“treat-
and-release” or T&R) were identified in the NEDS database.  T&R visits include ED visits in 
which the patient died in the ED, was admitted to a different hospital or was treated and 
subsequently discharged.  These dispositions were defined in NEDS according to the “ed_event” 
variable, which defines the disposition according to the following classifications: (1) ED visit in 
which the patient is treated and released, (2) ED visit in which the patient is admitted to this 
same hospital, (3) ED visit in which the patient is transferred to another short-term hospital, (9) 
ED visit in which the patient died in the ED, (98) ED visits in which patient was not admitted, 
destination unknown, (99) ED visit in which patient was discharged alive, destination unknown 
(but not admitted).  In this analysis, categories (1), (3), (9), (98) and (99) were considered as 
“treat-and-release” visits for the purposes of estimating ED costs. 
Although the NEDS database contains total charges, no standard mechanism is in place to 
convert these charges into costs.  A preliminary analysis conducted by HCUP provided cost to 
charge ratios based on hospital characteristics (Appendix B, Table B.1). 161  Though not useful 
for determining an individual hospital’s cost-to-charge ratio (CCR), these estimates are 
nonetheless useful in estimating an average cost.  The procedure used to estimate these CCRs is 
further explained in Appendix B.  
 Physician fees in the ED were estimated upon the basis of physician fee codes contained 
in the NEDS databases.  The database captures up to 15 Current Procedural Terminology (CPT) 
codes that were used to bill for physician services.  Each CPT code was linked to Centers for 
Medicare and Medicaid Services (CMS) national payment amounts publically available from the 
CMS. 162  Once the payment amount was linked to the CPT code, the sum for all CPT codes for 
each of these visits was calculated. 
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 Cases of opioid poisoning in the inpatient setting were identified using the NIS dataset 
using the same ICD-9-CM diagnoses used in Table 3.1.  Charges were converted to costs using 
hospital-specific CCRs provided by HCUP.  The CCR file contained all-payer inpatient CCRs 
and the group average all-payer inpatient CCRs.  Because not all hospitals have hospital-specific 
CCRs, the group average all-payer inpatient CCR was used where hospital-specific CCRs were 
missing.  Eighty-nine percent of hospitals in the dataset had hospital specific CCRs. 
Ambulance costs were obtained from a Government Accountability Office report in 
2006.  163  The proportion of ambulance utilization for all ED visits was assumed to be 38% and 
was based on an estimate that provided ambulance utilization information on various mental 
health ED visits. 164  Drug costs were based on the average wholesale price (AWP) obtained 
through the 2012 Red Book.  165  The total number of prescription naloxone vials dispensed per 
year was obtained from a 2012 report produced by the Centers for Disease Control and 
Prevention (CDC). 33  Direct costs were adjusted to 2011 U.S. dollars using the medical 
component of the CPI. 166   
Multiple Imputation Procedures for Direct Costs 
Charges were missing in approximately 20% of the ED visits and CPT codes were 
missing for 26% of the visits.  Charges were missing in approximately 3.7% of included 
inpatient visits.  Therefore, multiple imputation procedures (Markov Chain Monte Carlo method) 
were performed to estimate these values. 167 To implement this procedure, 5 separate imputations 
were created according to the relationship with these values to other variables in the dataset.  The 
relative efficiency168 of using m imputations for a proportion of missing data (γ)  is given by: 
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This resulted in a relative efficiency of 96% and 95% for the ED charges and physician 
fees.  The relative efficiency for the estimation of charges in the inpatient dataset was 99%.   
Variables in the multiple imputation procedure for ED visits included number of CPT codes, 
number of diagnoses, number of procedures, age, sex, intent of self-harm, payer status, 
urban/rural status of hospital, hospital ownership, region, teaching status, and opioid type.  In 
addition, the total physician fees were added as a variable for imputed ED charges and vice 
versa.  For the inpatient imputation procedure, number of procedures, length of stay, age, sex, 
sex, payer status, urban/rural designation, teaching status, race, hospital bed size, government 
ownership, hospital region, APR-DRG severity index, average wage index and Elixhauser 
comorbidities were used to impute missing charges.  Each imputation incorporated random 
variation, accounting for uncertainty in the imputed values.  Once these 5 imputations were 
created, results were combined incorporating the between- and within-imputation variance.  SAS 
© version 9.3 (SAS Institute Inc., Cary, NC) was used to conduct the multiple imputation 
procedures. 
Indirect Costs Estimation 
Indirect costs were calculated from lost productivity due to mortality, absenteeism, and 
foregone household activities.  Indirect costs were calculated by using data obtained from an 
analysis from Grosse et al. 169  In the analysis, the daily production value (DPV) was calculated 
based on the average daily hours working at a job, hours of household service, and hourly 
compensation for each by sex and age group.  The DPV was inflated to 2011 U.S. dollars using 
the Bureau of Labor Statistics’ Employment Cost Index (ECI) for all civilian workers. 170 The 
DPV was then multiplied by the average length of stay for opioid analgesics in the inpatient 
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setting.  Three days of recovery time for ED visits and 7 days for inpatient stays post-discharge 
was assumed.  This was based on recommendations on convalescence times for poisoning. 171   
Mortality was estimated from the 2009 Multiple Cause of Death file from the NVSS. 
This system records approximately 99% of all registered deaths in the United States.  For 
patients that die of non-natural causes, such as in cases of poisoning, it is required that coroners 
and medical examiners single out the cause of death.  Included in the file is the underlying cause 
of death identified by International Classification of Diseases 10 (ICD-10) codes, record axis 
fields, and place of death.  The record axis fields contain additional ICD-10 codes that allow for 
further characterization of the manner of death and may also include comorbidities that were 
involved in the causal pathway of the death.  Decedents of opioid poisoning were identified 
using this process: 1) Decedents due to poisoning due to narcotics and psychodysleptics and 
unspecified drugs were identified, (ICD-10 code X42, X44, X62, X64, Y12, and Y14). 2) 
Among those identified in (1), those where opioids were the contributory cause in the record axis 
fields (T40.0-T40.3) were selected.  It should be noted that ‘X64’ (i.e., unspecified drugs) was 
included to capture all relevant poisoning cases.  Combining the X- and Y-codes with the T-
codes for opioids in the record axis fields helps to ensure that opioids were a contributory cause 
of the poisoning.  Descriptions of each ICD-10 code are provided below in Table 3.2. The 
mortality file was analyzed using SAS © version 9.3 (SAS Institute Inc., Cary, NC). 
 Once mortality estimates were calculated, mortality costs were estimated by linking 
lifetime productivity estimates by age and sex provided by Grosse et al., incorporating household 
and market productivity. 169  These costs were adjusted to 2011 dollars using the ECI for the 
wages and salaries for all civilian workers. 170  A discount rate of 3% per annum was assumed.   
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Table 3.2: Opioid Poisoning ICD-10 Codes 
 
Description 
X42 
Accidental poisoning by and exposure to narcotics and 
psychodysleptics [hallucinogens], not elsewhere classified 
X44 
Accidental poisoning by and exposure to other and 
unspecified drugs, medicaments and biological substances 
X62 
Intentional self-poisoning by and exposure to narcotics and 
psychodysleptics, not elsewhere classified 
X64 
Intentional self-poisoning by and exposure to other and 
unspecified drugs, medicaments and biological substances 
Y12 
Poisoning by and exposure to narcotics and psychodysleptics 
[hallucinogens], not elsewhere classified, undetermined 
intent 
Y14 
Poisoning by and exposure to other and unspecified drugs, 
medicaments and biological substances, undetermined intent 
T40.0 Opium 
T40.1 Heroin 
T40.2 Other opioids 
T40.3 Methadone 
 
 Because abusers of these medications are likely to have lower workplace productivity 
and/or reduced labor participation, it is necessary to adjust productivity costs to reflect this.  
Illicit drug use has been estimated to result in a reduced productivity of between 17 and 18%.172  
Illicit drug use was defined as use of Schedule I drugs (i.e., heroin, marijuana, etc.) and non-
medical use of licit drugs (i.e., opiates).   This estimate was used to adjust lost productivity 
downwards.   
The base case scenario did not include reduced productivity due to cancer.  This was 
tested, however, in the sensitivity analysis.  The prevalence of cancer is likely to be higher 
among opioid users, meriting further consideration of workplace productivity in this population. 
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Based on the percent of opioid poisoning decedents with cancer reported by the study by Bohnert 
et al. 88, it was assumed that 8 percent have an accompanying cancer diagnosis. Kroenke et al. 
performed a study evaluating patients with cancer-related  and/or depression and estimated that 
43% of participants were unable to work due to health related reasons. 174  Multiplying 8% by 
43% yields a value of approximately 3%.  Assuming that cancer patients have no productivity 
whatsoever, the upper limit for the decrement in total productivity losses is assumed to be 8%.  
Calculation of Costs per Event 
When calculating the cost per poisoning event, it was assumed that all poisoning cases 
resulted in a healthcare encounter or death.  This assumption had to be made since the data 
available does not contain information on opioid poisoning cases that do not result in a 
healthcare encounter.  Additionally, no studies have reported the prevalence of poisoning cases 
not resulting in an encounter due to difficulties in detecting and measuring these cases.  
Preventive prescription naloxone costs were not considered in calculating the direct costs per 
event. Details for calculating the costs per event are provided in Appendix A.   
Calculation of Opioid-Specific Costs 
Opioid-specific direct costs and absenteeism costs were estimated by multiplying the 
prevalence of each opioid by the mean costs.  Mean costs for heroin were multiplied by the 
prevalence for heroin, while mean costs for prescription opioids were multiplied by the 
prevalence of each of the prescription opioids.  An exception was made for methadone, where 
methadone-specific costs obtained in HCUP ($2,144 in the ED and $10,683 in the inpatient 
setting) were multiplied by the prevalence estimates for methadone.  Opioid specific costs were 
calculated separately for ED and inpatient visits.  For costs related to mortality, mean methadone 
mortality costs were multiplied by the prevalence of these two opioids in the NVSS dataset. 
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Mean non-methadone, non-heroin opioid costs were then multiplied by the prevalence of non-
methadone, non-heroin mortality estimates to obtain a total estimate within this category.  Then, 
the proportion of specific opioids from non-heroin, non-methadone opioid-related ED visits was 
calculated in the DAWN dataset. A top-down approach was then used to apportion the total costs 
based on the proportions obtained from the DAWN data.
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Figure 3.1: Costs Flowchart 
 
 
T&R = treat-and-release; ED = emergency department; DPV = daily production value; LPV = lifetime production value 
*Indirect costs were reduced down by 17.5% in base case scenario to account for the reduced productivity among substance abusers. 
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Sensitivity Analysis 
  For the base case scenario, a one-way sensitivity analysis was performed on each of the 
following parameters: inpatient costs, ED costs, ambulance run costs, lifetime production values 
for men and women (for mortality), percent of decedents with cancer, daily production values for 
men and women (for absenteeism), proportion of ED visits involving an ambulance run and cost 
per ambulance run, and inpatient recovery time.  Mean inpatient and ED costs or expenditures 
were varied using the lower 5
th
 and higher 95
th
 percentiles.  Lifetime and daily production values 
and the reduction in DPV were varied between a 10% and 25%.  The proportion of ED visits 
involving an ambulance run was varied between +/- 25% of the base estimate.  Ambulance costs 
were varied within the 95% confidence interval reported in the GAO report.163  Inpatient 
recovery time was varied between from 0 days to 14 days and ED recovery time varied between 
0 and 7 days.  A tornado diagram was created to demonstrate the greatest sensitivity to costs with 
respect to each of the variables tested.  
Another set of sensitivity analyses was performed on the prevalence of ED T&R visits 
estimated from the DAWN dataset. The base case scenario excluded referrals or admissions to 
detoxification, withdrawal treatment, or psychiatry, and excluded cases classified as adverse 
reactions.  Other scenarios were tested in the sensitivity analysis using a combination of the 
restricted disposition types and inclusion/exclusion of adverse reactions.  The prevalence as 
estimated using ICD-9-CM codes in HCUP NEDS and NIS were also used to provide an 
estimate of opioid poisoning. 
To simultaneously account for uncertainty in the inputs, a probabilistic sensitivity 
analysis was performed for costs per poisoning event and total costs, stratified by opioid 
poisoning type (heroin vs. prescription opioid vs. all).  A total 10,000 simulations were 
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performed for each category of costs.  All inputs used to estimate costs were varied 
simultaneously according to a pre-specified distribution.  Gamma distributions were used for 
costs and were parameterized based on the means and standard errors.  Prevalence estimates and 
drug costs were varied randomly +/- 50% of the estimated values using uniform distributions.  A 
beta distribution was fit for the proportion of ED visits that involved an ambulance.  Finally, the 
reduction in productivity due to reduced labor participation for substance abusers was varied 
randomly between 10% to 25% using a uniform distribution.  Once all simulations were 
performed, non-parametric 95% confidence intervals were constructed using the lower and upper 
2.5% of the range of values.   Probabilistic sensitivity analyses were conducted using Microsoft 
Excel 2011.   
 
Section 3.2: Results 
 Using DAWN estimates, the prevalence of opioid poisoning visits to the ED was 
estimated to be 534,490 in 2009, or 174 per 100,000 population.  Approximately 75% of all 
opioid poisoning visits involved prescription opioids only, while the rest involved heroin and 
combinations.  Approximately 33% resulted in an inpatient admission. Table 3.3 provides 
prevalence estimates of specific prescription opioids by patient disposition (treat-and-release vs. 
hospitalized).  A total of 16,205 opioid poisoning mortalities were found in the dataset, of which 
3,282 involved heroin and 12,923 involved prescription opioid analgesics.   
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Table 3.3: Prevalence Estimates for Opioids in the ED and Inpatient Setting 
 
Weighted n (unweighted n) Sources 
Treat and Release 
  Heroin 109,269 (14,280) 
2009 DAWN Data 
Prescription Opioid 293,184 (19,948) 
   Oxycodone 108,576 (5,765) 
   Hydrocodone 66,149 (4,467) 
   Unspecified 57,420 (4,317) 
   Methadone 44,005 (4,681) 
   Morphine 21,138 (1,297) 
   Fentanyl  14,793 (671) 
   Hydromorphone 10,531 (731) 
   Propoxyphene 6,936 (298) 
   Codeine 7,604 (599) 
   Other 2,860 (123) 
All 402,453 (34228) 
 
Inpatient Admissions 
  Heroin 23,941 (4,298)
2009 DAWN Data 
Prescription Opioid 108,106 (7792) 
   Oxycodone 36,574 (2117) 
   Hydrocodone 27,602 (1811) 
   Unspecified 21,779 (1771) 
   Methadone 16,286 (1535) 
   Morphine 9,542 (729) 
   Fentanyl 4,744 (351) 
   Hydromorphone 3,628 (313) 
   Propoxyphene 3,771 (208) 
   Codeine 3,401 (278) 
   Other 793 (42) 
All 132,047 (12090) 
 
Mortality 
  Heroin 3,282
2009 NVSS Multiple Cause 
of Death File 
Prescription Opioid 12,923 
All 16,205 
 
Other 
  Percent ambulance usage 38.2 Larkin et al. 164 
Yearly prescription 
naloxone vials 38,860 MMWR Report 33 
Table 3.3 displays prevalence estimates for treat-and-release (T&R) ED visits, inpatient 
admissions, mortality, ambulance utilization, and yearly prescription naloxone vials 
dispensed at naloxone prescription programs. Prevalence of mortality for specific 
prescription opioids not shown since drug-specific mortality information is unavailable. 
 
 72 
Direct Costs 
 The average direct cost per poisoning event was estimated to be $4,006.  The average 
direct costs per poisoning event were lower for heroin than for prescription opioids ($3,198 vs. 
$4,255).  The mean ED treatment cost for all opioids was estimated to be $1,832 for all opioids, 
with prescription opioid treatment costs with prescription opioids having higher costs being 
higher compared to heroin ($1,967 vs. $1,379).  The total estimated direct costs to the United 
States were estimated to be approximately $2.2 billion per year.  Prescription opioid poisoning 
accounted for 80% of all direct medical costs. Total direct costs for each component after 
applying prevalence estimates are provided in Table 3.4.  Figure 3.2 provides estimates of cost 
by specific prescription opioid.  Total direct costs by prescription opioid were highest for 
oxycodone ($616 million), hydrocodone ($428 million), unspecified opioids ($350 million), and 
methadone ($289 million).    
Indirect Costs 
 The estimated indirect cost per opioid poisoning event was $33,267.  This was higher for 
prescription opioids ($34,285) than for heroin ($30,594).  When evaluating absenteeism costs 
only, prescription opioids were estimated to have greater costs than heroin, ($621 vs. $584).  
Total indirect costs to society were estimated to be $18.2 billion.   
 The average length of stay in the inpatient setting was estimated in NIS at approximately 
4 days among all opioid types. Assuming 2 days for recovery time after ED discharges and 7 
days recovery time for inpatient discharges, the total absent time was assumed to be 3 and 11 
days, respectively 171.  After multiplying by the respective prevalence estimates, the total 
absenteeism costs of heroin and prescription opioids were $79 million and $256 million, 
respectively.  Total absenteeism costs for all poisonings were estimated to be $335 million.  
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Total mortality costs were estimated at $17.9 billion per year.  Mortality costs attributed to 
heroin accounted for approximately $4.1 billion, and prescription opioids accounted for $13.9 
billion.   The greatest mortality costs were attributed to methadone ($5.1 billion), followed by 
oxycodone ($3.3 billion) and hydrocodone ($2.2 billion).  Indirect costs per event and total 
indirect costs for each of the general opioid types (heroin vs. prescription opioid) are listed in 
Table 3.5.  Total apportioned mortality costs for each of the specific prescription opioid types are 
shown in Figure 3.3.   
Total Costs 
 Combining all cost components yields a total yearly cost of approximately $20.4 billion 
per year.  Mortality costs were the largest component of costs, representing approximately 87% 
of the total costs associated with opioid poisoning.  The total cost for prescription opioids and 
heroin was $15.9 billion and $4.6 billion, respectively.  The average cost per opioid poisoning 
event when considering all sources of costs was $37,274.  The cost per case for prescription 
opioids was greater than for heroin ($38,541 vs. $33,793).   
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Table 3.4: Direct Costs in Opioid Poisoning 
Direct Costs Mean Cost (SE)  Total Costs Sources 
Inpatient Costs 
  
 Heroin $9,988 (410.54)  $239,122,708  2009 HCUP NIS, 2009 
HCUP Cost-to-charge 
ratio files 
Prescription Opioid $9,696 (126.58) $1,048,169,879  
All $9,723 (122.66) $1,287,204,213  
 
ED T&R Costs   
 Heroin $1,379 (28.07) $150,681,951  2009 HCUP NEDS, 
HCUP ED Costs Report 
161 
Prescription Opioid $1,967 (22.16) $576,789,271  
All $1,832 (16.37) $727,493,595  
 
Physician ED Costs   
 Heroin $173 (4.37) $18,903,537  2009 HCUP NEDS, 2009 
CMS National Payment 
Amounts 162 
Prescription Opioid $182 (2.25) $53,486,715  
All $181 (1.99) $72,443,289  
Ambulance Costs 
  
 All $504 (21.38) $26,293,934  2006 GAO Report 163 
Prescription Naloxone* 
 
 
All $16  $633,818  
2012 Red Book 165 , 
BuyEMP 175 
Direct Cost per Event 
 
 Heroin $3,199 $435,061,497  
 Prescription Opioid $4,255 $1,755,699,294  
 All $4,006 $2,197,529,605    
The estimated mean costs, standard errors (where appropriate), total costs, and data 
sources are displayed.  Total costs for inpatient costs, ED costs, and physician ED costs 
are obtained by multiplying prevalence estimates by their respective mean costs.  Total 
costs for ambulance transport and care is calculated using the total prevalence estimates 
and the percent of ambulance use reported by Larkin, et al. 164 Cost per opioid poisoning 
event reflects the proportions of poisoning cases defined as "Treat-and-Release" (T&R), 
inpatient cases, and deaths.  Total combined direct costs are the sum of all direct costs 
(See Appendix A) 
*Prescription naloxone attributed towards costs for heroin-related poisoning only. 
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Table 3.5: Indirect Costs in Opioid Poisoning 
 
Cost per Event ($)* 
Total Cost ($, 
thousands)** 
Absenteeism Costs 
  Heroin 584 79,307 
Prescription Opioid 621 256,173 
All 610 334,648 
Mortality Costs 
  
Heroin 30,010 4,075,566 
Prescription Opioid 33,664 13,887,512 
All 32,657 17,907,232 
All Productivity Costs 
  Heroin 30,594 4,155,966 
Prescription Opioid 34,285 14,143,685 
All 33,267 18,241,881 
*The cost per event for all productivity costs are weighted based on the 
proportions of identified poisoning cases that result in treat-and-release 
ED visits, inpatient admissions, or mortality.   
**Total estimated costs are based on the product of the cost per event 
multiplied by the total prevalence of opioid poisoning.  Productivity 
costs were obtained from Grosse, et al.  169 and prevalence estimates 
(Table 2) 
 
 Direct and absenteeism costs by opioid are depicted in Figure 3.2.  Oxycodone, 
hydrocodone, and unspecified opioids (i.e., opioids NOS) and methadone were associated with 
the highest direct and absenteeism costs combined ($718 million, $499 million, $408 million, 
and $332 million, respectively).  Mortality estimates by opioid are depicted in Figure 3.3.  
Methadone, oxycodone, and hydrocodone were estimated to have the highest total mortality 
costs ($6.4 billion, $5.5 billion, and $3.6 billion, respectively).   
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Figure 3.2:  Direct and Absenteeism Costs by Opioid 
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Figure 3.3: Mortality Costs by Opioid 
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Sensitivity Analysis 
 One-way sensitivity analyses on select variables are depicted in the tornado diagram in 
Figure 3.4.  Costs were most sensitive to the discounting scenarios.  Assuming a discounting 
scenario of 10% yielded an estimate of $10.6 billion, while assuming a 5% discounting scenario 
yielded an estimate of $16 billion.  Varying the DPV between 10% and 25% yielded estimates 
between $22.1 and $18.8, respectively.  Total cost estimates between the most conservative 
prevalence estimates (HCUP) and liberal DAWN estimates (all relevant DAWN cases) varied 
between $18.8 billion and $21.7 billion.  When analyzing direct costs only, costs ranged from 
$816 million in the most conservative case to $3.3 billion in the most liberal case.  Specific 
estimates resulting from the different combinations of “restricted dispositions” and “excluded 
adverse reactions” are provided in Table 3.6.  Minimal differences in total overall costs were 
observed for other variables. 
 In the base case analysis, opioids classified as “opioid, not otherwise specified (NOS)” 
were considered to be prescription opioids.  When this category was instead considered as heroin 
poisoning patients, the total estimate for heroin poisoning was estimated to be $5.0 billion 
(compared to $4.6 billion in the base case) with a cost per poisoning event of $22,556 (compared 
to $33,793 in the base case).  Prescription opioids were estimated to have a total cost of 
approximately $15.5 billion (compared o $15.9 billion in the base case) with a cost per poisoning 
event of $47,307 (compared to $38,541 in the base case).  Total estimates were maintained at 
$20.4 billion.   
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Figure 3.4: One Way Sensitivity Analysis on Selected Variables 
 
 
 
Table 3.6: Sensitivity Analysis on Prevalence of ED Visits and Inpatient Stays 
Scenarios 
Restricted 
Disposition 
Excludes 
Adverse 
Reactions 
Prevalence of 
Opioid 
Poisoning 
Direct Cost 
Estimate 
($, millions) 
Total Cost 
Estimate  
($, millions) 
 A* Yes Yes 550,705 1,756 20,439 
 B Yes No 773,254 2,673 21,413 
 C No Yes 590,533 2,444 20,722 
 D No No 813,501 3,291 21,699 
 E HCUP: ICD-9-CM Codes 144,993 816 18,842 
*Base Case 
 
10,629 
16,033 
18,781 
18,841 
20,339 
20,322 
20,384 
20,417 
22,098 
21,699 
20,640 
20,607 
20,493 
20,471 
-13000 -8000 -3000 2000 
Discounting (10% vs. 3%) 
Discounting (5% vs. 3%) 
DPV (25% vs. 10%) 
Prevalence (HCUP vs. All DAWN Cases) 
ED Recovery Days (0 vs. 7 Days) 
Inpatient Recovery Days (0 vs. 14 Days) 
Medical Costs (95% Lower vs. Upper 
Limit) 
Percent Ambulance Utilization (+/- 25%) 
Difference from Base Case (Millions) 
S
ce
n
a
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s 
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The mean estimates for heroin and prescription opioids and associated confidence 
intervals obtained from the probabilistic sensitivity analysis are shown in Table 3.7.  
Incorporating the uncertainty from each of the inputs, the total direct, indirect, and combined 
costs were estimated to be $2.2 billion (95% CI = [1.3, 3.1]), $14.1 (95% CI = [14.0, 14.3] and 
$20.4 (95% CI = [19.4, 21.5]), respectively.  The mean combined cost per poisoning case was 
estimated to be $38,968 (95% CI = [27,777,  58,239]).    
 
Table 3.7: Probabilistic Sensitivity Analysis on Direct, Indirect, and Combined Costs 
 
Mean Cost 
per Event 95% CI 
 
Total 
Cost 
(millions) 
95% CI 
(millions) 
Direct Costs 
     Heroin 3,263 2,431 - 4,477 
 
434 262 - 612 
Prescription Opioid 4,324 3,303 - 5,657 
 
1,759 1,062 - 2,454 
All 4,077 3,058 - 5,404 
 
2,199 1,335 - 3,084 
Indirect Costs 
     Heroin 32,330 21,792 - 51,034 
 
4,155 4,108 - 4,231 
Prescription Opioid 35,963 24,777 - 55,156 
 
14,146 13,996 - 14,357 
All 34,828 23,993 - 53,995 
 
18,246 18,047 - 18,539 
Combined Costs 
     Heroin 35,556 24,857 - 53,956 
 
4,590 4,388 - 4,806 
Prescription Opioid 40,232 28,816 - 59,654 
 
15,895 15,112 - 16,724 
All 38,968 27,777 - 58,239   20,443 19,443 - 21,471 
This table displays the results of the probabilistic sensitivity analysis.  Each mean value and 
associated 95% CI represents a separate set of 10,000 Monte Carlo simulations.  Direct and 
indirect costs may not add up exactly to total costs as each value was created from a 
separate simulation. 
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Section 3.3: Discussion 
 
This is the first study that specifically evaluates the economic burden of opioid poisoning 
in the United States.  Results from this analysis help define the scope of the problem and inform 
future economic evaluations of interventions intended to prevent or reverse opioid poisoning.  
This research illustrates that interventions seeking to reduce mortality by preventing and/or 
reversing opioid poisoning abusers can have the greatest economic benefits because mortality 
represented the largest percent of the total costs associated with opioid poisoning. In addition, 
prompt reversal of opioid poisoning through timely access to naloxone can potentially reduce 
medical costs by mitigating the severity of presentation and preventing complications related to 
prolonged hypoxia. 
Although the use of naloxone in the outpatient setting has the potential to save lives, 
physicians may be reluctant to prescribe naloxone. 34  Nevertheless, initiatives across the country 
have sought to increase the availability of naloxone to caregivers, friends, or family members to 
intervene in the event of an acute opioid poisoning. 33 Though some programs have only focused 
efforts toward injection drug users176-178, expert opinion and evidence supports expanding 
naloxone access to other populations such as high-risk users and abusers of prescription opioid 
analgesics. 179, 180  
Instead of measuring excess costs after an opioid poisoning event, such as in previous 
studies, costs directly associated with an opioid poisoning event were measured in this study. 
This is important because excess costs may include costs not only related to substance abuse 
treatment, but those related to treating medical complications and comorbidities.  Because 
substance abusers are inherently more likely to engage in riskier behaviors compared to the 
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general population, these costs do not necessarily represent costs related to treating the substance 
abuse symptoms. Finally, heroin is included in these estimates in addition to prescription opioids 
in our analysis. 
Costs for ED visits related to opioid poisoning were estimated to be $1,832.  As a rough 
comparison, ED costs for all visits in 2003 was estimated to be approximately $408 in 2011 
dollars 161.  Comparing across other injury types, our estimated mean cost for inpatient stays due 
to opioid poisoning ($9,723) was slightly lower than an estimate obtained from a previous report 
for hospital stays involving all injury related diagnoses ($10,300 in 2004) 181.  This is expected 
since other types of injury related diagnoses may involve different levels of trauma and may 
require a greater level of care. 
When only direct costs were considered, prescription opioid analgesics had a greater 
average cost per poisoning event than heroin.  This greater cost reflects the greater percentage of 
visits resulting in hospitalization for prescription opioids compared to heroin in the ED (18% vs. 
27%) and the lower observed costs associated with the ED treatment of heroin.  The lower costs 
for heroin in the ED may be due to the shorter half-life of heroin (8 to 22 minutes63) as compared 
to prescription opioid analgesics, which tend to have longer half-lives that vary by drug and 
formulation. The longer durations of action for prescription opioids may require longer 
monitoring periods and multiple naloxone administrations, resulting in greater resource 
utilization.  In contrast, there was little difference in mean costs in the inpatient setting between 
opioid types.  Once reaching a certain threshold of severity that necessitates admission, the 
presentation and management of prescription opioid and heroin poisoning and associated injuries 
may be similar.  This contrasts with the ED setting where a greater variation of severity is 
expected.     
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Indirect costs contribute the largest percentage of the total burden of opioid poisoning.  
Mortality accounted for the great majority of the $20.4 billion total yearly cost; absenteeism 
accounted for just $335 million.  The estimate of absenteeism costs serves as a lower bound as 
no caregivers for adults were assumed due to lack of data availability for caregiver burden 
among those who experience opioid poisoning.  It is also noted that the average indirect cost per 
poisoning event was greater for prescription opioids than for heroin.  This higher cost was 
largely driven by a larger number of mortality cases relative to ED visits or hospitalizations for 
prescription opioids than for heroin.   
It is helpful to compare estimates obtained in this study with previous studies that 
evaluate costs in prescription opioid abuse.  When evaluating prescription opioid abuse, the total 
costs in the most comprehensive study to date was approximately $55.7 billion. 37  Of this, $23.7 
billion were attributed to excess medical and drug costs.  Other yearly estimates of direct medical 
costs in opioid abuse were lower, between $2.2 and $2.6 billion. 36, 38 Differences in these 
estimates were due to the inclusion of caregiver medical burden and due to the addition of other 
sources of healthcare costs not included in studies with the lower estimates. In comparison, 
prescription opioids accounted for approximately $1.8 billion annually in direct costs related to 
the provision of care for patients that experienced opioid poisoning.  Estimates obtained in our 
analysis are consistent with the previous studies evaluating the economic burden of opioid abuse 
as it is lower than the estimates obtained for direct costs in these previous studies. Estimates 
obtained in this study for prescription opioid poisoning mortality are similar to previous 
mortality estimates that evaluated costs related to opioid misuse and abuse. 37, 38  Only one study 
has previously attempted to apportion prescription opioid mortality costs to specific opioid 
analgesics.38  In that study, mortality costs were apportioned based on prescription sales data and 
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reports of misuse according to the National Survey on Drug Use and Health (NSDUH).  
However, this assumes that each specific prescription opioid has the same likelihood of opioid 
poisoning mortality.  In this study, mortality costs were apportioned based on estimates from the 
DAWN data, which may be a better reflection of the relative proportions of opioid analgesics 
implicated in opioid-related mortality compared to prescription sales data.  One caveat should be 
mentioned with regards to interpreting the costs associated with methadone mortality compared 
to other prescription opioids.  The proportion of methadone mentions is lower than that other 
prescription opioids (see Table 3.3).  This discrepancy exists because the current estimates of 
methadone-related mortality are based on direct estimation of NVSS mortality data.  To check 
why this discrepancy exists, the ratio of the weighted number of non-methadone prescription 
opioid ED mentions to non-methadone prescription opioid deaths was calculated and compared 
to the ratio of methadone visits to methadone-related deaths.     The ratio of ED visits to deaths 
for non-methadone opioids was 43.1 to 1 where as for methadone it was 12.8 to 1, which may 
explain why mortality costs for methadone are higher compared to direct and indirect costs.  In 
other words, there were more recorded methadone-related deaths per methadone-related ED 
visits than there were for non-methadone related prescription opioid deaths per non-methadone 
related prescription opioid deaths.  Although this is a crude analysis, it may give a clue as to why 
this discrepancy was observed.   
It is also helpful to compare total estimates obtained in this study with estimates for other 
conditions to provide context to the economic burden that opioid poisoning imposes on society.  
Diabetes, a commonly occurring chronic condition with high costs and significant long-term 
morbidity has been estimated to cost $218 billion in 2007. 182  Stroke, an acute condition with 
long-term morbidities for survivors, was estimated to have an economic burden of $65.5 billion 
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in terms of combined direct and indirect costs in 2008. 183  One should note of these conditions 
tend to have long-term complications unlike opioid poisoning which usually only have short-
term consequences in uncomplicated cases.  Another comparison can be drawn with food allergy 
and anaphylaxis.  In a approach similar to the one used in this analysis, food allergies and 
anaphylaxis cost $340 million in 2007 in terms of direct costs from ED visits, outpatient visits, 
hospital runs, drug costs and indirect costs arising from absenteeism and premature mortality. 184  
Indeed, opioid poisoning carries a significant economic burden to society and efforts to attenuate 
opioid poisoning should be a high priority. Several limitations exist with this analysis.  First, 
only non-federal hospitals were considered when obtaining estimates of cost and prevalence; 
therefore, direct cost estimates do not apply to those receiving treatment at the Veterans Health 
Affairs Hospital System.  However, the VHA system represents a relative small percent of all 
ED visits and inpatient stays.  For example, the mean annual census for VHA emergency 
departments is 13,371. 185  In contrast, the total estimated number of ED visits in non-federal 
hospitals in 2009 was 128,885,040. 186  Second, defining opioid poisoning cases using currently 
available datasets results in several challenges. There is uncertainty with regards to the true 
prevalence of opioid poisoning in the United States.  Using ICD-9-CM codes alone may 
underestimate opioid poisoning codes since model insurance policies do not extend liability for 
intoxication diagnoses to the insurer. 187  Physicians or coders may underreport these diagnoses to 
ensure coverage, which would lower prevalence estimates derived from ICD-9-CM codes.  
Hence, the DAWN database was used to measure prevalence since it captures all mentions of the 
implicated drug independent of the written diagnoses.  This may be a more complete 
representation of all cases related to opioid poisoning.  Although the possibility exists that non-
poisoning cases are included in the DAWN prevalence estimates, the sample in the base case 
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scenario was limited to those patients not referred to or admitted to services/visits related to 
detoxification or psychiatric illness or who presented due to adverse reactions.  Furthermore, this 
uncertainty was accounted for in the probabilistic sensitivity analysis, allowing for wide 
variation in the true prevalence of poisoning (+/- 50%).  
 Because treatment costs were estimated using ICD-9-CM codes, bias may exist if codes 
do not accurately reflect cases of opioid poisoning.  For example, cases that result in physical 
injury indirectly associated with opioids may not be captured in the dataset as a poisoning case.  
Since diagnoses were not available in the DAWN dataset, costs were also estimated using the 
prevalence estimates derived from ICD-9-CM codes in the NEDS and NIS datasets.  The 
prevalence of opioid poisoning was estimated to be lower than DAWN-derived estimates, at 
128,788, or 42 per 100,000 population, with approximately 87% involving prescription opioids.  
This resulted in total costs of $18 billion per year compared with the estimated $20 billion in the 
base case analysis.  The difference between total cost estimates is relatively small due to the 
large scale of mortality costs compared to other components of costs.   
 The costs per poisoning event assumes that all cases of poisoning resulted in either ED 
treatment, hospitalization, or death. This does not capture cases that resolve without medical 
treatment outside the hospital setting.  Because of this possibility, the costs per poisoning event 
may be biased upwards.  Additionally, the 95% confidence intervals obtained using the 
probabilistic sensitivity analysis for costs per poisoning event were wide.  The wideness of the 
confidence intervals is due to the high sensitivity of this estimate to the calculated prevalence 
estimates along with the variation in the productivity reduction for the DPVs.  When assuming 
lower prevalence estimates in the ED and inpatient settings, mortality costs get weighted more, 
and hence would increase the cost per poisoning event since mean mortality costs are greater 
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than direct costs.  Similarly, assuming a higher prevalence in the ED and inpatient settings would 
result in a lower cost per poisoning event.   Assuming a greater reduction in the DPV would lead 
to a lower cost per event, and vice versa. 
 To convert charges to costs in the inpatient setting, hospital specific CCRs were available 
to perform the conversion.  Currently however, there are no standard procedures to convert ED 
charges to costs in the national HCUP NEDS data, requiring the use of summary CCRs 
published by HCUP in 2003. 161  The CCRs may have changed since 2003, but no further updates 
to these CCRs have ben provided. This may be a major limitation as evidence has suggested that 
ED reimbursement relative to ED charges decreased from 1996 to 2004 in the face of rising 
charges without parallel rises in total reimbursement. 188    
 Cost data for specific opioid analgesics were not available in the HCUP datasets, so it 
was assumed that the mean treatment cost for poisoning was equal for each prescription opioid 
when apportioning costs.  An exception was made for methadone, since mean treatment costs for 
methadone can be calculated separately using ICD-9-CM codes within the NIS and NEDS 
datasets.  Second, apportionment of mortality costs to specific prescription opioids was based on 
ED and inpatient data.  If there was a difference in the proportions of prescription opioids 
involved in the hospital setting from instances of opioid poisoning mortality outside the hospital 
setting, then results may be biased. 
Finally, this study did not examine medical costs associated with prevention of poisoning 
or any downstream costs subsequent to the poisoning event.  Costs of naloxone prescription 
programs, abuse education, and other efforts to prevent opioid poisoning were not examined.  In 
addition, healthcare utilization after and beyond an opioid poisoning event was not evaluated.  
Indeed, a poisoning may be the first contact of many with the healthcare system and may result 
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in follow-up visits to address substance abuse issues and rehabilitation. One study in Medicaid 
patients found healthcare utilization and associated costs after opioid poisoning were almost 
$10,000 per year more compared to non-abusers. 39  In this study, the acute costs of opioid 
poisoning are provided, but further studies should evaluate downstream costs in both privately 
and publically insured populations.   
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Chapter IV: 
 
Methods, Results and Discussion for Specific Aim II: 
Evaluating differences in hospital costs, length of stay, and inpatient mortality between patients 
hospitalized for heroin, methadone, and non-methadone opioid analgesic poisoning 
 
Section 4.1: Methods 
Database & Sample Selection 
 The HCUP NIS database in 2009 was used for this specific aim.  This database has been 
described in Specific Aim I.  The sample included all with an ICD-9-CM diagnosis of opioid 
poisoning (Table 3.1).  Once the sample was identified, patients were categorized based on 
opioid type.  To make direct comparisons between opioid types, it was necessary to produce 
mutually exclusive categories.  All patients with a diagnosis of heroin poisoning were 
categorized as heroin patient. Next, all those with a diagnosis of methadone, but not heroin, were 
categorized as methadone patients.  Finally, all other opioid poisoning diagnoses, with the 
exception of unspecified opioids were considered prescription opioids.  Because of the 
uncertainty for the type of opioids that are involved with “unspecified” opioids, it was decided to 
separate out poisoning by opium (965.00, alkaloids, unspecified) to better distinguish between 
opioid types.  For coding purposes, the ICD-9-CM code for ‘965.09’ is used when specific 
opioids are identified.  For the purposes of clarity in this specific aim, diagnoses for ‘965.09’ will 
be referred to as “opioid analgesics” or “prescription opioids” and ‘965.00’ will be referred to as 
“unspecified opioids”. 
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Charges were transformed to reflect costs using hospital-specific cost-to-charge ratios 
and adjusted to 2011 U.S. dollars using the medical component of the CPI. 166 Patient and 
hospital characteristics by opioid type were reported.  Unadjusted costs, LOS, and in-hospital 
mortality were also reported.  Outcomes were adjusted based on patient characteristics, hospital 
characteristics, and Elixhauser comorbidities.  Costs were additionally adjusted using the area 
wage index (AWI) to control for geographic area labor market differences in wages.  Patient 
characteristics included age, sex, race and primary payer status.  Hospital characteristics included 
urban/rural designation, teaching status, hospital bed size, ownership, and region.  Elixhauser 
comorbidities included congestive heart failure, valvular disease, pulmonary circulation 
disorders, peripheral vascular disease, hypertension, other neurological disorders, chronic 
pulmonary disease, diabetes with complications, diabetes without complications, renal failure, 
liver disease, chronic peptic ulcer disease, HIV/AIDS, lymphoma, solid tumor without 
metastasis, rheumatoid arthritis/collagen vascular diseases, coagulation deficiency, obesity, 
blood loss anemia, deficiency anemias, drug abuse, psychoses, and depression. 
 
Sensitivity Analyses 
Other comorbid conditions 
 Adjustment of comorbidities using the Elixhauser method is a validated method of risk 
adjustment when evaluating outcomes.  Although this method is validated, it is a general tool 
that may not adjust for all important comorbidities in specific conditions.  Therefore, it was of 
interest to explore if other potential conditions aside from the included Elixhauser comorbidities 
were important in explaining costs, and if inclusion of these conditions are important when 
estimating adjusted costs associated with each opioid type.  Specific conditions that were 
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evaluated are listed in Table 4.1 and were based on previous comorbidities evaluated in this 
population. 39  Comorbidities were evaluated for redundancy after cross-referencing these 
comorbidities with Elixhauser comorbidities (See Table 4.1)  In the next step, the differences in 
the frequencies of these comorbidities were evaluated by drug type.  Those comorbidities shown 
to vary by drug type were considered for further analyses.  Bivariate analyses were done on the 
remaining comorbidities for costs, LOS, and mortality.  Only ones that were significant in this 
step were entered into each of the models for the sensitivity analysis.  
Inclusion of Median Income by ZIP Code 
 Because median income by ZIP code was not available for all states, it was decided to 
exclude median income as a covariate.  This was included in a subsequent sensitivity analysis. 
Exclusion of Non-Poisoning DRGs 
 The various outcomes were also compared between opioid types using DRGs related to 
poisoning.  This was done because many other DRGs were observed in this analysis.  Below in 
Table 4.2 are the top 10 DRGs observed in the sample.  In the sensitivity analysis, only visits 
with DRGs 917 and 918 were included. 
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Table 4.1: Specific Opioid Abuse-Related Comorbidities 
Initial Comorbidities Considered Comorbidites after Exclusions* 
Sedative/hypnotic involvement 
Alcohol involvement 
Involvement of other drugs of abuse 
Depression 
Anxiety 
HIV/AIDS 
Endocarditis 
Skin infections 
Gastrointestinal bleed 
Cirrhosis/chronic or acute liver disease 
Hepatitis A,B, C 
Alcoholic hepatitis  
Other hepatitis 
Pancreatitis 
Sexually transmitted disease 
Herpes simplex 
Burns 
Trauma 
Motor vehicle accidents 
Cancer 
Back/neck 
Arthritis 
Neuropathic pain 
Headache/migraine 
 
Sedative/hypnotic/anxiolytic involvement 
Alcohol involvement 
Involvement of other drugs of abuse 
Endocarditis 
Skin infections 
Gastrointestinal bleed  
Pancreatitis 
Sexually transmitted infection 
Herpes simplex 
Burns 
Trauma 
Motor vehicle accidents 
Back/neck pain 
Acute pain NOS 
Chronic pain NOS 
Neuropathic pain 
Headache/migraine 
Suicide 
 
*Exclusions were applied after cross-referencing against Elixhauser comorbidities and 
evaluating whether differences existed in the presence of these conditions by opioid type.  For 
ICD-9-CM diagnoses used, see Appendix D. 
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Table 4.2 Descriptions and Frequencies of Most Common DRGs 
DRG Code Description Frequency Percent 
918 Poisoning & toxic effects of drugs without 
major complications 
5,696 41.7 
917 Poisoning & toxic effects of drugs with major 
complications 
5,089 37.25 
885 Psychoses 452 3.31 
208 Respiratory system diagnosis with ventilator 
support 
178 1.3 
871 Septicemia or severe sepsis without 
mechanical ventilation 
135 1.0 
897 Alcohol/drug abuse or dependence without 
rehabilitation therapy without major 
complications 
112 0.8 
999 Ungroupable 108 0.8 
881 Depressive neuroses 107 0.8 
4 Percutaneous cardiovascular procedure with 
drug-eluting stent with major complications or 
4+ vessels/stents 
57 0.4 
907 Other operating room procedures for injuries 
with major complications 
53 0.4 
 
 
Statistical Analysis 
 Unadjusted estimates for inpatient costs, LOS, and in-hospital mortality were estimated 
for each of the separate opioid types (i.e., heroin, methadone, non-methadone opioid analgesics, 
and unspecified opioids).  Bivariate analyses were conducted with each outcome by age, race, 
sex, primary payer status, and each of the hospital characteristics.  Hospital characteristics 
included hospital bed size, teaching status, urban/rural status, hospital ownership and hospital 
region. Each bivariate analysis was conducted using Pearson’s χ2 test.  Under the assumption of 
the central limit theorem, ANOVA and t-tests were used to compare costs and LOS and costs 
between different characteristics.   
Generalized linear models were fitted to the cost and LOS models. Mortality was 
estimated using logistic regression.  Generalized linear models offer several key advantages over 
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ordinary least squares (OLS) regression.  One of the key requirements for OLS regression is 
homoscedasticity; that is, variance of the error must be constant.  However, as mean expenses 
increase, so does the variance, introducing heteroscedasticity. 189  To stabilize the variance, one 
can transform using the logarithm.  This requires retransforming back to the original scale, which 
can introduce bias. 189  The gamma and inverse Gaussian distributions have been proposed to take 
into account distributional characteristics of expenditure data. 189   
To test the most appropriate distribution for costs and LOS, the Quasi-Likelihood under 
the independence model criterion (QIC) was employed.  Robust standard errors were calculated 
in SAS by using PROC GENMOD with a REPEATED statement with an independent 
correlation matrix.  This invokes a GEE procedure that reduces down to estimates produced by 
generalized linear models accounting for intra-hospital correlation within each hospital for each 
observation.   The Akaike Information Criterion (AIC) is used to test model fit when using 
maximum likelihood estimation as in with generalized linear models.  However, since GEE does 
not use maximum likelihood estimation, model fit was assessed using the ‘Quasi-Likelihood 
under the independence model criterion’ (QIC). 190   
It was also of interest to determine whether or not there was an increase in the intensity of 
healthcare utilization independent of LOS.  To test this, hospital LOS was included as a regressor 
in the regression model assessing costs.  This was also tested in a separate Poisson regression 
model, with number of procedures as the outcome variable, while controlling for LOS, patient 
characteristics, hospital characteristics, and Elixhauser comorbidities.  
Costs were fitted using the gamma and inverse Gaussian distributions with a log-link.  
LOS was fitted using three different distributions, each with a log-link: log-normal, negative 
binomial, and a Poisson distribution.  Models with the lowest QIC were chosen for the analyses.  
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The reference category for the opioids was for specified opiates (965.09).  Other pairwise 
comparisons for opioid type were performed for the base case scenario only. Wald’s χ2 test was 
used to compare between opioid types and a Bonferroni adjustment for additional pairwise 
comparisons was performed.  An α level of 0.05 was used for all analyses.  For additional 
pairwise comparisons (3 pairwise comparisons), an α of 0.017 was used.  All statistical analyses 
were performed using SAS 9.3 (SAS Inc., Cary, NC).  PROC GENMOD was used to model the 
generalized linear models and the logistic regression.  The REPEATED statement was used to 
cluster visits by hospital and obtain robust standard errors.  The LSMEANS statement was used 
to estimate adjusted costs.   
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Section 4.2: Results 
Suspiciously High Charges and LOS 
 Suspiciously high charges were identified prior to analyzing the data for costs.  The 
methods for identifying suspiciously high charges have been previously described by HCUP 
(http://www.hcup-us.ahrq.gov/reports/statbriefs/sb97.jsp).  To identify suspiciously high charges, 
the top 1% of charges per hospital day was identified.  For the purposes of this calculation, all 
LOS values equal to 0 were set at a LOS of 1.  The difference between the 75
th
 percentile and the 
median of the top 1% was multiplied by 4 and added to the median.  This value served as the 
threshold for suspiciously high charges for exclusion.  When this was performed, three 
observations were identified and excluded from further analyses.  The charges per day for these 
observations ranged from $112,859 and $160,084.   As a conservative measure, the same 
procedure was applied to LOS.  When this procedure was applied, 9 observations were excluded.  
The LOS for the excluded observations ranged from 88 to 211 days. 
 
Distributions for Costs and LOS 
 Both costs and length of stay were highly skewed to the right.  Costs ranged from $299 to 
$359,297 after excluding suspiciously high charges.  The mean cost for the entire sample was 
$9,787 (SD = 14,536) and the median was $5,712 (IQR = [3,368 – 10,606]).   The LOS ranged 
from 0 days to 82 days after excluding suspiciously high lengths of stay.  The mean LOS was 3.9 
days (SD = 5.03) and the median LOS was 2 days (IQR = [1 – 5]).   
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Missing Data 
 Length of stay was not missing for any of the eligible visits.  Six-hundred thirty three 
eligible visits had missing cost information.   The indicator for death was missing in 10 visits.  
Missing observations for costs and death by drug type are provided in the Table 4.3.  Missing 
observations were excluded from the analysis.   
 
Table 4.3: Frequency of Missing Data 
 Heroin Prescription Opioid Methadone 
Costs 109 (7.6%) 436 (4.2%) 88 (4.9%) 
Died 4 (0.3%) 3 (0.2%) 3 (0.03%) 
 
 
Sample Characteristics by Opioid Type 
 Sample demographics and hospital characteristics according to opioid type are presented 
in Table 4.4.  For demographics, significant differences were found for age, sex, race and 
primary payer type.  Those with heroin poisoning were younger compared to patients with 
prescription opioid or methadone poisoning.  A majority of the patients in the heroin group were 
between the ages of 18 and 34 years of age.  A plurality of patients in the methadone, 
prescription opioid, and unspecified opioid groups were between the ages of 35 and 54 years.  
Heroin patients were less likely to be female compared to all the other opioid groups.  Compared 
to heroin poisoning patients, those with prescription opioid and methadone poisoning were more 
likely to be white.  Patients with poisoning involving heroin were more likely to be black and 
Hispanic compared to the other groups. Compared to the other groups, the prescription opioid 
group had a lower percentage of Medicaid beneficiaries (19.2% vs. over 30% in other groups).  
There were a higher percentage of patients with Medicare as the primary payer among those with 
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prescription opioid and methadone poisoning compared to all other groups.  A higher proportion 
in the prescription opioid group had private insurance compared to the other groups.  Compared 
to the other opioid types, a higher proportion of visits with heroin poisoning had “self-pay” (i.e., 
uninsured) or “other” listed as the primary payer.   
 Differences in the distribution of hospital characteristics were also observed depending 
on opioid type.  Most patients in all opioid categories were hospitalized in large hospitals.  No 
differences were observed between opioid types with respect to hospital bed size.  A majority of 
the heroin patients were hospitalized in teaching hospitals (58%) whereas the majority of visits in 
the other groups were in non-teaching hospitals.  Approximately 96% percent of hospital stays 
involving heroin were in urban hospitals.  Visits involving prescription opioids, methadone and 
unspecified opioids were less likely to be in urban hospitals (between 84% and 86%).   Most of 
the patients were hospitalized in private, non-for-profit hospitals.  The largest percentage of 
visits involving private not-for-profit hospitals was for heroin (74.7%) while the lowest was for 
methadone (67.7%).  Those hospitalized in government-owned hospitals comprised a slightly 
larger percent of methadone patients (17.1%) compared to heroin (13.6%) or prescription opioid 
patients (12.9%). Regional variations were noted, with the largest percentage of heroin patients 
in the northeast region, while the largest percentage for the rest of the opioid groups were in the 
South. 
 Patients hospitalized for prescription opioid poisoning were less likely to be hospitalized 
in medium size hospitals (19.2%) compared to either heroin (28.5%) or methadone (27.9%).  A 
larger share of heroin patients were hospitalized in teaching hospitals (58.0%) compared to either 
prescription opioid patients (38.7%) or methadone patients (45.3%).   Heroin patients were also 
more likely to be hospitalized in urban hospitals (95.7%) than prescription opioid patients 
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(84.3%) or methadone patients (85.9%).   A larger percentage of heroin patients were 
hospitalized in private not-for-profit hospitals (74.6%) compared to the other categories (70.7% 
for prescription opioids and 67.2% for methadone).    Methadone patients were more likely to be 
hospitalized in a government hospital  (17.4%) compared to either heroin (13.7%) or prescription 
opioid patients (13.3%).   Finally, a smaller percentage of heroin patients 17.6% were 
hospitalized in the south compared to the other categories (41.9% and 35.1%).   
Costs, LOS, and Mortality by Patient and Hospital Characteristics 
Older age was significantly associated with greater costs and length of stay.  Those over 
the age of 65 had a mean cost of $11,323 and a LOS of 4.9 days while those less than 18 years of 
age had a mean cost of $6,481 and a LOS of 2.5 days.  Though a positive trend was observed 
with mortality and age, there were no significant differences.  Males were observed to have a 
higher cost than females, but the difference was not significant.  Differences between sexes were 
not observed with regards to LOS.  Males, however, did have a statistically significantly greater 
likelihood of mortality compared to females (3.2% vs. 2.4%).  Differences were not observed in 
costs or mortality between race categories.  However, differences were observed with regards to 
LOS.  Blacks had the longest LOS (4.3 days) while Asians/Pacific Islanders had the shortest (3.3 
days).   Significant differences were observed with respect to payer type in costs, LOS, and 
inpatient mortality.  Patients with Medicare and Medicaid had the greatest costs ($10,752 and 
$10,705, respectively) compared to all other payer types.   Mean LOS was greater for visits 
involving Medicare and Medicaid (4.5 and 4.0 days, respectively).  
 All hospital categories were observed to have significant differences in costs.  Medium 
and large hospitals ($9,946 and $9,897, respectively) were shown to have greater mean costs 
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than small hospitals.  The same trend was observed for length of stay with medium and large 
hospitals (3.7 and 4.2 days, respectively) having a greater man LOS than small hospitals (3.4 
days), though no differences were observed with respect to mortality.  Teaching hospitals were 
also shown to have greater costs and LOS than non-teaching hospitals ($10,704 and $9,148, 
respectively and 4.5 and 3.6 days, respectively).  No differences in mortality were observed 
between teaching and non-teaching status.  Though patients in urban hospitals had higher costs 
than in rural hospitals ($10,235 vs. $7,127), they had a lower LOS than in rural hospitals (2.9 vs. 
4.2 days).   Private not-for-profit hospitals were associated with the greatest mean cost ($9,990) 
while private, for-profit hospitals were associated with the least ($8,978).  Hospitals in the 
western and northeastern regions of the U.S. had the greatest costs ($12,187 and $11,183, 
respectively) while those in the southern and Midwestern regions had the lowest costs ($8,588 
and $8,676, respectively).  
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Table 4.4: Patient and Hospital Characteristics by Opioid Type 
      
 Heroin (%) Methadone (%) Prescription 
Opioid (%) 
Unspecified 
(%) 
p-value 
   (χ2) 
Age 
 < 18 
 18 – 34 
 35 – 54 
 55 – 64 
 > 65 
 
20 (1.4) 
751 (53.3) 
518 (36.7) 
105 (7.5) 
16 (1.1) 
 
48 (2.9) 
499 (29.6) 
746 (44.2) 
290 (17.2) 
104 (6.2) 
 
195 (2.9) 
1,485 (22.2) 
2,732 (40.8) 
1,206 (18.0) 
1,079 (16.1) 
 
 
94 (2.5) 
887 (23.8) 
1,701 (45.6) 
683 (18.3) 
368 (9.9) 
 
 
< 0.0001 
(862.8) 
Female (%) 368 (26.1) 796 (46.9) 3,910 (57.7) 2,080 (55.2) < 0.0001 
(499.2) 
Race (%) 
 White 
 Black 
 Hispanic 
 Asian/P.I. 
 Other 
 
872 (70.3) 
170 (13.7) 
134 (10.8) 
16 (1.3) 
49 (4.0) 
 
1,168 (79.6) 
97 (6.6) 
93 (6.3) 
33 (2.3) 
77 (5.3) 
 
4,916 (84.3) 
392 (6.7) 
312 (5.4) 
108 (1.9) 
107 (1.8) 
 
2,562 (80.2) 
277 (8.7) 
188 (5.9) 
58 (1.8) 
109 (3.4) 
 
 
 
< 0.0001 
(205.0) 
Primary payer 
 Medicare 
 Medicaid 
 Private 
 No Charge 
 Self-Pay 
 Other 
 
 
121 (8.6) 
448 (31.9) 
260 (18.5) 
41 (2.9) 
470 (33.5) 
64 (4.6) 
 
459 (17.2) 
521 (30.8) 
266 (15.7) 
31 (1.8) 
343 (20.3) 
70 (4.1) 
 
2,380 (35.2) 
1,295 (19.2) 
1,868 (27.6) 
78 (1.2) 
848 (12.5) 
292 (4.3) 
 
886 (23.6) 
1,138 (30.3) 
890 (23.7) 
46 (1.2) 
617 (16.4) 
179 (4.8) 
 
 
 
< 0.0001 
(866.2) 
Hospital Bed Size 
 Small 
 Medium 
 Large 
 
151 (10.7) 
402 (28.6) 
854 (60.7) 
 
170 (10.2) 
451 (27.1) 
1,042 (62.7) 
 
793 (12.0) 
1,678 (25.3) 
4,166 (62.8) 
 
419 (11.4) 
945 (25.7) 
2,318 (63.0) 
 
0.0868 
(11.1) 
Teaching Status 
 Non-teaching 
 Teaching 
 
591 (42.0) 
816 (58.0) 
 
905 (54.4) 
758 (45.6) 
 
4,187 (63.1) 
2,450 (36.9) 
 
2,135 (58.0) 
1,547 (42.0) 
 
< 0.0001 
(226.8) 
Urban/rural Status 
 Urban 
 Rural 
 
1,352 (95.9) 
58 (4.1) 
 
1,461 (86.0) 
238 (14.0) 
 
5,682 (83.8) 
1,101 (16.2) 
 
3,213 (85.2) 
557 (14.8) 
 
< 0.0001 
(140.8) 
Hospital Ownership 
 Government 
 Private, NFP 
 Private, FP 
 
191 (13.6) 
1,051 (74.7) 
165 (11.7) 
 
284 (17.1) 
1,125 (67.7) 
254 (15.3) 
 
854 (12.9) 
4,652 (70.1) 
1,131 (17.0) 
 
525 (14.3) 
2,632 (71.5) 
525 (14.3) 
 
< 0.0001 
(50.5) 
Region 
 West 
 Northeast 
 Midwest 
 South 
 
291 (20.6) 
467 (33.1) 
404 (18.7) 
248 (17.6) 
 
439 (25.8) 
354 (20.8) 
314 (18.5) 
592 (34.8) 
 
1,543 (22.8) 
950 (14.0) 
1,444 (21.3) 
2,846 (42.0) 
 
764 (20.3) 
642 (17.0) 
801 (21.3) 
1,563 (41.5) 
 
 
< 0.0001 
(508.1) 
NFP = not for profit; FP = for profit 
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Table 4.5: Mean Costs by Patient & Hospital Characteristics 
 Mean Costs (SD) Test statistic p-value 
Age 
 < 18 
 18 – 34 
 35 – 54 
 55 – 64 
 > 65 
 
6,481 (14,622) 
7.942 (12,631) 
9,907 (15,583) 
11,817 (14,851) 
11,323 (13,936) 
 
 
F4,12890 = 33.9 
 
 
< 0.0001 
Sex 
 Male 
 Female 
 
10,043 (15,319) 
9,571 (13,816) 
 
t = 1.83 
 
0.067 
Race 
 White 
 Black 
 Hispanic 
 Asian/P.I. 
 Other 
 
9,922 (15,071) 
10,307 (15,830) 
11,337 (16,045) 
9,552 (14,272) 
10,064 (16,612) 
 
 
 
F4, 11106  = 1.53 
 
 
 
0.1914 
Primary payer 
 Medicare 
 Medicaid 
 Private 
 No Charge 
 Self-Pay 
 Other 
 
10,752 (13,177) 
10,705 (19,384) 
9,399 (13,535) 
8,294 (11,713) 
7,728 (10,930) 
9,118 (10,370) 
 
 
F5, 12973 = 16.03   
 
 
< 0.0001 
Hospital Bed Size 
 Small 
 Medium 
 Large 
 
8,818 (11,957) 
9,946 (14,251) 
9,897 (15,052) 
 
 
F2, 12752 = 3.69 
 
 
0.0251 
Teaching Status 
 Non-teaching 
 Teaching 
 
9,148 (12,801) 
10,704 (16,654) 
 
t12753 = -5.96 
 
< 0.0001 
Urban/rural Status 
 Rural 
 Urban 
 
7,127 (7,961) 
10,235 (15,322) 
 
T4525 = 13.22 
 
< 0.0001 
Hospital Ownership 
 Government 
 Private, not for profit 
 Private, for profit 
 
9,693 (14,868) 
9,990 (14,502) 
8,978 (14,279) 
 
 
F2,12752 = 4.04 
 
 
< 0.0176 
Region 
 West 
 Northeast 
 Midwest 
 South 
 
12,187 (17,112) 
11,183 (17,038) 
8,676 (12,723) 
8,588 (12,650) 
 
 
F3,13024 = 50.54 
 
 
< 0.0001 
ANOVA and t-tests were used for comparisons, where appropriate.   
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Table 4.6: Mean LOS by Patient Characteristics 
 Mean LOS (SD) Test statistic p-value 
Age 
 < 18 
 18 – 34 
 35 – 54 
 55 – 64 
 > 65 
 
2.47 (3.80) 
3.16 (4.73) 
3.82 (4.86) 
4.76 (5.81) 
4.86 (5.01) 
 
 
F4,13513 = 59.0 
 
 
< 0.0001 
Sex 
 Male 
 Female 
 
3.89 (5.30) 
3.89 (4.78) 
 
t = 0.05 
 
0.9635 
Race 
 White 
 Black 
 Hispanic 
 Asian/P.I. 
 Other 
 
3.90 (5.08) 
4.31 (6.05) 
4.14 (5.02) 
3.31 (3.93) 
3.96 (5.80) 
 
 
F4,11724 = 2.4 
 
 
 
0.0481 
Primary payer 
 Medicare 
 Medicaid 
 Private 
 No Charge 
 Self-Pay 
 Other 
 
4.51 (4.96) 
4.02 (5.75) 
3.66 (4.94) 
3.85 (5.97) 
3.02 (4.08) 
3.54 (4.10) 
 
 
 
F4,13601 = 28.6 
 
 
 
 
< 0.0001 
Hospital Bed Size 
 Small 
 Medium 
 Large 
 
3.36 (6.71) 
3.71 (4.97) 
4.21 (6.64) 
 
 
F2,13386 = 16.2 
 
 
< 0.0001 
Teaching Status 
 Non-teaching 
 Teaching 
 
3.62 (5.20) 
4.48 (7.48) 
 
t13387 = 7.77 
 
< 0.0001 
Urban/rural Status* 
 Rural 
 Urban 
 
4.17 (6.62) 
2.85 (3.08) 
 
t1953 = 14.23 
 
< 0.0001 
Hospital Ownership 
 Government 
 Private, not for profit 
 Private, for profit 
 
3.79 (5.22) 
4.02 (6.59) 
3.97 (5.54) 
 
 
F2,13386 = 1.00 
 
 
0.3691 
Region 
 West 
 Northeast 
 Midwest 
 South 
 
4.04 (6.65) 
4.46 (6.62) 
3.56 (4.58) 
3.97 (6.65) 
 
 
F3,13658 = 9.25 
 
 
< 0.0001 
ANOVA and t-tests were used for comparisons, where appropriate.  Unequal variance t-
test was used instead for urban/rural status 
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Table 4.7: In-hospital Mortality by Patient & Hospital Characteristics 
 n (%) χ2 p-value 
Age 
 < 18 
 18 – 34 
 35 – 54 
 55 – 64 
 > 65 
 
5 (1.4) 
103 (2.9) 
154 (2.7) 
58 (2.5) 
59 (3.8) 
 
 
8.68 
 
 
0.07 
Sex 
 Male 
 Female 
 
206 (3.2) 
174 (2.4) 
 
6.89 
 
0.0087 
Race 
 White 
 Black 
 Hispanic 
 Asian/P.I. 
 Other 
 
279 (2.9) 
23 (2.5) 
21 (2.9) 
6 (2.8) 
7 (2.1) 
 
 
1.54 
 
 
0.8193 
Primary payer 
 Medicare 
 Medicaid 
 Private 
 No Charge 
 Self-Pay 
 Other 
 
110 (2.7) 
113 (3.6) 
70 (2.1) 
9 (4.6) 
58 (2.6) 
16 (2.7) 
 
 
 
15.86 
 
 
 
0.0072 
Hospital Bed Size 
 Small 
 Medium 
 Large 
 
37 (2.4) 
92 (2.7) 
243 (2.9) 
 
1.42 
 
0.4901 
Teaching Status 
 Non-teaching 
 Teaching 
 
202 (2.6) 
170 (3.1) 
 
2.66 
 
0.1028 
Urban/rural Status 
 Rural 
 Urban 
 
341 (2.9) 
39 (2.0) 
 
5.24 
 
0.0221 
Hospital Ownership 
 Government 
 Private, not for profit 
 Private, for profit 
 
52 (2.8) 
255 (2.7) 
65 (3.1) 
 
 
1.21 
 
 
0.5461 
Region 
 West 
 Northeast 
 Midwest 
 South 
 
110 (3.6) 
60 (2.5) 
68 (2.3) 
142 (2.7) 
 
 
11.36 
 
 
0.0099 
Pearson’s χ2 test was used for comparisons. 
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Model Fit for Costs LOS Specifications 
Model fit for the cost LOS models were assessed with the QIC for the base case models.  
The QIC for the Poisson, negative binomial, and gamma distributions were -9781, -40,649, and 
55,102, respectively.  The QIC for the gamma and inverse Gaussian distributions were 192,057 
and -10,252, respectively.  Therefore, the Poisson distribution was assigned to the LOS models 
and the inverse Gaussian distribution was assigned to the cost models. 
 
Findings from Regression Models 
Unadjusted outcomes are shown in Table 4.8.  Mean costs were greatest for methadone, 
followed by unspecified opioids, heroin, and prescription opioids.  LOS was greatest for 
methadone and unspecified opioids, and lowest for prescription opioids.  Mortality was greatest 
for heroin and lowest for unspecified opioids and methadone.   
Adjusted outcomes are given in Table 4.9.  After adjusting for covariates, significant 
differences were observed with respect to opioid type with each of the outcomes.  Pairwise tests 
for opioid type were performed with the regression model coefficients in a subsequent step.  
Methadone was associated with the highest costs ($9,996), followed by unspecified opioids 
($9,455), heroin ($9,279) and prescription opioids ($8,131). The adjusted LOS was highest for 
methadone at 3.8 days, followed by heroin (3.7), unspecified opioids (3.6) and prescription 
opioids (3.5).  The adjusted probability of death was highest for heroin (2.1%), followed by 
unspecified opioids (1.4%), methadone (1.1%) and prescription opioids (0.9%).   
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Table 4.8 Unadjusted Costs, LOS, and In-hospital Mortality  
 Cost (95% CI) LOS (95% CI)  Mortality* (95% CI) 
Heroin 10,182 (9,091 to 11,405) 3.9 (3.6 to 4.3) 4.9% (3.7% to 6.4%) 
Methadone 10,766 (9,803 to 11,823) 4.2 (3.9 to 4.6) 2.5% (1.8% to 3.4%) 
Rx Opioid** 9,154 (8,703 to 9,629) 3.8 (3.7 to 4.0) 3.3% (2.8% to 3.9%) 
Unspecified 10,361 (9,769 to 10,988) 4.2 (3.9 to 4.5) 2.3% (2.0% to 2.7%) 
Results are different from mean estimates from Specific Aim I since this analysis does not take 
into account sample design variables and also due to multiple imputation procedures performed in 
Specific Aim I. 
* Unadjusted probability of death; ** Rx = prescription 
 
Table 4.9 Adjusted Costs, LOS, and In-hospital Mortality  
 Cost (95% CI) LOS (95% CI) Mortality* (95% CI) 
Heroin 9,279 (8,563 to 10,055) 3.7 (3.3 to 4.0) 2.1% (1.2% to 3.5%) 
Methadone 9,996 (9,260 to 10,792) 3.8 (3.6 to 4.1) 1.1% (0.7% to 1.9%) 
Rx Opioid** 8,131 (7,844 to 8,428) 3.5 (3.4 to 3.6) 0.9% (0.6% to 1.4%) 
Unspecified 9,455 (8,984 to 9,951) 3.6 (3.5 to 3.8) 1.4% (0.9% to 2.2%) 
* Adjusted probability of death; ** Rx = prescription 
 
Costs 
The total number of observations in the cost model was 12,751.  The output for the 
regression model is provided in Table 4.10.  The coefficients in the model are referenced to those 
who have non-methadone opioid analgesic poisoning, are less than 18 years of age, male, white, 
have a private payer as primary payer status, or who are hospitalized in a small government-
owned hospital in the West.  Heroin, methadone, and unspecified opioids had 1.14 (95% CI = 
[1.05 to 1.24]), 1.23 (95% CI = [1.13 to 1.34]) and 1.16 (95% CI = [1.11 to 1.22]) times greater 
costs than prescription opioids, respectively.  Other pairwise comparisons by opioid type were 
not significant.   
 Increases in age were associated with greater costs.  Those older than age 65 had 1.48 
(95% CI = [1.31 to 1.68]) times greater costs than those less than 18 years of age.  Females had 
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costs 11% (95% CI = [8% to 15%]) lower compared to males.  Interestingly, visits in which 
“self-pay” was the designated primary payer status had lower costs compared to visits in which 
private payers were listed (exp(β) = 0.86, 95% CI = [0.80 to 0.91]).  Asian ethnicity was 
associated with decreased costs compared to whites.  The Midwest region was associated with 
10% lower costs compared to the west.   
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Table 4.11:  Parameter Estimates from Costs Regression Model 
Parameter β SE Exp(β) (95% CI)  Z p-value 
Intercept 7.578 0.215  99.80 < 0.0001 
Opioid Type 
 RxO* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.132 
0.207 
0.151 
 
-- 
0.042 
0.043 
0.025 
 
-- 
1.14 (1.05 to 1.24) 
1.23 (1.13 to 1.34) 
1.16 (1.11 to 1.22) 
 
-- 
3.17 
4.85 
6.07 
 
-- 
0.0015 
< 0.0001 
< 0.0001 
Age Group 
 < 18* 
 18 to 34 
 35 to 54 
 55 to 64 
 > 65 
 
-- 
0.124 
0.240 
0.366 
0.393 
 
-- 
0.054 
0.054 
0.060 
0.065 
 
-- 
1.13 (1.02 to 1.26) 
1.27 (1.14 to 1.41) 
1.44 (1.28 to 1.62) 
1.48 (1.31 to 1.68) 
 
-- 
2.31 
4.45 
6.11 
6.08 
 
-- 
0.0211 
< 0.0001 
< 0.0001 
< 0.0001 
Sex 
 Male* 
 Female 
 
-- 
-0.122 
 
-- 
0.021 
 
-- 
0.89 (0.85 to 0.92) 
 
-- 
-5.70 
 
-- 
< 0.0001 
Race 
 White* 
 Black 
 Hispanic 
 Asian 
 Other Race 
 
-- 
-0.121 
0.079 
-0.207 
-0.020 
 
-- 
0.053 
0.069 
0.099 
0.0762 
 
-- 
0.89 (0.80 to 0.98) 
1.08 (0.95 to 1.24) 
0.81 (0.67 to 0.99) 
0.98 (0.84 to 1.14) 
 
-- 
-2.30 
-1.14 
1.14 
-0.27 
 
-- 
0.0217 
0.2532 
0.0367 
0.7899 
Payer 
 Private* 
 Medicare 
 Medicaid 
 Self-pay 
 No Charge 
 Other 
 
-- 
0.001 
0.058 
-0.155 
0.01 
0.0014 
 
-- 
0.028 
0.032 
0.033 
0.082 
0.048 
 
-- 
1.00 (0.95 to 1.06) 
1.06 (0.99 to 1.13) 
0.86 (0.80 to 0.91) 
1.01 (0.86 to 1.19) 
1.00 (0.91 to 1.10) 
 
-- 
0.04 
1.79 
-4.69 
0.12 
0.03 
 
-- 
0.9719 
0.0738 
< 0.0001 
0.9021 
0.9773 
Urban/Rural 
 Urban 
 Rural 
 
-- 
-0.002 
 
-- 
0.046 
 
-- 
1.00 (0.91 to 1.09) 
 
-- 
-0.05 
 
-- 
0.959 
Hospital Bed Size 
 Small bed* 
 Medium bed 
 Large bed 
 
-- 
0.050 
0.028 
 
-- 
0.055 
0.051 
 
-- 
1.05 (0.94 to 1.17) 
1.03 (0.93 to 1.14) 
 
-- 
0.91 
0.54 
 
-- 
0.3623 
0.5894 
Teaching Status 
 Non-teaching* 
 Teaching 
 
-- 
0.094 
 
-- 
0.034 
 
-- 
1.10 (1.03 to 1.17) 
 
-- 
2.80 
 
-- 
0.0051 
Hospital Ownership 
 Government* 
 Private, non-profit 
 Private, for profit 
 
-- 
0.034 
-0.030 
 
-- 
0.049 
0.061 
 
-- 
1.03 (0.94 to 1.14) 
0.97 (0.86 to 1.09) 
 
-- 
0.69 
-0.50 
 
-- 
0.4891 
0.6182 
Hospital Region 
 West* 
 Northeast 
 Midwest 
 South 
 
-- 
-0.076 
-0.167 
-0.104 
 
-- 
0.057 
0.052 
0.054 
 
-- 
0.93 (0.83 to 1.04) 
0.90 (0.81 to 1.00) 
0.90 (0.81 to 1.00) 
 
-- 
-1.33 
-3.21 
-1.92 
 
-- 
9.1828 
0.0013 
0.0553 
Area wage index 0.959 0.172 2.61 (1.86 to 3.66) 5.56 < 0.0001 
Parameter estimates for Elixhauser comorbidities are found in Appendix C.   
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Table 4.12: Additional Pairwise Comparisons for Costs 
 exp(β) (SE) 95% CI Wald’s χ2 p-value 
Met vs. Her 0.91 (0.043) 0.82 to 1.02 3.87 0.05 
Met. vs. Unsp 1.02 (0.037) 0.93 to 1.11 0.21 0.650 
Her vs. Unsp 0.93 (0.038) 0.84 to 1.02 3.41 0.065 
Met = methadone; Her = heroin; Unsp = unspecified. Adjusted α = 0.017 
 
Length of Stay 
 A total of 13,376 observations were used in the LOS model.  There were no significant 
differences observed between heroin and prescription opioids.  Methadone was associated with a 
10% (95% CI = [2% to 19%]) increase in LOS compared to prescription opioids.  No other 
differences were observed between opioid types.  Parameter estimates are shown in Table 4.13. 
 Older age was associated with increased length of stay, especially among those 35 years 
and older (See Table 4.13).  Visits with “self-pay” as the designated primary payer were 
associated with a 13% lower LOS compared to those with a private payer (95% CI = [7% to 
18%]).   Visits in teaching hospitals had a 12% (95% CI = [5% to 20%]) greater LOS compared 
to visits in non-teaching hospitals.  Visits in rural hospitals had 22% (95% CI = [15% to 28%]) 
lower LOS compared to visits in urban hospitals.  Compared to visits in small hospitals, visits in 
medium and large bed hospitals had a 13% (95% CI = [3% to 24%]) and 28% (95% CI = [18% 
to 40%]) greater LOS, respectively.  Compared to visits in hospitals from the western United 
States, visits in hospitals in the northeast had a 22% (95% CI = [11% to 35%]) greater LOS.  
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Table 4.13: Parameter Estimates from LOS Regression Model 
Parameter β SE Exp(β) (95% CI)  Z p-value 
Intercept 0.6769 0.0907 1.97 (1.65 to 2.35) 7.46 < 0.0001 
Opioid Type 
 RxO* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.050 
0.096 
0.046 
 
-- 
0.0512 
0.0399 
0.0248 
 
-- 
1.05 (0.95 to 1.16) 
1.10 (1.02 to 1.19) 
1.05 (1.00 to 1.10) 
 
-- 
0.56 
1.61 
1.87 
 
-- 
0.5777 
0.0162 
0.0609 
Age Group 
 < 18* 
 18 to 34 
 35 to 54 
 55 to 64 
 > 65 
 
-- 
0.060 
0.159 
0.256 
0.297 
 
-- 
0.0670 
0.0662 
0.0690 
0.0718 
 
-- 
1.06 (0.93 to 1.21) 
1.17 (1.03 to 1.34) 
1.29 (1.13 to 1.48) 
1.35 (1.17 to 1.55) 
 
-- 
0.90 
2.40 
3.71 
4.14 
 
-- 
0.3707 
0.0162 
0.0002 
< 0.0001 
Sex 
 Male* 
 Female 
 
-- 
-0.030 
 
-- 
0.0228 
 
-- 
0.97 (0.93 to 1.02) 
 
-- 
-1.3 
 
-- 
0.193 
Race 
 White* 
 Black 
 Hispanic 
 Asian 
 Other Race 
 
-- 
-0.055 
0.026 
-0.114 
-0.050 
 
-- 
0.0513 
0.0482 
0.0813 
0.1080 
 
-- 
0.95 (0.86 to 1.05) 
1.03 (0.93 to 1.13) 
0.89 (0.76 to 1.05) 
0.95 (0.81 to 1.11) 
 
-- 
-1.08 
0.54 
-1.41 
-0.62 
 
-- 
0.2808 
0.5893 
0.1599 
0.5350 
Payer 
 Private* 
 Medicare 
 Medicaid 
 Self-pay 
 No Charge 
 Other 
 
-- 
0.031 
0.051 
-0.141 
0.100 
-0.018 
 
-- 
0.0286 
0.0327 
0.0326 
0.1138 
0.0490 
 
-- 
1.03 (0.98 to 1.09) 
1.05 (0.99 to 1.12) 
0.87 (0.82 to 0.93) 
1.11 (0.88 to 1.38) 
0.98 (0.89 to 1.08) 
 
-- 
1.09 
1.55 
-4.32 
0.88 
-0.37 
 
-- 
0.2754 
0.1222 
< 0.0001 
0.3776 
0.7084 
Teaching Status 
 Non-teaching* 
 Teaching 
 
-- 
0.116 
 
-- 
0.0326 
 
-- 
1.12 (1.05 to 1.20) 
 
-- 
3.56 
 
-- 
0.0004 
Urban/Rural 
 Urban 
 Rural 
 
-- 
-0.247 
 
-- 
0.0419 
 
-- 
0.78 (0.72 to 0.85) 
 
-- 
-5.9 
 
-- 
< 0.0001 
Hospital Bed Size 
 Small bed* 
 Medium bed 
 Large bed 
 
-- 
0.120 
0.252 
 
-- 
0.0473 
0.0432 
 
-- 
1.13 (1.03 to 1.24) 
1.28 (1.18 to 1.40) 
 
-- 
2.54 
5.83 
 
-- 
0.0111 
< 0.0001 
Hospital Ownership 
 Government* 
 Private, non-profit 
 Private, for profit 
 
-- 
-0.046 
0.049 
 
-- 
0.0472 
0.0609 
 
-- 
0.96 (0.87 to 1.05) 
1.05 (0.93 to 1.18) 
 
-- 
-0.97 
0.81 
 
-- 
0.3325 
0.4206 
Hospital Region 
 West* 
 Northeast 
 Midwest 
 South 
 
-- 
0.202 
-0.049 
0.024 
 
-- 
0.0493 
0.0443 
0.0396 
 
-- 
1.22 (1.11 to 1.35) 
0.95 (0.87 to 1.04) 
1.02 (0.95 to 1.11) 
 
-- 
4.09 
-1.10 
0.59 
 
-- 
< 0.0001 
0.5531 
0.7646 
Parameter estimates for Elixhauser comorbidities are found in Appendix C.   
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Table 4.14: Additional Pairwise Comparisons for LOS 
 exp(β) (SE) 95% CI* Wald’s χ2 p-value 
Met vs. Her 1.05 (0.055) 0.92 to 1.19 0.72 0.3959 
Met. vs. Unsp 1.05 (0.042) 0.95 to 1.16 1.40 0.2373 
Her vs. Unsp 1.00 (0.053) 0.88 to 1.14 0.00 0.9532 
Met = methadone; Her = heroin; Unsp = unspecified. Adjusted α = 0.017 
 
 
In-hospital Mortality 
 A total of 11,351 visits were included in this analysis.  Results for the regression are 
found in Table 4.15.  Patients with heroin poisoning had 2.3 times (95% CI = [1.5 to 3.5]) greater 
odds of in-hospital mortality compared to patients with non-methadone opioid analgesic 
poisoning.  Heroin also had 1.8 times (95% CI = [1.12 to 2.95]) greater odds of in-hospital 
mortality than methadone.  Significant differences were not observed between methadone and 
non-methadone opioid analgesics. Compared to prescription opioids, patients with unspecified 
opioid poisoning had a 1.5 (95% CI = [1.2 to 2.0]) times greater odds of death.  Compared to 
heroin, methadone was associated with a 45% (95% CI = [1% to 69%]) lower odds of mortality. 
 Compared to those less than 18 years of age, those in the ‘18 to 34’ and ‘35 to ‘54’ age 
group were 3.0 times greater odds of experiencing in-hospital mortality (95% CI = [1.0, 8.9]).  
Those greater than age 65 had 4.0 times (95% CI = [1.3, 12.8]) greater odds of in-hospital 
mortality compared to those less than 18 years of age.  No differences were observed with 
respect to race when compared to whites.  Females were 22% (95% CI = [1% 39%]) lower odds 
of in-hospital compared with males.  When compared with private payers, patients with 
Medicaid had 1.95 times (95% CI = [1.35 to 2.81]) greater odds of mortality.  When compared to 
small bed sizes, no significant differences were observed with respect to medium and large bed 
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hospitals.  There were also no significant differences between government-owned hospitals and 
privately-owned hospitals.  
4.15: Odds Ratios from Mortality Regression Model 
Parameter OR SE  95% CI χ2 p-value 
Opioid Type 
 RxO* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
2.28 
1.25 
1.53 
 
-- 
0.489 
0.258 
0.213 
 
-- 
1.50 to 3.47 
0.84 to 1.88 
1.16 to 2.01 
 
-- 
14.8 
1.21 
9.23 
 
-- 
0.0151 
0.2722 
0.0024 
Age Group 
 < 18* 
 18 to 34 
 35 to 54 
 55 to 64 
 > 65 
 
-- 
3.03 
3.02 
2.36 
4.01 
 
-- 
1.6668 
1.6633 
1.3427 
2.3721 
 
-- 
1.03 to 8.90 
1.03 to 8.89 
0.77 to 7.20 
1.26 to 12.78 
 
-- 
4.09 
4.04 
2.28 
5.51 
 
-- 
0.0432 
0.0443 
0.1307 
0.0189 
Sex 
 Male* 
 Female 
 
-- 
0.78 
 
-- 
0.0961 
 
-- 
0.61 to 0.99 
 
-- 
4.05 
 
-- 
0.0442 
Race 
 White* 
 Black 
 Hispanic 
 Asian 
 Other Race 
 
-- 
0.71 
0.80 
0.89 
0.66 
 
-- 
0.1748 
0.2048 
0.3265 
0.2281 
 
-- 
0.44 to 1.15 
0.49 to 1.32 
0.44 to 1.83 
0.33 to 1.30 
 
-- 
1.90 
0.75 
0.10 
1.47 
 
-- 
0.1680 
0.3872 
0.7562 
0.2247 
Payer 
 Private* 
 Medicare 
 Medicaid 
 Self-pay 
 No Charge 
 Other 
 
-- 
1.15 
1.95 
1.13 
1.94 
1.34 
 
-- 
0.233 
0.363 
0.239 
0.752 
0.431 
 
-- 
0.77 to 1.71 
1.35 to 2.81 
0.74 to 1.71 
0.91 to 4.15 
0.72 to 2.52 
 
-- 
0.48 
12.78 
0.32 
2.93 
0.86 
 
-- 
0.4873 
0.0003 
0.5733 
0.0869 
0.3551 
Teaching Status 
 Non-teaching* 
 Teaching 
 
-- 
1.18 
 
-- 
0.173 
 
-- 
0.89 to 1.57 
 
-- 
0.59 
 
-- 
0.4437 
Urban/Rural Status 
 Urban* 
 Rural 
 
-- 
0.80 
 
-- 
0.1869 
 
-- 
0.50 to 1.26 
 
-- 
1.31 
 
-- 
0.2520 
Hospital Bed Size 
 Small bed* 
 Medium bed 
 Large bed 
 
-- 
0.94 
1.09 
 
-- 
0.247 
0.271 
 
-- 
0.56 to 1.57 
0.67 to 1.77 
 
-- 
0.06 
0.12 
 
-- 
0.8042 
0.7316 
Hospital Ownership 
 Government* 
 Private, non-profit 
 Private, for profit 
 
-- 
1.12 
1.37 
 
-- 
0.173 
0.297 
 
-- 
0.83 to 1.52 
0.89 to 2.09 
 
-- 
0.59 
2.10 
 
-- 
0.4437 
0.1476 
Hospital Region 
 West* 
 Northeast 
 Midwest 
 South 
 
-- 
0.73 
0.76 
0.97 
 
-- 
0.144 
0.157 
0.153 
 
-- 
0.50 to 1.07 
0.50 to 1.14 
0.71 to 1.32 
 
-- 
2.53 
1.81 
0.03 
 
-- 
0.1115 
0.1779 
0.8561 
Odds ratios for Elixhauser comorbidities are found in Appendix C. 
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Table 4.16: Additional Pairwise Comparisons for Mortality 
 OR (SE) 95% CI Wald’s χ2 p-value 
Met vs. Her 0.55 (0.135) 0.31 to 0.99 5.90 0.0151 
Met. vs. Unsp 0.82 (0.175) 0.49 to 1.37 0.86 0.3545 
Her vs. Unsp 1.49 (0.315) 0.90 to 2.47 3.62 0.0571 
Met = methadone; Her = heroin; Unsp = unspecified. Adjusted α = 0.017 
 
 
Intensity of Resource Utilization 
It was of interest to determine whether or not there was an increase in the intensity of 
resource utilization independent of LOS. To test this hypothesis, LOS was included as 
explanatory variables in the costs model.  If increases in costs were not related to LOS, then this 
would indicate that other sources of increased costs unrelated to LOS exist.  To test this in an 
initial step, LOS was included as an explanatory variable in the model.  Even after controlling for 
LOS, heroin (exp(B) = 1.07, 95% CI = [1.03 to 1.12]), methadone (exp(B) = 1.10, 95% CI = 
[1.06 to1.15]) and unspecified opioids (exp(B) = 1.09, 95% CI = [1.06 to 1.12]) were all 
associated with greater costs compared to prescription opioids.   
The number of procedures was also fitted to the model using a Poisson distribution and a 
log-link, while controlling for length of stay.  Methadone and unspecified opioids were 
associated with a 1.24 times (95% CI = [1.12 to 1.36]) and 1.12 times (95% CI = [1.04 to 1.20]) 
greater number of procedures compared with prescription opioids.  Methadone was also 
associated with a 1.14 times (95% CI = [1.02 to 1.29]) greater number of procedures compared 
with heroin.  This seems to confirm that there are also differences in the intensity of resource 
utilization in terms of number of procedures performed, independent of LOS.   
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Sensitivity Analyses 
Controlling for Other Select Comorbidities 
 Results from the analysis evaluating the differences in the select comorbidities are 
located in Appendix D, Table D.2.  Univariate comparisons of costs, LOS and mortality 
associated with the presence of the comorbidities are displayed in Appendix D, Tables D.3 
through D.5. Appendix D, Table D.6 displays the variables included for each regression model.  
Results from controlling for these select comorbidities are shown in Tables 4.17 through 4.19.  
Table 4.20 displays the adjusted coefficients for opioid type after inclusion of the additional 
comorbidities.  Coefficients did not change substantially from the base case analyses, and were 
largely insensitive to the inclusion of these select comorbidities.  Coefficient estimates for the 
additional select comorbidities are found in Appendix D, Tables D.7, D.8, and D.9.  
Table 4.17: Sensitivity Analysis for Costs, Including Other Select Comorbidities 
Parameter β SE Exp(β) (95% CI)  Z p-value 
Costs 
 Rx Opioid* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.107 
0.193 
0.143 
 
-- 
0.043 
0.041 
0.024 
 
-- 
1.11 (1.02 to 1.21) 
1.21 (1.12 to 1.32) 
1.15 (1.10 to 1.21) 
 
-- 
2.51 
4.68 
5.87 
 
-- 
0.012 
< 0.0001 
< 0.0001 
Only coefficient estimates for opioid type are shown here. Coefficient estimates refer to the 
multiplicative increase in costs for the opioid type compared to prescription opioids (RxO).  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching hospital 
status, hospital size, hospital ownership, hospital region, area wage index (for costs), Elixhauser 
comorbidity indicators and the added covariates.  For coefficient estimates of the added 
comorbidities, see Appendix D, Table D.7. 
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Table 4.18: Sensitivity Analysis for LOS, Including Other Select Comorbidities 
Parameter β SE Exp(β) (95% CI)  Z p-value 
LOS      
 Rx Opioid* 
 Heroin 
 Methadone 
 Unspecified 
-- 
0.0249 
0.1045 
0.0556 
-- 
0.055 
0.040 
0.024 
-- 
1.03 (0.92 to 1.14) 
1.11 (1.03 to 1.20) 
1.06 (1.01 to 1.11) 
-- 
0.46 
2.61 
2.28 
-- 
0.6481 
0.009 
0.0225 
Only coefficient estimates for opioid type are shown here.  Coefficient estimates refer to the 
multiplicative increase in LOS for the opioid type compared to prescription opioids (RxO).  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching hospital 
status, hospital size, hospital ownership, hospital region, area wage index (for costs), Elixhauser 
comorbidity indicators and the added covariates.  For coefficient estimates of the added 
comorbidities, see Appendix D, Table D.8. 
 
Table 4.19: Sensitivity Analysis for Mortality, Including Other Select Comorbidities 
Parameter OR SE  95% CI χ2 p-value 
Opioid Type 
 Rx Opioid* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
2.13 
1.24 
1.49 
 
-- 
0.452 
0.254 
0.207 
 
-- 
1.40 to 3.23 
0.83 to 1.85 
1.14 to 1.96 
 
-- 
12.63 
1.06 
8.32 
 
-- 
0.0004 
0.3036 
0.0039 
Only odds ratios opioid type are shown here compared to prescription opioids.  This regression 
controls for age, race, sex, payer status, hospital rural/urban status, teaching hospital status, 
hospital size, hospital ownership, hospital region, and Elixhauser comorbidity indicators and 
the added covariates.  For coefficient estimates of the added comorbidities, see Appendix D, 
Table D.9. 
 
 
 
Table 4.20 Adjusted Outcomes, Including Other Select Comorbidities 
 Cost LOS Probability of Death 
Heroin 9,033 (8,316 to 9,812) 3.5 (3.2 to 3.9) 1.9% (1.1% to 3.2%) 
Methadone 9,848 (9,127 to 10,625) 3.8 (3.6 to 4.1) 1.1% (0.7% to 1.9%) 
Rx Opioid 8,117 (7,844 to 8,400) 3.4 (3.3 to 3.6) 0.9% (0.6% to 1.4%) 
Unspecified 9,367 (8,910 to 9,848) 3.6 (3.5 to 3.8) 1.3% (0.9% to 2.1%) 
 
Sensitivity Analysis Including Median Income as a Covariate 
 In the first model, median income was not included as a control variable.  Because 
median income can be a proxy for socioeconomic status, it may be an important variable when 
evaluating costs as they relate to the health of the patient.  As median income was missing for 
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various states, it was excluded in the first model to preserve the sample size. Median income by 
ZIP code obtained from the dataset was therefore included as a control variable.  Tables 4.21 
through 4.23 display coefficient estimates for opioid type and median income by ZIP code.  
Table 4.24 displays adjusted outcomes, when incorporating median income.   
Table 4.21: Sensitivity Analysis for Costs, Incorporating Median Income  
Parameter β SE Exp(β) (95% CI)  Z p-value 
Opioid Type 
 Rx Opioid* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.133 
0.206 
0.151 
 
-- 
0.042 
0.042 
0.025 
 
-- 
1.14 (1.05 to 1.24) 
1.23 (1.13 to 1.34) 
1.16 (1.11 to 1.22) 
 
-- 
3.18 
4.85 
6.07 
 
-- 
0.0015 
< 0.0001 
< 0.0001 
Median Income -0.016 0.034 0.98 (0.92 to 1.05) -0.45 0.6525 
Only coefficient estimates for opioid type are shown here.  Coefficient estimates refer to the 
multiplicative increase in costs for the opioid type compared to prescription opioids.  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching hospital 
status, hospital size, hospital ownership, hospital region, area wage index, median income, and 
Elixhauser comorbidity indicators. 
 
 
 
Table 4.22: Sensitivity Analysis for LOS, Incorporating Median Income  
Parameter β SE Exp(β) (95% CI)  Z p-value 
Opioid Type 
 Rx Opioid* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.050 
0.096 
0.046 
 
-- 
0.051 
0.040 
0.025 
 
-- 
1.05 (0.95 to 1.16) 
1.10 (1.02 to 1.19) 
1.05 (1.00 to 1.10) 
 
-- 
0.97 
2.42 
1.87 
 
-- 
0.3338 
0.0156 
0.0617 
Median Income -0.003 0.032 1.00 (0.94 to 1.06) -0.1 0.9226 
Only coefficient estimates for opioid type are shown here.  Coefficient estimates refer to the 
multiplicative increase in LOS for the opioid type compared to prescription opioids.  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching hospital 
status, hospital size, hospital ownership, hospital region, median income, and Elixhauser 
comorbidity indicators. 
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Table 4.23: Sensitivity Analysis for Mortality, Incorporating Median Income 
Parameter OR SE  95% CI χ2 p-value 
Opioid Type 
 Rx Opioid* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
2.28 
1.24 
1.52 
 
-- 
0.489 
0.256 
0.213 
 
-- 
1.50 to 3.47 
0.82 to 1.86 
1.16 to 2.00 
 
-- 
14.8 
1.05 
9.11 
 
-- 
0.0001 
0.3050 
0.0025 
Median Income 0.81 0.140 0.58 to 1.13 1.51 0.2188 
Only odds ratios opioid type are shown here compared to prescription opioids.  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching 
hospital status, hospital size, hospital ownership, hospital region, median income, and 
Elixhauser comorbidity indicators.   
  
 
Table 4.24: Adjusted Outcomes Incorporating Median Income 
 Cost LOS Probability of Death 
Heroin 9,283 (8,565 to 10,061) 3.7 (3.3 to 4.0) 2.1% (1.2% to 3.5%) 
Methodone 9,991 (9,257 to 10,784) 3.8 (3.6 to 4.1) 1.1% (0.7% to 1.9%) 
Rx Opioid 8,131 (7,844 to 8,428) 3.5 (3.4 to 3.6) 0.9% (0.6% to 1.4%) 
Unspecified 9,456 (8,985 to 9,953) 3.6 (3.5 to 3.8) 1.4% (0.9% to 2.1%) 
 
 
Sensitivity Analysis using Poisoning DRGs Only 
 The first model considered all visits that resulted in a primary or secondary diagnosis for 
opioid poisoning.  However, patients may be hospitalized primarily for reasons other than 
poisoning, which may just act as a contributory factor in the disease process or a secondary 
complication unrelated to the reason for hospitalization.  Because of this limitation, the original 
analysis was repeated using visits that resulted in DRG codes 917 and 918, which comprised 
41.7% and 37.3% of all opioid poisoning visits, respectively.  
 After excluding non-opioid poisoning DRGs, the total number included in the sample 
was 10,785.  After excluding suspiciously high LOS (n = 2), the total number of observations 
was 10,783. No observations had a missing LOS. Excluding missing charges (n = 488) and 
suspiciously high charges (n = 3) yielded a total of 10,294.   
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 Mean costs and LOS were less than that than when all opioid poisoning hospitalizations 
were considered in the analysis.  Adjusted mean costs and LOS were less than unadjusted costs.  
These outcomes were also less than that for when all opioid poisoning hospitalizations were 
included.  The adjusted probability of in-hospital mortality could not be calculated due to a low 
number of events per included parameter (240 recorded deaths).  Although the adjusted mean 
costs were lower than estimates obtained when considering all poisoning estimates, the 
coefficients did not substantially change.  
Table 4.25: Sensitivity Analysis for Costs, Excluding Non-Poisoning DRGs  
Parameter β SE Exp(β) (95% CI)  Z p-value 
Costs      
Opioid Type 
 RxO* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.983 
0.191 
0.174 
 
-- 
0.035 
0.040 
0.026 
 
-- 
1.10 (1.03 to 1.18) 
1.21 (1.11 to 1.31) 
1.19 (1.13 to 1.25) 
 
-- 
2.80 
4.82 
6.82 
 
-- 
0.0051 
< 0.0001 
< 0.0001 
Only coefficient estimates for opioid type are shown here.  Coefficient estimates refer to the 
multiplicative increase in costs for the opioid type compared to prescription opioids.  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching 
hospital status, hospital size, hospital ownership, hospital region, area wage index (for 
costs), median income, and Elixhauser comorbidity indicators. 
 
Table 4.26 Sensitivity Analysis for LOS, Excluding Non-Poisoning DRGs 
Parameter β SE Exp(β) (95% CI)  Z p-value 
LOS      
Opioid Type 
 RxO* 
 Heroin 
 Methadone 
 Unspecified 
 
-- 
0.061 
0.132 
0.095 
 
-- 
0.040 
0.036 
0.024 
 
-- 
1.06 (0.98 to 1.15) 
1.14 (1.06 to 1.22) 
1.10 (1.05 to 1.15) 
 
-- 
1.51 
3.67 
3.91 
 
-- 
0.1318 
0.0002 
< 0.0001 
Only coefficient estimates for opioid type are shown here.  Coefficient estimates refer to the 
multiplicative increase in LOS for the opioid type compared to prescription opioids.  This 
regression controls for age, race, sex, payer status, hospital rural/urban status, teaching 
hospital status, hospital size, hospital ownership, hospital region, median income, and 
Elixhauser comorbidity indicators. 
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Table 4.27: Adjusted Outcomes after Excluding Non-Poisoning DRGs  
 Cost LOS Mortality* 
Heroin 7,638 (7,146 to 8,163 3.0 (2.8 to 3.3) -- 
Methodone 8,376 (7,803 to 8,990) 3.3 (3.0 to 3.5) -- 
Rx Opioid 6,922 (6,680 to 7,174) 2.8 (2.7 to 3.0) -- 
Unspecified 8,236 (7,819 to 8,674) 3.1 (3.0 to 3.3) -- 
*Mortality model did not converge due to low number of events per parameter (240 total deaths) 
Only odds ratios opioid type are shown here compared to prescription opioids.  This regression 
controls for age, race, sex, payer status, hospital rural/urban status, teaching hospital status, 
hospital size, hospital ownership, hospital region, and Elixhauser comorbidity indicators.   
 
Section 4.3: Discussion 
 
This study is unique in that no other studies have evaluated differences in cost between 
opioid types in the setting of opioid poisoning.  The prevalence and incidence of prescription 
opioid misuse and abuse and associated poisoning have been increasing each year and is 
associated with significant costs to society (as observed with Specific Aim I).  This helps to shed 
some light on various determinants of increased direct medical costs in the inpatient treatment of 
opioid poisoning. 
Interesting differences between opioid poisoning types were found with respect to patient 
characteristics.  Heroin patients were younger compared to those who overdosed with either 
prescription opioids or methadone.  This confirms findings in the literature, which have shown 
that heroin abusers tend to be younger than those who use or even misuse/abuse prescription 
opioids.  It may also be a reflection of the conditions for which prescription opioids are 
prescribed.  Chronic pain may be a more common occurrence among older adults compared to 
younger adults.   
 Another interesting finding was that a larger percentage of heroin poisoning patients were 
male compared to either prescription opioids or methadone.  This is also consistent with findings 
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in 2010 from the National Survey on Drug Use and Health, which reported a larger percentage of 
males among those reporting drug abuse. 191  Race also differed, with prescription opioids and 
methadone patients more likely to be white compared to heroin patients.  This may reflect 
differences in the type of access to these medications.  Prescription opioids are generally 
accessed through prescriptions written by physicians, although forgery and diversion are 
increasing problems with these agents.  Some of these cases may represent improper use of these 
drugs used to legitimately treat pain.  These reasons may be due to geography (urban vs. rural 
associations) or race-related differences in access to prescription opioids.   
 A larger percentage of heroin patients had Medicaid or “self-pay” as the primary payer.  
This is expected as patients who abuse heroin are likely to come from lower socioeconomic 
backgrounds that may qualify them for Medicaid or render them uninsured.  Conversely, a larger 
percentage of prescription opioid patients had Medicare or private payers compared to heroin 
patients as their primary payers.  Differences in Medicare in part reflect differences in age 
(greater percentage of patients over age 65) and other characteristics that may potentially qualify 
them for Medicare (i.e., disability).  With regards to primary payer status (e.g., Medicaid, private 
insurance, no charge and self/pay), methadone patients interestingly appeared to be more similar 
to heroin poisoning patients. One possibility for this observation is that methadone can be used to 
treat opioid dependence, so some overlap may exist between patients dependent on heroin and 
those that use methadone to treat dependence.  It would appear, however, that the overlap does 
not occur in other characteristics.  In other characteristics such as age, sex, and race, methadone 
patients appeared more similar to those who overdose on prescription opioids.  Though the 
reason for these differences is unclear, it can be postulated that methadone patients come from 
similar socioeconomic backgrounds as heroin patients, but that disparities exist with regards to 
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methadone as a treatment for opioid dependence.  It is important to note that these findings are 
not conclusive, but merit further investigation into characteristics of these users. 
 As expected, older patients were associated with greater mean costs than younger 
patients.  Older age was also associated with greater LOS and in-hospital mortality compared to 
those less than 18 years of age, especially among those greater than age 65.  This is expected as 
older individuals are more frail and may be also be more susceptible to the effects of opioids.  
Differences in pharmacokinetic parameters have been demonstrated among older adults.  For 
example, studies have shown that clearance of oxycodone is delayed with increasing age. 127, 192, 
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Females had lower mean costs than males and were less likely to experience in-hospital 
mortality compared to males.  However, no differences in LOS were found between males and 
females.  Although it was not formally tested with respect to sex, this may indicate that factors 
other than length of stay (i.e., increased resource utilization) are responsible for the differences 
observed with regards to cost.  The finding with mortality is consistent with other findings that 
have found that males are more likely to die from drug poisoning compared to females. 194  
Interestingly, blacks were found to have lower costs than whites. It is not clear why this may be 
the case, though no differences were observed with LOS or in-hospital mortality.  In 2008, it was 
estimated that the age-adjusted rate of drug poisoning deaths per 100,000 population was 14.7 
for whites and 8.5 for blacks. 194  This can be a function of both the frequency of poisoning 
events and the severity of the poisonings.  However, in 2010, the prevalence for substance abuse 
for blacks and whites was estimated to be 8.4% and 8.9%, respectively. 191  As similar differences 
were not found with in-hospital mortality or length of stay, the effect of race on costs is 
inconclusive.  
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Visits with a designation of “self-pay” as the primary payer were associated with lower 
costs and lower length of stay compared to those with private insurance.  Hospitals may be 
pressured to reduce the length of stay for individuals without insurance to reduce the burden of 
costs for the patient and possibly the hospital.  Case management programs at hospitals may 
expedite care and length of stay for the uninsured. 195  However, those with Medicaid had almost 
two times the odds of mortality compared to those with private insurance.  It is possible that this 
population may experience more severe poisonings as the prevalence of drug abuse is higher 
among those with lower socioeconomic status. 191   
Although hospital characteristics and their effects on each of the outcomes are discussed 
here, it should be noted that this study was not specifically designed to evaluate the effect of 
these characteristics at the hospital level since the analysis was weighted at the visit level using 
discharge weights.  Therefore, results for these characteristics are not generalizable to hospitals.   
Teaching status was associated with higher costs and greater LOS.   The findings with respect to 
cost were consistent with other studies. 146, 149 The higher costs may also be reflective of greater 
LOS observed in this study for visits in teaching hospitals.  The effect of teaching hospital status 
on LOS is unclear.  In one regional study in Ohio, for example, it was found that risk-adjusted 
length of stay was lower for teaching hospitals compared to non-teaching hospitals. 196  Another 
study in a pediatric population found that teaching hospitals were associated with greater LOS. 197 
It is possible that teaching hospitals admit more complex patients with greater severity of opioid 
poisoning that necessitates a longer length of stay.  The models did not adjust for poisoning 
severity, and may be why teaching status was associated with greater LOS.   
 Rural hospitals were associated with lower LOS.  This could be a reflection of rural 
hospitals handling less complex cases of opioid poisoning compared to their urban counterparts.  
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Urban hospitals may be located in inner-city areas where lower socioeconomic status might 
confer a lower health status.  Furthermore, rural hospitals do not have the same breadth of 
services that are typically available at urban hospitals, especially for more specialized services.  
Complex cases may require a transfer from rural hospitals to urban hospitals where these 
services can be made available.  This does not explain, however, why differences with costs were 
not observed for rural hospitals compared to urban hospitals despite the observe difference in 
length of stay.  This is inconsistent with the findings that suggest that urban hospitals have higher 
administrative costs per admission than rural hospitals. 145  It is unclear why differences in costs 
were not observed in these categories.   
 Larger hospital bed size was associated with greater LOS, but was not associated with 
increased costs or mortality.  It is unclear why there is a difference in LOS but not costs, as one 
would expect an increase in costs with an increase in LOS.  Larger hospitals are more likely to 
see more complex patients than smaller hospitals, so longer lengths of stay at larger hospitals 
would be expected.  On the other hand, larger hospitals may also be less efficient that smaller 
hospitals. 154-156   
 Differences were observed with costs, LOS, and in-hospital mortality with each of the 
opioid types. As expected, methadone poisoning resulted in higher inpatient costs and LOS and 
poisoning by prescription opioid.  Because of its longer half-life, methadone has the potential to 
cause prolonged symptoms of opioid poisoning.  It was not, however, significantly different in 
costs or LOS compared with heroin.  Of note, methadone was less likely to cause in-hospital 
mortality compared to heroin.  Against expectations, heroin poisoning was associated with 
greater costs and mortality than prescription opioids, even after controlling for comorbidities. 
Although prescription opioids may have greater potencies as a whole, most prescription opioids 
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are ingested orally.  Because heroin is most commonly injected and due to potential differences 
in concentrations in its street drug form, there may be a greater potential for more severe 
poisonings.  No differences in LOS were observed comparing heroin to prescription opioids, 
however.  Unspecified opioids were also associated with greater costs and mortality compared to 
prescription opioids.  This is likely due to these agents being unspecified due to the lack of 
available history among patients with more severe presentations. 
 Several limitations exist with this analysis.  First, beyond methadone poisoning, no 
further distinction was possible between other opioid analgesics.  Opioid analgesics were broken 
down into “confirmed” prescription opioids and those that were unspecified.  Unspecified 
opioids were separated since they can be due to heroin or other unknown opioid.  This was 
somewhat apparent when comparing patient characteristics of those with unspecified opioids to 
either heroin or prescription opioids.  For example, a similar percentage of visits with 
unspecified opioids had Medicaid listed as a primary payer as with heroin visits.  On the other 
hand, some similarities were observed with prescription opioids with respect to race.  
Unspecified opioids seem to be associated with more severe poisonings than prescription 
opioids, as evidenced by increased costs and mortality.  There is the danger of pre-selecting for 
less severe opioids by separating out the unspecified opioids.  However, this can be justified as 
unspecified opioids can either be comprised of heroin or prescription opioid poisoning and 
separating it out can produce a cleaner analysis.  These results should be interpreted with this 
caveat in mind.  Clearer is the distinction with methadone.  Methadone is quite unique in its 
pharmacokinetic parameters compared to other opioid types.  It also plays a unique role in the 
treatment of opioid dependence.  Evaluating the cost of treating methadone poisoning can inform 
policy efforts in directing interventions towards this specific patient population.  
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For simplicity, missing observations were excluded from the analysis.  Additionally, only 
a total of 3.6% of visits had missing charges.  Charges were more frequently missing for heroin 
patients than for either prescription opioids or methadone.  Because of this, multiple imputation 
procedures would be inappropriate when comparing between opioid types because missing 
values can no longer be considered as missing at random, one of the core requirements for 
multiple imputation.  If the distribution of costs for missing observations was different than those 
for non-missing observation, results may be biased.  
To better understand the context under which the slight increase in costs occur with 
methadone, number of procedures was evaluated as an outcome variable while controlling for 
LOS along with the other factors.  However, this analysis did not measure the cost of each of 
these procedures and essentially assumes that procedures are equal in terms of their resource 
utilization.  Nevertheless, increases in the number of procedures are likely to increase costs.  
Survey design variables were not used to adjust the standard errors due to software limitations.  
Although survey design variables were not included the analyses, robust standard errors were 
applied to account for non-independence between observations at each hospital, reducing the 
potential for Type I error.   
In conclusion, differences exist in costs, LOS and in-hospital mortality depending on 
opioid type. Heroin is associated with greater costs and mortality compared to specified 
prescription opioids.  Methadone is associated with greater costs and LOS than specified 
prescription opioids.  Unspecified opioids were associated with greater costs than specified 
prescription opioids, but were not found to be different from methadone or heroin in any other 
pairwise comparison. 
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Chapter V: 
 
Methods, Results and Discussion for Specific Aim III: 
Evaluation of Opioids as Determinants of Hospitalization and Hospitalization Type Among 
Opioid-Related ED Visits 
 
Section 5.1: Methods 
Database 
 The Drug Abuse Warning Network (DAWN) database from 2009 was used for this 
specific aim.  DAWN is a public health surveillance system administered by the Substance 
Abuse and Mental Health Services Administration (SAMHSA) that monitors drug-related visits 
to emergency departments. 160  The target sample for DAWN hospitals are non-Federal, short-
stay, general medical and surgical hospitals across the United States that have at least one 24-
hour ED. 160  Hospitals are sampled using a multistage sampling design from twelve metropolitan 
statistical areas that can be weighted to produce national estimates of drug-related ED visits.  
Data were collected directly from the medical records of patients treated in the ED by trained 
DAWN reporters using a standardized case report form.  Data collected on the form include the 
facility number, date of visit, time of visit, age, home ZIP code, sex, race/ethnicity, case 
description, case type, diagnoses, case dispositions, involved substances (up to 22), route of 
administration, toxicology confirmations, and other general comments. 160  Although all of these 
data are collected, diagnoses, comments, and specific case descriptions are not included in 
available datasets.   
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DAWN visits did not include those where there was no evidence of recent drug use, if the 
patient left the ED without being treated, consumed a nonpharmaceutical substance but did not 
inhale it, history of drug use without recent use, alcohol only among those age 21 years or older, 
if drugs were mentioned in the ED record or identified in the toxicology reports but were not 
related to the ED visits, and if the patient was treated due to undermedication. 160   
DAWN reporters assign each case to one of eight case types.  These case types are 
assigned based an algorithm using a “DAWN Decision Tree”, depicted in Appendix E.  Of note, 
most cases of drug abuse fall in the “other” category due to lack of explicit documentation of 
substance abuse. 160  Furthermore, descriptions of symptoms are not provided, rendering the 
categorization of opioid poisoning difficult.    
Disposition includes three broad categories: treated and released (T&R), admitted to 
same hospital, or other disposition.  T&R visits can be categorized into three subcategories: 
discharged home, released to police/jail, or referred to detoxification/treatment.  Same-hospital 
admissions can be categorized into those admitted to intensive or critical care units (hereby 
referred to as ICU), surgery, chemical dependency/detoxification unit, psychiatric unit, or other 
inpatient units.  Psychiatric and chemical dependency units were combined into one category in 
the available dataset.  Dispositions classified as “other” include those who were transferred, left 
against medical advice, died, “other disposition”, or not documented.   
Sample Selection 
Drugs are coded in DAWN using a modified version of the Multum Lexicon, © 2011 
(Multum Information Services Inc.).  Because this coding system only categorizes legal drugs, it 
was modified in the DAWN dataset to include illegal drugs and other substances not typically 
included in the Multum database. Opioids that were considered were based on the frequency of 
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their appearance in the dataset.  A category called “collapsed” was created for low-frequency 
opioids.  These included opiums, meperidine, oymorphone, and butorphanol.   
 As it is of interest to evaluate ED visits that are likely to be poisoning-related, it is 
important to carefully select the types of cases that are included in the final sample.  Unlike in 
Specific Aim I, it was decided to apply more liberal inclusion criteria for the visits.  Case types 
classified as “seeking detoxification” were excluded since these cases are unlikely to have 
presented with symptoms of poisoning.  However, T&R visits that resulted in a referral for 
detoxification or dependency treatment were retained in the denominator as it is still possible that 
these cases may represent poisoning events after applying the exclusion criterion for case type 
“seeking detoxification”.  Visits were also excluded from the analysis if the disposition was 
missing or undocumented or if the patient died after entering the ED but before being discharged 
or admitted.  For the purposes of the analysis, “transfers” were considered as admissions.   
Statistical Analysis 
 Unweighted and weighted demographic and patient characteristics were described and 
reported.  These included age, sex, race, and case type.  Pearson’s χ2 test was used to compare 
the proportions of admissions within each subcategory for the unweighted analysis.  In the 
weighted analysis, the Rao-Scott χ2 test was used to account for the complex survey design.  
Unweighted and weighted estimates for each of the opioid types were reported for all visits and 
proportions of admitted patients for each opioid type were reported.  Unadjusted logistic 
regression was used to evaluate the likelihood of admission for each opioid, compared to all 
other opioids.  Adjusted logistic regression was used to evaluate the likelihood of admission for 
each opioid, after adjusting for patient characteristics such as age, sex, race, and case type.  Age 
category “< 18” was chosen as the reference group to show possible trends in coefficient 
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estimates with increasing age.  Whites were chosen as the comparison group for race as this 
group represented the most frequently occurring race.  The “other” category was chosen as the 
reference category for case type of most cases of “other” are abuse-related.  This made it 
possible to make the best comparison between abuse-related visits and other types of visits such 
as overmedication and suicide attempts.   
 Unweighted and weighted estimates of each opioid type were estimated by admission 
type among all visits that resulted in a same-hospital admission or transfer.   The categories that 
were evaluated included ICU admissions, surgery, psychiatric/detoxification admissions, “other” 
admissions, and transfers.  Unadjusted and adjusted multinomial logistic regression were 
performed on opioids using “other” admissions as the referent category for the dependent 
variable.  By exclusion, “other” admissions are likely to consist of other general types of 
admission.  Surgery was excluded from the multinomial logistic regression due to small cell 
sizes. Because each opioid was entered in separately, the referent category for each opioid was 
all other opioids (i.e., heroin vs. all other non-heroin opioids).  
 SAS 9.3 was used to conduct the analyses.  PROC SURVEYFREQ and PROC 
SURVEYLOGISTIC were used to conduct the weighted frequency estimates along with the 
binomial and multinomial logistic regression.  An α of 0.05 was used to assess significant of the 
variables that were tested.   
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Section 5.2: Results 
 
Patient Characteristics 
 Unweighted and weighted estimates for patient characteristics and the percentages for 
each that are admitted are found in Table 5.1 and 5.2.  A total of 66,296 visits met the inclusion 
and exclusion criteria, representing a weighted sum of 795,898 for the sample. The largest group 
comprised individuals aged 34 to 54 years (44.1%), followed by those aged 18 to 34 years 
(33.1%), 55 to 64 years (11.7%), greater than 65 years (8.7%) and less than 18 years of age 
(2.5%).  There were more males than females in the sample (53.5% vs. 46.5%).  Whites were the 
most frequently occurring group (55.8%), followed by blacks (17.4%), Hispanics/Latinos 
(11.2%) and other (1.5%).  A significant percent of observations did not have a documentation of 
race (14.1%).  The most frequently occurring case type was for the “other” category (61.6%). 
Adverse reaction, overmedication, and suicide attempt were the next three most commonly 
occurring case types (21.7%, 12.0% and 4.1%, respectively).  The least commonly occurring 
case types were for accidental ingestion and malicious poisoning (0.5% and 0.1%, respectively).   
Significant differences were found with respect to age, race, and case type in both the 
weighted and unweighted analyses.  Differences in weighted estimates are discussed here.  The 
most frequently admitted group was those aged 65 years and older (37.3%) while the least 
frequently admitted group was those between the ages of 18 and 34 years (26.7%).  Whites, 
blacks and “other” races had the highest admission rates (32.5%, 33.2%, and 32.0%, 
respectively) while those identified as Hispanic/Latino or undocumented races had lower 
admission rates (20.8% and 29.7%, respectively).  The most frequently admitted case type was 
for those cases classified as suicide attempt (78.0%), followed by overmedication (48.6%), 
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“other” (28.9%), accidental ingestion (22.8%), and adverse reaction (21.6%).  Weighted 
estimates for malicious poisoning were unable to be estimated due to small unweighted cell sizes 
for that subgroup.   
 
Table 5.1: Unweighted Patient Characteristics for Opioid-Related ED Visits 
 Total (% of sample)* Admitted (% in group)* p-value 
Age Category 
 < 18 
 18 to 34 
 34 to 54 
 55 to 64 
 > 65 
 
1,625 (2.5) 
21,956 (33.1) 
29,224 (44.1) 
7,734 (11.7) 
5,736 (8.7) 
 
513 (31.6) 
6,185 (28.2) 
10,006 (34.2) 
3,078 (39.8) 
2,681 (46.7) 
 
< 0.0001 
(χ2df=4 = 869.32) 
Sex 
 Male 
 Female 
 
35,464 (53.5) 
30,802 (46.5) 
 
12,099 (34.1) 
10,358 (33.6) 
 
0.1851 
(χ2df=1 = 1.76) 
Race 
 White 
 Black 
 Hispanic/Latino 
 Other 
 Undocumented 
 
36,966 (55.8) 
11,557 (17.4) 
7,437 (11.2) 
1,020 (1.5) 
9,316 (14.1) 
 
12,768 (34.5) 
3,978 (34.4) 
2,137 (28.7) 
296 (29.0) 
3,292 (35.3) 
 
< 0.0001 
(χ2df=4 = 116.14) 
Case Type 
 Suicide attempt 
 Adverse reaction 
 Overmedication 
 Malicious poisoning 
 Accidental ingestion 
 Other 
 
2,692 (4.1) 
14,393 (21.7) 
7,945 (12.0) 
65 (0.1) 
346 (0.5) 
40,855 (61.6) 
 
2,065 (76.7) 
3,448 (24.0) 
4,000 (50.4) 
13 (20.0) 
95 (27.5) 
12,850 (31.5) 
 
< 0.0001 
(χ2df=5 = 3,917.24) 
*% of sample represents the unweighted percent of the sample that have the particular 
characteristic (e.g., 2.5% of the entire sample are less than age 18).  % in group represents the 
unweighted percent within each subgroup (e.g., percent admitted within age category less than 
18).. 
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Table 5.2: Weighted Patient Characteristics for Opioid-Related ED Visits* 
 Total (% of sample) Admitted (% in group) p-value 
Age Category 
 < 18 
 18 to 34 
 34 to 54 
 55 to 64 
 > 65 
 
27,159 (3.4) 
286,215 (36.0) 
296,533 (37.3) 
89,972 (11.3) 
95,955 (12.1) 
 
7,764 (28.6) 
76,504 (26.7) 
99,514 (33.6) 
30,040 (33.4) 
35,797 (37.3) 
 
< 0.0001 
(χ2df=4 = 28.28 
Sex 
 Male 
 Female 
 
399,161 (50.2) 
396,640 (49.8) 
 
128,661 (32.2) 
120,940 (30.5) 
0.1583 
(χ2df=1 = 1.99) 
Race 
 White 
 Black 
 Hispanic/Latino 
 Other 
 Undocumented 
 
573,232 (72.0) 
79,950 (10.0) 
66,551 (8.4) 
8,574 (1.1) 
67,591 (8.5) 
 
186,386 (32.5) 
26,538 (33.2) 
13,914 (20.9) 
2,741 (32.0) 
20,078 (29.7) 
 
0.0008 
(χ2df=4 = 19.08) 
Case Type 
 Suicide attempt 
 Adverse reaction 
 Overmedication 
 Malicious poisoning 
 Accidental ingestion 
 Other 
 
34,389 (4.3) 
221,847 (27.9) 
100,520 (12.6) 
1,018 (0.1) 
6,367 (0.8) 
431,758 (54.2) 
 
26,813 (78.0) 
47,980 (21.6) 
48,815 (48.6) 
** 
1,449 (22.8) 
124,565 (28.9) 
 
 
< 0.0001 
(χ2df=5 = 249.17) 
*Numbers may not add up to the total due to missing values 
** Estimates were unable to be computed due to a low unweighted cell size. 
 
Frequencies for Opioids 
 Tables 5.3 and 5.4 provide unweighted and weighted estimates of opioids and the percent 
admitted for each type.  The most frequently reported opioid was for heroin (31.9%), followed 
by oxycodone (19.7%), hydrocodone (18.2%) and methadone (11.5%).  After weighting the 
sample, however, oxycodone was the most frequently reported (27.5%), followed by 
hydrocodone (22.4%), heroin (18.8%), and methadone (9.3%).  Patients with documented 
morphine use had the highest weighted proportion of patients admitted (39.4%), while the lowest 
was for codeine (23.8%).   
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Table 5.3: Unweighted Frequencies for Opioids in Sample 
 Total n (% of sample) Admitted n (% within group) 
Heroin 21,124 (31.9) 7,236 (34.3) 
Hydrocodone 12,066 (18.2) 4,023 (33.3) 
Oxycodone 13,068 (19.7) 4,278 (32.7) 
Methadone 7,623 (11.5) 2,352 (30.9) 
Morphine 3,166 (4.8) 1,310 (41.4) 
Hydromorphone 1,832 (2.8) 633 (34.5) 
Fentanyl 1,852 (2.8) 765 (41.3) 
Codeine 2,297 (3.5) 648 (28.2) 
Buprenorphine 1,200 (1.8) 290 (24.2) 
Propoxyphene 1,133 (1.7) 462 (40.8) 
Opioid, NOS 7,648 (11.5) 3,113 (40.7) 
Collapsed 320 (0.5) 100 (31.3) 
All 66,296 (100.0) 22,471 (31.4) 
 
 
Table 5.4: Weighted Frequencies for Opioids 
 Total n (% of sample) Admitted n (% within group) 
Heroin 149,836 (18.8) 45,005 (30.0) 
Hydrocodone 178,488 (22.4) 54,608 (30.6) 
Oxycodone 218,803 (27.5) 69,782 (31.9) 
Methadone 73,860 (9.3) 25,122 (34.0) 
Morphine 49,368 (6.2) 19,462 (39.4) 
Hydromorphone 25,171 (3.2) 7,536 (29.9) 
Fentanyl 34,679 (4.4) 12,700 (36.6) 
Codeine 29,051 (3.7) 6,914 (23.8) 
Buprenorphine 18,424 (2.3) 4,763 (25.9) 
Propoxyphene 23,109 (2.9) 7,935 (34.3) 
Opioid, NOS 92,084 (11.5) 34,361 (37.3) 
Collapsed 6,998 (0.9) 2,024 (29.9) 
All 795,898 (100.0) 249,656 (31.4) 
 
Determinants of Hospitalization 
 In the unadjusted logistic regression, only visits with hydrocodone, methadone, 
morphine, fentanyl and unspecified opioids were shown to be significantly associated with 
admission to the hospital. Odds ratios and associated 95% confidence intervals for each of the 
opioids are provided in Table 5.5.  Hydrocodone was associated with 1.3 times (95% CI = 1.0 to 
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1.6) greater odds of admission compared to other opioids.  Methadone and fentanyl visits had a 
1.4 times (95% CI = [1.0 to 1.9]) and 1.6 times (95% CI = [1.0 to 2.4]) greater odds of admission 
compared to other opioids, respectively.  Visits involving unspecified opioids were associated 
with 1.8 times (95% CI = [1.3 to 2.4]) greater odds in hospitalization compared to other opioids.  
Table 5.6 displays results of the adjusted logistic regression.  After adjusting for age, sex, 
race and case type, heroin, methadone, morphine, and unspecified opioids were observed to be 
associated with hospital admission.  Visits involving heroin had 1.5 times (95% CI = [1.1 to 2.1]) 
times greater odds of hospital admission compared to other opioids.  Visits involving methadone 
had 1.4 times (95% CI  = [1.0 to 1.9]) greater odds in hospitalization and visits with morphine 
had 1.7 times (95% CI = [1.2 to 2.5]) times greater odds hospital admission compared to other 
opioids.  Visits involving unspecified opioids had 1.9 times (95% CI = [1.5 to 2.5]) greater odds 
of hospital admission compared to other opioids.  After adjusting for other patient characteristics, 
fentanyl was no longer significantly associated with admission.  Compared to those less than 18 
years of age, those aged 18 to 34 years had 29% (95% CI = [8% to 45%]) lower odds of 
admission.  Conversely, those greater than age 65 had 1.9 (95% CI = [1.5 to 2.4]) times greater 
odds of admission compared to those less than 18 years of age.  Males had 1.1 times (95% CI = 
[1.0 to 1.3]) greater odds of admission compared to females.   Compared to whites, those of 
Hispanic or Latino descent had 49% (95% CI = [29% to 64%]) lower odds of admission.  
Compared to those in the “other” case type category, suicide attempts were associated with a 
10.8 (95% CI = [6.0 to 19.3]) times greater odds of admission.  Cases of overmedication were 
associated with a 2.4 times (95% CI = [2.0 to 2.8]) greater odds of admission.  Visits for adverse 
reactions had 38% (95% CI = [26% to 49%] lower odds of admission. 
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Table 5.5 Unadjusted Logistic Regression for Hospitalization 
 OR 95% CI Wald’s χ2 p-value 
Heroin 1.28 0.93 to 1.76 2.25 0.1335 
Hydrocodone 1.28 1.03 to 1.60 4.75 0.0293 
Oxycodone 1.31 0.95 to 1.79 2.73 0.0986 
Methadone 1.40 1.04 to 1.89 5.04 0.0248 
Morphine 1.80 1.29 to 2.51 11.82 0.0006 
Hydromorphone 1.15 0.93 to 1.44 1.65 0.1993 
Fentanyl 1.58 1.03 to 2.43 4.35 0.0371 
Codeine 0.92 0.67 to 1.27 0.25 0.6176 
Buprenorphine 0.97 0.74 to 1.26 0.06 0.8021 
Propoxyphene 1.48 0.65 to 1.88 3.21 0.0730 
Opioid, NOS 1.77 1.30 to 2.41 13.10 0.0003 
Collapsed 1.10 0.65 to 1.88 0.13 0.7204 
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Table 5.6: Adjusted Logistic Regression for Hospitalization 
 OR 95% CI Wald’s χ2 p-value 
Age Category 
 < 18* 
 18 to 34 
 34 to 54 
 55 to 64 
 > 65 
 
-- 
0.71 
0.99 
1.10 
1.85 
 
-- 
0.55 to 0.92 
0.74 to 1.32 
0.82 to 1.48 
1.45 to 2.37 
 
-- 
46.84 
1.57 
0.12 
57.01 
 
-- 
< 0.0001 
0.2105 
0.7301 
< 0.0001 
Sex 
 Female* 
 Male 
 
-- 
1.14 
 
-- 
1.04 to 1.26 
 
-- 
7.30 
 
-- 
0.0069 
Race 
 White* 
 Black 
 Hispanic/Latino 
 Other 
 Undocumented 
 
-- 
1.04 
0.51 
1.04 
0.92 
 
-- 
0.79 to 1.37 
0.36 to 0.71 
0.69 to 1.56 
0.68 to 1.25 
 
-- 
2.36 
21.5 
1.18 
0.12 
 
-- 
0.1244 
< 0.0001 
0.2775 
0.6365 
Case Type 
 Other* 
 Suicide attempt 
 Adverse reaction 
 Overmedication 
 Accidental ingestion 
 Malicious poisoning 
 
-- 
10.81 
0.62 
2.37 
0.81 
0.09 
 
-- 
6.04 to 19.32 
0.51 to 0.74 
2.02 to 2.77 
0.44 to 1.46 
0.03 to 0.25 
 
-- 
64.42 
25.32 
112.77 
0.50 
21.46 
 
-- 
< 0.0001 
< 0.0001 
< 0.0001 
0.4794 
< 0.0001 
Heroin 1.54 1.14 to 2.09 7.84 0.0051 
Hydrocodone 1.13 0.90 to 1.42 1.05 0.3051 
Oxycodone 1.24 0.89 to 1.69 1.70 0.1918 
Methadone 1.41 1.03 to 1.93 4.50 0.0339 
Morphine 1.73 1.18 to 2.53 7.87 0.0050 
Hydromorphone 1.22 0.97 to 1.54 2.76 0.0968 
Fentanyl 1.47 0.87 to 2.48 0.38 0.1499 
Codeine 0.94 0.67 to 1.32 0.13 0.7179 
Buprenorphine 1.10 0.87 to 1.39 0.70 0.4025 
Propoxyphene 1.38 0.86 to 2.21 1.76 0.1840 
Opioid, NOS 1.92 1.47 to 2.49 23.36 < 0.0001 
Collapsed 1.16 0.69 to 1.97 0.32 0.5738 
*Referent category     
 136 
 
Table 5.7: Unweighted Frequencies of Admission Type by Opioid  
 ICU Surgery Psychiatry/Detox Other Admit Transfer 
Heroin (n = 7,236) 508 (7.0) 241 (3.3) 1,604 (22.2) 3,549 (49.1) 1,334 (18.4) 
Hydrocodone (n = 4,023) 593 (14.7) 36 (0.9) 575 (14.3) 2,153 (53.5) 666 (16.6) 
Oxycodone (n = 4,278) 618 (14.5) 20 (0.5) 505 (11.8) 2,426 (56.7) 709 (16.6) 
Methadone (n = 2,352) 380 (16.2) 18 (0.8) 339 (14.4) 1,333 (56.7) 282 (12.0) 
Morphine (n = 1,310) 245 (18.7) 19 (1.5) 76 (5.8) 838 (64.0) 132 (10.1) 
Hydromorphone (n = 633) 90 (14.2) 7 (1.1) 35 (5.5) 443 (70.0) 58 (9.2) 
Fentanyl (n = 765) 135 (17.7) 6 (0.8) 33 (4.3) 535 (69.9) 56 (7.3) 
Codeine (n = 648) 88 (13.6) 8 (1.2) 64 (9.9) 374 (57.7) 114 (17.6) 
Buprenorphine (n = 290) 26 (9.0) 1 (0.3) 51 (17.6) 128 (44.1) 84 (29.0) 
Propoxyphene (n = 462) 85 (18.4) 3 (0.7) 51 (11.0) 252 (54.6) 71 (15.4) 
Opioid, NOS (n = 3,113) 452 (14.5) 28 (0.9) 592 (19.0) 1,523 (48.9) 518 (16.6) 
Collapsed (n = 100) 16 (16.0) 0 (0.0) 11 (11.0) 57 (57.0) 16 (16.0) 
All (n = 22,471) 2,796 (12.4) 368 (1.6) 3,529 (15.7) 12,184 (54.2) 3,594 (16.0) 
 
Table 5.8: Weighted Frequencies of Admission Type by Opioid  
 ICU Surgery Psychiatry/Detox Other Admit Transfer 
Heroin (n = 45,005) 4,625 (10.3) 665 (1.5) 8,305 (18.5) 18,651 (41.4) 12,759 (28.4) 
Hydrocodone (n = 54,608) 14,148 (25.9) 1,406 (2.6) 3,860 (7.1) 26,349 (48.3) 8,846 (16.2) 
Oxycodone (n =69,782) 17,384 (24.9) * 4,132 (5.9) 32,378 (46.4) 15,733 (22.5) 
Methadone (n = 22,471) 7,142 (28.4) * 1,618 (6.4) 10,920 (43.5) 4,981 (3.6) 
Morphine (n = 19,462) 5,705 (19.3) * 363 (1.9) 9,448 (48.5) 3,447 (17.7) 
Hydromorphone (n = 7,536) 1,191 (15.8) * 232 (3.1) 5,050 (67.0) 849 (11.3) 
Fentanyl (n = 12,700) 3,418 (26.9) * 689 (5.4) 7,420 (28.4) 1,060 (8.3) 
Codeine (n = 6,914) 1,304 (18.9) * 148 (2.1) 4,061 (58.7) 1,133 (3.8) 
Buprenorphine (n = 4,763) * * 431 (9.1) 1,524 (32.0) 1,896 (39.8) 
Propoxyphene (n = 7,935) 2,085 (26.3) * 303 (3.8) 3,943 (49.7) 1,596 (20.1) 
Opioid, NOS 8,747 (15.5) * 3,176 (9.2) 14,610 (42.5) 7,758 (22.6) 
Collapsed (n = 2,024) * * * 658 (32.5) * 
All (n = 249,656) 54,287 (21.7) 3,505 (1.4) 20,859 (8.4) 119,647 (47.9) 51,358 (3.9) 
*Weighted estimates not provided due to low unweighted sample sizes. 
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Frequencies for Hospitalization Type 
 Unweighted and weighted cell counts by opioid and admission type for admitted patients 
are provided in Tables 5.7 and 5.8.  The most common admission category for all opioid 
admissions was for “other” admissions (47.9%), followed by ICU admissions (21.7%), 
psychiatric/detoxification admissions (8.4%), transfers (3.9%) and surgery (1.4%).  The highest 
proportion for ICU admissions among all admissions was observed for methadone, hydrocodone, 
oxycodone and fentanyl (28.4%, 25.9%, 24.9% and 26.9%, respectively).  The lowest proportion 
of ICU admissions was observed for unspecified opioids, hydromorphone, codeine, and 
morphine (15.5%, 15.8%, 18.9%, and 19.3%, respectively).  Psychiatric or detoxification 
admissions were highest for morphine (18.5% vs. 9.1% or less for other categories).  The lowest 
proportion of psychiatric admissions was observed for morphine and codeine (1.9% and 2.1%, 
respectively).   Highest proportions for “other” admissions were observed for hydromorphone 
and codeine (67.0% and 58.7%, respectively) while the lowest were for “other” opioids and 
buprenorphine (32.5% and 32.0%, respectively).   Transfers were greatest for buprenorphine 
(39.8%).  This was followed by heroin (28.4%), oxycodone (22.5%), and propoxyphene (20.1%).  
The lowest percentages of transfers were found for methadone (3.6%) and codeine (3.8%).  
 
Determinants of Hospitalization Type among Admitted Patients 
 Results for the unadjusted multinomial logistic regression are in Table 5.9.  The odds 
ratios refer to the odds of being admitted into a particular unit instead of being admitted to 
“other” (i.e., non-psychiatric, non-ICU, non-transfers) units for a particular opioid when 
compared to all other opioids.  Heroin was associated with a 4.45 (95% CI = [2.71 to 7.31]) 
times greater odds of admission to a psychiatric or detoxification unit and 2.80 (95% CI = [1.57 
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to 4.99]) times greater odds of transfer instead of being admitted to “other” units, when 
compared to all other opioids.  Patients with documented hydrocodone, methadone, and 
morphine use had 2.04 (95% CI = [1.45 to 2.88]), 2.23 (95% CI = [1.29 to 3.84]), and 2.03 (95% 
CI = [1.45 to 2.84]) times greater odds of admission to the ICU instead of “other” units, 
respectively.  Patients with in the ED due to morphine, hydromorphone, and codeine use had 
64% (95% CI = [13% to 85%]), 60% (95% CI = [18% to 80%]) and 65% (95% CI = [19% to 
85%]) lower odds of admission to psychiatric or detoxification units instead of other units when 
compared to all other opioids.  Patients in the ED due to buprenorphine had 2.35 (95% CI = 
[1.09 to 5.05]) times greater odds of hospitalization in a psychiatric or detoxification unit instead 
of “other” units, compared to all other opioids.  Visits in which opioids were unable to be 
identified had 2.36 (95% CI = [1.24 to 4.47]) and 2.11 (95% CI = [1.15 to 3.86]) times greater 
odds of hospitalization in the ICU or transferred instead of being admitted in “other” units 
compared to all else.   
 After adjusting for age, sex, race, and case type, fewer significant associations were 
observed with specific opioids (Table 5.10). Heroin patients had 2.20 (95% CI = [1.37 to 3.54]) 
times greater odds of hospitalization in a psychiatric or detoxification unit instead of “other” 
units compared to all other opioids.  Compared with all other opioids, hydrocodone, methadone, 
morphine and fentanyl patients had 1.67 (95% CI = [1.09 to 2.55]), 1.84 (95% CI = [1.10 to 
3.09]), 2.32 (95% CI = [1.63 to 3.32], and 2.12 (95% CI = [1.22 to 3.68]) times greater odds of  
hospitalization in the ICU instead of “other” units, respectively. Oxycodone and morphine 
patients were associated with a 1.54 (95% CI = [1.03 to 2.31]) and 1.71 (95% CI = [1.19 to 
2.45]) times greater odds of transfer than hospitalization in “other” units compared to all other 
opioids.  Compared to all other opioids, codeine patients had 67% (95% CI = [14% to 87%]) 
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lower odds of admission to a psychiatric or detoxification unit instead of “other” units.  Finally, 
patients with unidentified opioid had 1.97 (95% CI = [1.21 to 3.19]) times greater odds of 
hospitalization in the ICU instead of “other” units compared to all other opioids.   
 Older age was associated with a decreased odds of being hospitalized in the ICU instead 
of “other” units.  This association was significant for those aged 34 to 54 years (OR = 0.43, 95% 
CI = [0.21 to 0.88]), 55 to 64 years (OR = 0.35, 95% CI = [0.16 to 0.74]), and greater than 65 
years (OR = 0.27, 95% CI = [0.13 to 0.56) when compared to those less than 18 years of age.  
Similar patterns were noted for transfers, with decreasing odds of transfer with greater age (see 
Table 5.10).  Greater age was also associated with a decreased odds of psychiatric or 
detoxification admissions when comparing those aged 55 to 64 years (OR = 0.31, 95% CI = 
[0.12 to 0.77]) and those greater than 65 years of age (OR =0.07, 95% CI = [0.02 to 0.28]) to 
those less than 18 years of age.  
 No significant associations were observed for sex.  Compared to whites, blacks had 46% 
(95% CI = [2% to 71%]) lower odds of transfer instead of admission to “other” units.  No other 
significant associations were observed for race.  Compared to case types classified as “other”, 
suicide attempt cases were significantly associated with greater odds of an ICU admission (OR = 
3.06, 95% CI = [1.65 to 5.67]), psychiatric/detoxification admission (OR = 2.81, 95% CI = [1.35 
to 5.86]) or a transfer (OR = 3.13, 95% CI = [2.07 to 4.74]) instead of hospitalization in “other” 
units.  Conversely, cases classified as “adverse reactions” were associated with lower of 
admission into these three categories (OR = 0.39, 95% CI = [0.22 to 0.69]; OR = 0.07, 95% CI = 
[0.03 to 0.14]; OR = 0.19 (95% CI = [0.11 to 0.34]).   
 
 
 140 
Table 5.9: Unadjusted Multinomial Logistic Regression for Hospitalization Type 
 OR (Reference = “Other Admission”) 
 ICU Psychiatry/Detox Transfer 
Heroin 0.98 (0.68 to 1.43) 4.45 (2.71 to 7.31) 2.80 (1.57 to 4.99) 
Hydrocodone 2.04 (1.45 to 2.88) 1.48 (0.80 to 2.76) 1.32 (0.90 to 1.95) 
Oxycodone 1.88 (0.78 to 4.56) 1.21 (0.74 to 1.96) 1.91 (1.20 to 3.04) 
Methadone 2.23 (1.29 to 3.84) 1.23 (0.51 to 2.95) 1.55 (0.94 to 2.53) 
Morphine 2.03 (1.45 to 2.84) 0.36 (0.15 to 0.87) 1.34 (0.86 to 2.09) 
Hydromorphone 0.72 (0.39 to 1.33) 0.40 (0.20 to 0.82) 0.57 (0.30 to 1.17) 
Fentanyl 1.42 (0.87 to 2.31) 0.90 (0.36 to 2.23) 0.47 (0.19 to 1.18) 
Codeine 1.16 (0.69 to 1.97) 0.35 (0.15 to 0.81) 1.12 (0.63 to 2.00) 
Buprenorphine 2.03 (0.93 to 4.42) 2.35 (1.09 to 5.05) 4.36 (1.51 to 12.64) 
Propoxyphene 1.80 (0.83 to 3.89) 0.73 (0.24 to 2.20) 1.53 (0.99 to 2.37) 
Opioid, NOS 2.36 (1.24 to 4.47) 2.12 (0.98 to 4.59) 2.11 (1.15 to 3.86 
Collapsed 2.95 (0.60 to 14.45) 3.62 (0.41 to 32.4) 3.0 (0.89 to 10.1) 
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Table 5.10: Adjusted Multinomial Logistic Regression for Hospitalization Type 
 OR (Reference = “Other Admission”) 
 ICU Psychiatry/Detox Transfer 
Age Category 
 < 18 
 18 to 34 
 34 to 54 
 55 to 64 
 > 65 
 
-- 
0.43 (0.17 to 1.08) 
0.43 (0.21 to 0.88) 
0.35 (0.16 to 0.74) 
0.27 (0.13 to 0.56) 
 
-- 
0.68 (0.24 to 1.93) 
0.55 (0.23 to 1.32) 
0.31 (0.12 to 0.77) 
0.07 (0.02 to 0.28) 
 
-- 
0.37 (0.11 to 1.31) 
0.27 (0.09 to 0.82) 
0.12 (0.04 to 0.33) 
0.11 (0.03 to 0.43) 
Sex 
 Female 
 Male 
 
-- 
1.17 (0.89 to 1.54) 
 
-- 
0.82 (0.59 to 1.14) 
 
-- 
1.02 (0.78 to 1.34) 
Race 
 White 
 Black 
 Hispanic/Latino 
 Other 
 Undocumented 
 
-- 
0.62 (0.33 to 1.16) 
0.67 (0.35 to 1.30) 
0.63 (0.18 to 2.15) 
0.83 (0.40 to 1.74) 
 
-- 
1.15 (0.70 to 1.91) 
1.21 (0.57 to 2.57) 
0.68 (0.18 to 2.50) 
1.44 (0.77 to 2.70) 
 
-- 
0.54 (0.29 to 0.98) 
0.89 (0.35 to 2.22) 
1.18 (0.48 to 2.91) 
0.37 (0.15 to 0.95) 
Case Type 
 Other 
 Suicide attempt 
 Adverse reaction 
 Overmedication 
 Malicious poisoning 
 Accidental ingestion 
 
-- 
3.06 (1.65 to 5.67) 
0.39 (0.22 to 0.69) 
1.45 (0.90 to 2.34) 
0.46 (0.09 to 2.46) 
0.21 (0.03 to 1.58) 
 
-- 
2.81 (1.35 to 5.86) 
0.07 (0.03 to 0.14) 
0.68 (0.44 to 1.06) 
0.52 (0.06 to 4.54) 
** 
 
-- 
3.13 (2.07 to 4.74) 
0.19 (0.11 to 0.34) 
0.68 (0.44 to 1.06) 
0.60 (0.11 to 3.30) 
1.18 (0.34 to 4.07) 
Heroin 0.82 (0.57 to 1.17) 2.20 (1.37 to 3.54) 1.62 (0.90 to 2.93) 
Hydrocodone 1.67 (1.09 to 2.55) 1.25 (0.60 to 2.61) 1.06 (0.63 to 1.79) 
Oxycodone 1.65 (0.72 to 3.77) 1.09 (0.70 to 1.70) 1.54 (1.03 to 2.31) 
Methadone 1.84 (1.10 to 3.09) 0.97 (0.46 to 2.04) 1.17 (0.69 to 1.98) 
Morphine 2.32 (1.63 to 3.32) 0.50 (0.20 to 1.24) 1.71 (1.19 to 2.45) 
Hydromorphone 0.83 (0.43 to 1.62) 0.53 (0.24 to 1.15) 0.73 (0.37 to 1.14) 
Fentanyl 2.12 (1.22 to 3.68) 2.06 (0.81 to 5.25) 0.88 (0.35 to 2.17) 
Codeine 1.09 (0.58 to 2.04) 0.33 (0.13 to 0.86) 1.11 (0.58 to 2.15) 
Buprenorphine 1.54 (0.64 to 3.71) 1.79 (0.87 to 3.70) 2.33 (0.75 to 7.25) 
Propoxyphene 1.81 (0.72 to 4.57) 0.75 (0.21 to 2.77) 1.59 (0.94 to 2.68) 
Opioid, NOS 1.97 (1.21 to 3.19) 1.32 (0.68 to 2.58) 1.40 (0.87 to 2.25) 
Collapsed 3.65 (0.71 to 18.84) 5.37 (0.78 to 36.84) 4.16 (1.10 to 15.78) 
** Estimate was omitted due to a cell size of 0 
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Section 5.3: Discussion 
 This study is the first of its kind to evaluate the relationship between specific opioids and 
admission to a hospital from the emergency department.  In addition, it provides further 
explanation into factors related to increased costs, as hospitalization is an especially costly 
component of medical care.  Beyond just looking at hospitalization, this study is further 
strengthened by examining the nature of hospitalization and factors associated with 
hospitalization type. 
  Determinants of Hospitalization 
In this analysis, it was shown that heroin, methadone, morphine and unidentified opioids 
were associated with a significantly increased odds of admission compared to other opioids even 
after adjusting for patient characteristics and case type.  Heroin is a drug of abuse that is 
frequently injected and which does not come in standard formulations, raising the risk for 
unintended overdoses that may be more severe.  Methadone is a longer acting agent with unique 
pharmacokinetics that can more easily result in more severe presentations.  It was also not 
surprising to find that visits in which opioids could not be specifically identified were more 
likely to result in hospitalization.  These cases may be those where patients present more 
severely and are unable to give a verbal account of the offending opioid.   
Somewhat surprisingly, morphine was associated with greater odds of hospitalization 
compared to all other opioids as morphine is considered to be less potent than other opioid 
analgesics.  It was suspected that morphine might be injected more often compared to other 
opioids.  The route of administration was compared between morphine and all other opioid 
analgesic types.  Morphine was injected in 6.4% of cases in the sample compared to 2.7% for all 
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other opioid analgesics.  Whether or not this indeed contributed to the higher odds of 
hospitalization for these patients was not formally tested.  Nonetheless, it may provide a clue for 
why morphine patients were more likely to be hospitalized.   
Age- and sex-related differences in hospitalization were also interesting.  Compared to 
those younger than 18 years of age, those aged 18 to 34 years had lower odds of admission, all 
else constant.  This may be due to differences in the severity of presentations or may be due to 
the need to hospitalize minors for other social-related reasons.   As expected, those greater than 
65 years of age had greater odds of hospitalization than those less than 18 years of age.  Older 
age can render the effects of opioids and other drugs less predictable and may need closer 
monitoring to ensure the patients’ safety.  Males were associated with greater odds of 
hospitalization than with females.  Males have been shown to have higher mortality compared to 
females among patients that present to the ED due to nonmedical use of opioids despite 
comparable ED use. 130  This suggests that males may use these agents in a riskier manner 
compared to females.   
No differences were found with respect to race, except for Hispanics/Latinos, who had 
lower odds of hospitalization compared to whites.  The reason for this is unclear.   Clinically, 
race or ethnicity is unlikely to be a reason for deciding to admit patients.  The difference found 
with respect to Hispanics or Latinos is more likely due to unobserved confounders, such as 
insurance status.  In 2009, approximately 32% of Hispanics were uninsured compared to 12% of 
non-Hispanic whites. 198  Providers in the ED may be less willing to admit patients without 
insurance due to the high costs of hospitalization.  Therefore, they may try to manage patients 
with less severe presentations on an outpatient basis instead of admitting them.  
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 Cases of suicide attempt had the greatest odds of admission compared to the “other” 
category.  Patients with suicidal ideation who have attempted suicide represent higher risk 
patients that need to be closely monitored and treated with psychiatric care.  Furthermore, it is 
possible that patients who intentionally overdose may consume more of the drug than medically 
appropriate or even more than amounts used for abuse. It is therefore unsurprising that these 
types of patients have the highest likelihood of admission.  Cases of overmedication were also 
more likely to result in admission compared to case types of “other”.  Cases of overmedication 
are invariably cases where agents prescribed for the individual were taken in greater amounts 
than medically appropriate, whereas cases in the “other” category are more heterogeneous (some 
may present due to withdrawal, others due to abuse-related behaviors, and others for toxicity).  
This is an important finding, especially when one considers that this is in comparison to those in 
the “other” case type category (most of which are abuse-related).  Patients that overdose on their 
own medications that were prescribed to them had greater odds of hospitalization compared to 
abusers (“other” category).  
Determinants of Hospitalization Type among Admitted Patients 
 A few interesting results were found when evaluating hospital type.  In the adjusted 
analysis, hydrocodone, methadone, morphine, and fentanyl all had greater odds of ICU 
admission than having an “other” admission, compared to all other opioids, all other things 
constant.  Heroin was not associated with ICU disposition, and is at odds with results from 
Specific Aim II, which showed greater costs for heroin compared to prescription opioids.  This 
may be due to differences in the sample, as this sample may contain individuals who do not 
present for poisoning.  Additionally, if those with ICD-9-CM diagnoses for poisoning are 
systematically different from those without, then this may explain some of the differences in 
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findings.  Methadone and morphine were associated with greater odds of being hospitalized in 
the ICU.  These results are consistent with the previous findings that showed that both are 
associated with increased odds of hospitalization and with the discussion that they may be related 
to the severity of presentation. The finding for methadone is also consistent with findings from 
Specific Aim II, in which it was found that methadone was associated with greater costs and 
LOS. Fentanyl was not shown to be a predictor of hospitalization in the analysis evaluating the 
probability of admission, but among those that were admitted, fentanyl patients had greater odds 
of ICU admission instead of an “other” admission, compared to all other opioids.  This indicates 
that among opioid-related ED visits that merit admission to a hospital, fentanyl patients have a 
more severe presentation.  This is consistent with its pharmacological properties, as it is the most 
potent opioid analgesic with long acting formulations that can increase the risk of a severe 
overdose.  It was interesting to find that among all patients admitted for opioid use, hydrocodone 
patients had greater odds of hospitalization in the ICU than in “other” units.  The results for this 
are unclear as oxycodone is a similarly used agent that is considered to be more potent than 
hydrocodone.  Given the lack of face validity of this finding, the interpretability is limited.  
Finally, unspecified opioids (i.e., opioids NOS) were associated with greater odds of ICU 
admission instead of admission to “other” units.  This is likely because those these patients 
represent those who are unable to give a history of their drug use due to severe presentations. 
 Increasing age was associated with decreased odds of hospitalization in the ICU vs. 
“other” units.  This is in contrast to the previous findings, which found those greater than 65 had 
the highest odds of hospitalization. Though these patients are at a higher risk of hospitalization, 
they had lower odds of hospitalization in an ICU unit among all admitted patients than younger 
individuals.  While this may seem counterintuitive, it indicates that older individuals have a 
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lower threshold in the severity of presentation required for hospitalization.  Patients admitted for 
suicide had greater odds of ICU admission vs. “other” admission compared to patients with a 
case type of “other”.  Cases of suicide are likely to represent more severe presentations that 
require closer monitoring.  In contrast, patients that visited the ED due to an “adverse reaction” 
had the lowest odds of ICU admission vs. “other” admission.  This seems to indicate that those 
classified as having adverse reactions experience mild symptoms that are less likely to merit 
close monitoring.  
 Heroin patients had greater odds of hospitalization in a psychiatric or detoxification unit 
instead of “other “ units compared to all other opioids.  It is important to remember that not all 
cases of prescription opioid analgesic related ED-visits are necessarily due to abuse.  Conversely, 
all heroin patients would be considered as abusers as heroin is an illicit drug with no approved 
medical uses.  Thus, it would be expected that these patients would be more likely to be 
hospitalized in detoxification or chemical dependency units compared with prescription opioids.  
Relative to “other” admissions, codeine was shown to be less likely to result in a 
psychiatric/detoxification admission compared to all other opioids.  This finding is consistent 
with the pharmacological properties of the drug as codeine is a weak opioid that has a lower 
potential for abuse.   
 A similar pattern as was seen with the ICU units was observed with respect to age and 
admission to a psychiatric or detoxification clinic.  Increased age was associated with decreased 
odds of admission into these units, compared to “other” units.  This indicates that older 
individuals are more likely to be hospitalized in these “other” units for more general reasons in 
order to monitor their care.  In 2009, it was reported that illicit drug use was highest for those 
aged 18-20 (22.2%) and lowest for those aged 65 years and older (0.9%).191  As older individuals 
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are less likely to engage in drug abuse compared to younger individuals, they are thus are less 
likely to need psychiatric/detoxification care. Similar to findings with the ICU admissions, cases 
of suicide were associated with greater odds of admission to a psychiatric or detoxification unit 
and adverse reactions were associated with lower odds when compared to the “other” case type 
category (i.e., abusers).  Clearly, attempts at suicide would result in an increased need for 
psychiatric observation over an admission into “other” units.  Adverse reactions, by definition, 
were those that resulted from normally approved uses of the drug.  These cases are therefore less 
likely to be cases of abuse that require psychiatric or chemical dependency care.  
 The significance of transfers is unclear.  It was assumed that a transfer meant that the 
patient would get transferred from the ED to an inpatient unit elsewhere.  Transfers may occur 
because of the lack of beds in a particular hospital or quite possibly for the lack of services 
needed to treat the patient for the given condition.  For example, some hospitals may be ill 
equipped to handle providing care related to detoxification or chemical dependency.  Others may 
not be able to handle severe cases that require close monitoring in the ICU.  Whatever the case 
may be, this category is likely to represent complex patients that likely require specialized care 
elsewhere.   
 Oxycodone and methadone were both associated with a greater odds of transfer compared 
to other opioids instead of being admitted to the same hospital in an “other” unit.  Reasons for 
this are also unclear.  If transfers represented those with greater complexity of care, one might 
expect similar findings for transfers as was found in either the ICU or psychiatric/detoxification 
units.  However, there was no clear congruence with either the ICU admissions or 
psychiatric/detoxification admissions. Interpretability of these findings is limited as there does 
not seem to be a plausible explanation for these findings.   
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Older age was also associated with decreased odds of transfer, similar to patterns noted 
for ICU admissions or psychiatric and detoxification units. This reinforces the suspicion that 
older individuals are more likely to be hospitalized for general reasons rather than for specific 
needs (e.g., ICU or psychiatric/detoxification units).  The only race-related association found to 
be significant in the adjusted regression was for blacks compared to whites.  Blacks had lower 
odds of transfer compared to whites.  This finding may be a spurious association as plausible 
explanations are difficult to gather and the confidence interval approaches one.  Suicide attempts 
and adverse reactions were found to have similar directions of effect for transfers as was seen 
with ICU and psychiatric or detoxification admissions.  This would be expected as suicide 
attempts represent more complex cases while adverse reactions represent less complex cases. 
Limitations 
 This study carries several limitations.  First, this was an exploratory, cross-sectional study 
with multiple comparisons across different variables.  The level of significance was not adjusted 
to account for this multiplicity, increasing the chance for Type I error for any given variable.  
Because this was an exploratory study intended to generate hypotheses, it was chosen to leave 
the significance level unadjusted.  
 Second, descriptions of symptoms were not available in the dataset.  This made it 
impossible to determine whether cases were due to poisoning or due to other reasons.  In 
Specific Aim I, different combinations of case definitions were used to define likely cases of 
poisoning.  The base case scenario assumed a more conservative definition, excluding those who 
were referred or admitted to detoxification clinics or units.  In this aim, a more liberal approach 
was used to capture all potential cases of poisoning.  For example, all cases were used despite 
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being admitted to psychiatric and detoxification units.   In addition, cases of adverse reactions 
were included.  This was done since the presentation of poisoning does not preclude one from 
being admitted or referred to detoxification or chemical dependency clinics or units.  Depending 
on the opioid in question, opioid poisoning can be rapidly reversed.  In addition, naloxone may 
induce withdrawal symptoms necessitating detoxification treatment.  The only explicit restriction 
imposed with regards to case type was for those that were actively seeking detoxification, in 
which case were unlikely to represent true poisoning cases.  Adverse reactions were included as 
symptoms of poisoning may occur despite appropriate use of the drug.  However, one should 
note that adverse reactions may also include other symptoms such as hypersensitivity reactions 
or chronic side effects of the opioids such as constipation.   
 Third, diagnoses were unavailable.  Diagnoses would have been helpful to better classify 
cases based upon their symptoms.  It would also help to adjust for comorbidities that may act as 
confounders to the outcome.  Although reporting diagnoses would be helpful analytically, the 
inclusion of such would also be limited regardless.  Recording of comorbidities and other 
diagnoses would not be as robust or complete as in an inpatient setting.  Thus, it was difficult to 
adjust for comorbidities in ED settings where data were retrospectively obtained. 
 Fourth, payer information was not collected.  Providers may be less willing to admit a 
patient who does not have insurance to avoid incurring high costs.  For these patients, outpatient 
management would result in a decreased financial burden for the patient and for the hospital.  
This was one potential explanation for why Hispanics were shown to be less likely to be 
hospitalized compared to whites.  This was unable to be assessed due to the lack of availability 
of insurance information. 
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 Fifth, many patients fell into the case type category of “other”.  This was because 
information collected in the chart reviews were often lacking in terms of the details for the 
context in which these events occurred.  Because of this, many types of patients are included in 
the “other” category, which may include patients with withdrawal symptoms as well as those 
with intoxication.  It was therefore not possible to separate cases of intoxication from those with 
other symptoms unrelated to poisoning.   
 Finally, patients hospitalized to a unit with combined psychiatric and detoxification units 
were classified as “other” admissions as well.  Those hospitalized to either psychiatric or 
detoxification units that were separated were classified as a “psychiatric/detoxification” unit.  
Because of this limitation, the effect of being admitted to a psychiatric or detoxification unit may 
be understated since “other” was the referent group. 
 In conclusion, hospitalization was found to depend on specific opioids, even after 
adjusting for various patient characteristics.  Heroin, methadone, and morphine were associated 
with greater odds for hospitalization. Among admitted patients, morphine, fentanyl and 
methadone were associated with the greatest odds of ICU admission.  Heroin was found to be 
positively associated with psychiatric/detoxification admissions, while codeine was negatively 
associated with psychiatric admissions.  
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Chapter VI: 
 
Summary & Conclusions 
 
 Opioid poisoning is an important public health problem that has increased significantly in 
the past decade.  Naloxone prescription programs have been initiated across the country to better 
address this issue and to prevent and reverse opioid poisoning and related mortality.  Although 
previous studies have attempted to quantify the economic burden associated with opioid abuse, 
none have focused on opioid poisoning.  The first aim of this dissertation focused on quantifying 
the economic burden of opioid poisoning in terms of direct and indirect costs to society.  It is 
estimated to cost society $20.4 billion annually, most of which is related to mortality costs.  
Approximately $2.2 billion dollars of this estimate are due to direct costs, incorporating 
ambulance costs, emergency department costs, naloxone prescription costs, and inpatient costs.   
The greatest mortality costs were for methadone, followed by oxycodone and hydrocodone.  The 
greatest economic impacts can be realized through the prevention of opioid poisoning mortality.   
 In addition to quantifying the economic burden of opioid poisoning, it is also important to  
dig deeper to understand the relationship with different characteristics with increased costs in 
this population.  The second aim of this study focused on evaluating the relationship between 
opioid type and costs, length of stay, and in-hospital mortality.  Heroin, methadone and 
“unspecified” opioids were associated with the greatest costs compared to prescription opioids.  
An effect was also seen with length of stay, with methadone associated with a greater length of 
stay compared to prescription opioids.  Patients with heroin or unspecified poisoning were most 
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likely to die in-hospital from opioid poisoning, though patients with methadone poisoning were 
no more likely to experience in-hospital mortality compared to heroin or prescription opioids.  
 The third aim of this study evaluated specific opioids and their propensity to result in 
hospitalization.  It also looked beyond just hospitalization and evaluates differences in the types 
of admission among admitted patients.  This is important as the type of hospitalization can have 
implications for cost (i.e., ICU care associated with greater costs).  It can also shed light on the 
types of issues that are being addressed among patients in the hospital.  Patients in the ED due to 
heroin, methadone, morphine, and unspecified opioids were more likely to result in 
hospitalization.  Among those that were hospitalized, visits involving heroin, methadone, 
morphine and unspecified opioids had greater odds of hospitalization in the ICU, while heroin 
was more likely to result in a psychiatric or detoxification admission.  The effect of age was 
interesting, with greater odds of hospitalization with increasing age, but lower odds of ICU 
admission versus “other” admissions with increasing age, indicating that there are more 
“precautionary” admissions for older adults.   Cases of “overmedication” (i.e., those who took 
more of their own prescribed medication) were more likely to be hospitalized compared to cases 
of “other.”  
 In each of these analyses, there were recurring themes.  One is the potential high cost of 
methadone poisoning relative to other types of opioid poisoning.  Methadone is implicated in the 
largest share of mortality costs relative to other prescription opioids.  It is a predictor of 
hospitalization, ICU admission, greater hospitalization costs, and greater length of stay.  Age was 
a predictor of hospitalization and was associated with greater hospital costs, length of stay, and 
in-hospital mortality.  Male gender was associated with increased costs and LOS and a greater 
odds of hospitalization and in-hospital mortality.   
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 The information produced from these results can help to provide a rationale for funding 
interventions designed to prevent or reverse opioid poisoning.  Given the high costs associated 
with methadone-related mortality and the increased costs associated with methadone in the 
hospital setting, it makes sense to target this population.  Heroin-dependent individuals are 
commonly treated for their dependence in methadone clinics, but use of methadone is especially 
risky.  Although the risk associated with methadone is well known, these findings confirm the 
risk associated with the use of methadone.  This should not discount, however, the potential 
benefit for such interventions to also target those at high risk of prescription opioid abuse with 
other opioids.    
Future research should evaluate those in the “at-risk” population to evaluate types of 
patients most likely to experience a poisoning event.  The research in this dissertation evaluates 
predictors of increased costs once a poisoning event has occurred, but does not evaluate the 
likelihood of experiencing opioid poisoning in a cohort of prescription opioid misusers and 
abusers.  Evaluating the likelihood of experiencing opioid poisoning among those who are at risk 
of poisoning should further aid in identifying specific populations on which to focus intervention 
efforts. 
More efforts need to be realized to fully characterize true opioid poisoning.  Neither 
DAWN nor HCUP provided the ideal data needed to identify patients with opioid intoxication.  
Work should focus on assessing the sensitivity and specificity of available ICD-9-CM codes 
and/or specifically characterizing drug-related ED visits in DAWN depending on symptoms or 
diagnoses.   
Finally, evaluation of the costs associated with the provision of naloxone prescription 
intervention efforts should be performed.  Assessing the costs of providing such programs 
 154 
against the costs of opioid poisoning can help in determining the value of these programs.   Costs 
should incorporate those related to naloxone, education, medical and administrative personnel, 
facility costs, and other costs related to the provision of these services. 
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Appendix A 
Costs per Event Calculation*: 
Direct Cost per Event: 
                     
   
            
         
   
            
 
                 
       
            
  
Indirect Cost per Event: 
                  
 
  
 
  
  
  
  
   
            
 
  
 
  
  
  
  
   
 
        
 
   
 
  
  
  
  
   
  
Total Cost per Event: 
                        
 
      = mean estimated treatment cost for ED treat-and-release visits 
       = mean estimated ED physician reimbursement 
      = mean estimated treatment cost for inpatient discharges 
       = mean cost for ambulance transport 
         = mean absenteeism cost for ED treat-and-release visits 
         = mean absenteeism cost for inpatient discharges 
      = mean mortality cost 
     = prevalence of ED treat-and-release visits 
     = prevalence of inpatient discharges 
      = prevalence of mortality 
       = percent transported by ambulance 
 
*To avoid double counting events in the ED and inpatient setting that resulted in death, the 
weighted number of deaths obtained through DAWN was subtracted from the total sum of all 
events (i.e., denominator) for heroin (n = 683) and prescription opioids (n = 1,682) and all 
opioids (n = 2,365). 
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Appendix B 
As a limitation, NEDS does not provide the same categories of hospital characteristics as 
reported in this report.   The classifications provided in NEDS and the urban/rural classification 
are provided in Table B.2.  Hospital control is defined in NEDS as 1) government or private, 
collapsed category, 2) private, non-profit, voluntary, 3) private, invest-own, 4) private, collapsed 
category.  Because bed size was not available in the NEDS dataset, this attribute could not be 
considered when assigning CCRs.  As HCUP does not provide the equivalent distinct 
classifications as reported, certain CCRs had to be combined and weighted based on the reported 
sample sizes. For example, to assign a CCR to the rural/government category in NEDS, the 
sample sizes in the report for “rural, low volume, government” and “rural, non-low volume, 
government” were used to estimate a combined weighted CCR for “rural, government”.  Using 
the provided numbers this is calculated as the following: 
  
       
       
  
       
             
 The same basic procedures were used to calculate weighted CCRs in accordance with the 
classifications provided by HCUP.  The final CCRs used to convert charges to costs are provided 
in Table B.3. 
Table B.1:  2003 ED Cost-to-Charge Ratios (CCRs) Provided by HCUP 
 
n Weighted mean CCR 
Rural, Low volume, Gov’t 41 0.570 
Rural, low volume, PNFP or Prof 33 0.571 
Rural, non-low volume, Gov't 70 0.527 
Rural, non-low volume, PNFP 110 0.529 
Rural, non-low volume, Profit 42 0.361 
Urban, Gov't 30 0.457 
Urban, PFNP 185 0.552 
Urban, Profit 46 0.395 
All 556 0.514 
PNFP = private, not for profit; Gov’t = government; Prof = for profit 
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Appendix B, continued 
Table B.2: HCUP NEDS Classifications of Urban/Rural Status 
HCUP Classifications Urban/rural 
classification 
1) Large metropolitan areas with at least 1 
million residents 
Urban 
2) Small metropolitan areas with less than 1 
million residents 
Urban 
3) Micropolitan areas Urban 
4) Not metropolitan or micropolitan Rural 
5) Metropolitan, collapsed category of large and 
small metropolitan 
Urban 
6) Non-metropolitan, collapsed category of 
micropolitan and rural 
Rural 
Urban/rural classification based on U.S. Census Definitions199 
 
Table B.3: Calculated ED CCRs 
 
CCR 
Rural, gov't or private (collapsed) 0.515 
Rural, Gov't 0.543 
Rural, PNFP 0.537 
Rural, For profit 0.385 
Rural, private collapsed 0.498 
Urban, gov't or private 
(collapsed) 0.513 
Urban, Gov't 0.457 
Urban, PNFP 0.552 
Urban, Prof 0.395 
Urban, private collapsed 0.521 
PNFP  = private, no for profit,  
Gov’t = government 
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Appendix C 
 
Table C.1: Parameter Estimates for Elixhauser Comorbidities in Costs Model 
Parameter β SE Exp(β) Z p-value 
HIV/AIDS -0.037 0.1032 0.96 (0.79 to 1.18) 0.13 0.8944 
Alcohol 0.004 0.0283 1.00 (0.95 to 1.06) 0.13 0.8944 
Anemia 0.287 0.0342 1.33 (1.25 to 1.42) 8.41 < 0.0001 
Arthritis 0.126 0.0688 1.13 (0.99 to 1.30) 1.84 0.0662 
Blood loss 0.384 0.1681 1.47 (1.06 to 2.04) 2.28 0.0225 
Congestive  heart 
failure 
0.253 0.0429 1.29 (1.18 to 1.40) 5.89 < 0.0001 
Chronic lung disease 0.079 0.0252 1.08 (1.03 to 1.14) 3.12 0.0018 
Coagulation disorder 0.529 0.056 1.70 (1.52 to 1.90) 9.31 < 0.0001 
Depression -0.076 0.0279 0.93 (0.88 to 0.98) -2.72 0.0066 
Diabetes -0.007 0.0317 0.99 (0.93 to 1.06) -0.23 0.8198 
Diabetes, with CC 0.061 -0.129 0.99 (0.88 to 1.12) -0.16  0.8748 
Drug Abuse 0.030 0.0255 1.03 (0.98 to 1.08) 1.16 0.2479 
Hypertension -0.006 0.0240 0.99 (0.95 to 1.04) -0.24 0.8085 
Hypothyroidism -0.22 0.0328 0.98 (0.92 to 1.04) -0.68 0.4957 
Liver -0.031 0.0464 0.97 (0.92 to 1.04) -0.66 0.5094 
Lymphoma 0.401 0.1806 1.49 (1.05 to 2.13) 2.22 0.0263 
Fluid/Electrolytes 0.415 0.0233 1.51 (1.45 to 1.59) 17.84 < 0.0001 
Metastatic cancer 0.168 0.1003 1.18 (9.97 to 1.44) 1.67 0.094 
Neurological disorder -0.081 0.0274 0.92 (0.87 to 0.97) -2.97 0.0030 
Obesity 0.207 0.0359 1.23 (1.15 to 1.32) 5.77 < 0.0001 
Paralysis 0.362 0.0841 1.44 (1.22 to 1.70) 4.32 < 0.0001 
Peripheral vascular 0.178 0.0731 1.20 (1.04 to 1.38) 2.44 0.0148 
Psychiatric 0.011 0.0256 1.01 (0.96 to 1.06) 0.42 0.6742 
Pulmonary circulation 0.404 0.0723 1.50 (1.300 to 1.73) 5.59 < 0.0001 
Renal Failure 0.122 0.0548 1.13 (1.02 to 1.26) 2.24 0.0252 
Tumor 0.004 0.0889 1.00 (0.84 to 1.19) 0.04 0.9659 
Ulcer -0.388 0.1840 0.67 (0.47 to 0.97) -2.13 0.035 
Valve 0.133 0.066 1.14 (1.00 to 1.30) 2.02 0.0432 
Weight Loss 0.747 0.0874 2.11 (1.78 to 2.50) 8.54 < 0.0001 
 
 
 
 
 
 
 185 
Appendix C, continued 
Table C.2: Parameter Estimates for Elixhauser Comorbidities in LOS Model 
Parameter β SE Exp(β) Z p-value 
HIV/AIDS 0.031 0.1023 1.03 (0.84 to 1.26) 0.3 0.7646 
Alcohol 0.043 0.0301 1.04 (0.98 to 1.11) 1.42 0.1543 
Anemia 0.265 0.0319 1.30 (1.22 to 1.39) 8.30 < 0.0001 
Arthritis 0.066 0.0655 1.07 (0.94 to 1.21) 1.01 0.3119 
Blood loss 0.453 0.1704 1.57 (1.13 to 2.20) 2.66 0.0079 
Congestive  heart failure 0.186 0.0454 1.20 (1.10 to 1.32) 4.10 < 0.0001 
Chronic lung disease 0.057 0.0270 1.06 (1.00 to 1.12) 2.12 0.0339 
Coagulation disorder 0.412 0.0558 1.51 (1.35 to 1.68) 7.38 < 0.0001 
Diabetes -0.042 0.0367 0.96 (0.89 to 1.03) -1.14 0.2550 
Diabetes with complications -0.0274 0.0551 0.97 (0.87 to 1.08) -0.50 0.6191 
Depression -0.109 0.0279 0.90 (0.85 to 0.95) -3.9 < 0.0001 
Drug Abuse 0.076 0.0272 1.08 (1.02 to 1.14) 2.81 0.0049 
Hypertension -0.005 0.026 1.00 (0.95 to 1.05) -0.18 0.8555 
Hypothyroidism -0.029 0.0349 0.97 (0.91 to 1.04) -0.82 0.4134 
Liver 0.013 0.0498 1.01 (0.92 to 1.12) 0.27 0.7850 
Lymphoma 0.170 0.1816 1.18 (0.83 to 1.70) 0.93 9.3503 
Fluid/Electrolytes 0.301 0.0231 1.35 (1.29 to 1.41) 13.03 < 0.0001 
Metastatic cancer 0.1712 0.0813 1.19 (1.01 to 1.39) 2.10 0.0354 
Neurological disorder -0.067 0.0280 0.94 (0.89 to 0.99) -2.38 0.0173 
Obesity 0.184 0.0351 1.20 (1.12 to 1.29) 5.24 < 0.0001 
Paralysis 0.495 0.1022 1.64 (1.34 to 2.00) 4.85  0.0001 
Peripheral vascular 0.109 0.0699 1.12 (0.97 to 1.28) 1.56 0.1191 
Psychosis 0.041 0.0284) 1.04 (0.99 to 1.10) 1.44 0.1488 
Pulmonary circulation 0.324 0.0654 1.38 (1.22 to 1.57) 4.95 < 0.0001 
Renal Failure 0.148 0.0495 1.16 (1.05 to 1.28) 3.00 0.0027 
Tumor 0.055 0.1005 1.05 (0.87 to 1.29) 0.55 0.5838 
Ulcer -0.548 0.2573 0.58 (0.35 to 0.96) -2.13 0.0334 
Valve 0.148 0.0678 1.16 (1.02 to 1.32) 2.19 0.0287 
Weight Loss 0.659 0.0621 1.93 (1.71 to 2.18) 10.62 < 0.0001 
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Table C.3: Parameter Estimates for Elixhauser Comorbidities in Mortality Model 
Parameter OR SE 95% CI χ2 p-value 
HIV/AIDS 1.78 1.282 0.43 to 7.30 0.64 0.4232 
Alcohol 0.92 0.155 0.66 to 1.28 0.23 0.6630 
Anemia 1.42 0.247 1.01 to 2.00 4.12 0.0423 
Arthritis 1.13 0.474 0.50 to 2.57 0.09 0.7705 
Blood loss 1.54 1.135 0.36 to 6.53 0.34 0.5611 
Congestive  heart failure 1.11 0.276 0.68 to 1.81 0.17 0.6823 
Chronic lung disease 1.07 0.177 0.77 to 1.48 0.16 0.6935 
Coagulation disorder 0.20 0.036 0.14 to 0.29 82.3 < 0.0001 
Depression 1.72 0.292 1.23 to 2.40 10.2 0.0014 
Diabetes 1.35 0.287 0.89 to 2.05 2.00 0.1573 
Diabetes with 
complications 
3.65 1.89 1.32 to 10.09 6.25 0.0124 
Drug Abuse 1.87 0.273 1.40 to 2.49 18.2 < 0.0001 
Hypertension 1.23 0.196 0.90 to 1.68 1.63 0.2021 
Hypothyroidism 1.58 0.480 0.87 to 2.87 2.27 0.1315 
Liver 1.12 0.317 0.64 to 1.95 0.16 0.6888 
Lymphoma 0.73 0.555 0.16 o 3.24 0.17 0.6778 
Fluid/Electrolytes 0.34 0.044 0.27 to 0.44 68.9 < 0.0001 
Metastatic cancer 0.21 0.055 0.12 to 0.35 34.9 < 0.0001 
Neurological disorder 1.17 0.177 0.87 to 1.56 1.12 0.2902 
Obesity 1.20 0.313 0.72 to 2.00 0.51 0.4767 
Paralysis 1.40 0.736 0.50 to 3.92 0.42 0.5183 
Peripheral vascular 0.57 0.190 0.29 to 1.09 2.86 0.0910 
Psychosis 2.90 0.573 1.96 to 4.27 28.8 < 0.0001 
Pulmonary circulation 0.37 0.133 0.18 to 0.74 7.70 0.0055 
Renal Failure 0.65 0.148 0.41 to 1.01 3.60 0.0579 
Tumor 0.43 0.193 0.18 to 1.03 3.55 0.0594 
Ulcer 0.07 0.036 0.03 to 0.19 28.7 < 0.0001 
Valve 1.52 0.713 0.60 to 3.81 0.79 0.3740 
Weight Loss 0.66 0.179 0.39 to 1.13 2.31 0.1286 
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Table D.1: ICD-9-CM Codes for Select Opioid Abuse-Related Comorbidities 
Sedative/hypnotic/anxiolytic involvement 
 
304.1X, 305.4X, 967.X, 969.4 
Involvement of other drugs of abuse 305.2 – .3, 305.6 – .9, 969.0 – .3, 969.5 – .9 
Endocarditis 421.x 
Skin infections 680.x – 686.x 
Gastrointestinal bleed  578.x 
Pancreatitis 577.0, 577.1 
Sexually transmitted infection 090.0 – 099.9 
Herpes simplex 054.X  
Burns 940.X – 949.X 
Trauma 800.X – 904.X, 910.X – 939.X, 959.X 
Motor vehicle accidents E810.X – E819.X 
Cancer 140.X – 239.X, 338.3, V10.X 
Back/neck pain 724.2, 724.5, 723.1 
Acute pain NOS 338.1 
Chronic pain NOS 338.2 
Neuropathic pain 350.1-.9, 353.0-.9, 354 - 355, 357.1,.4-.9, 
053.13, 072.72 
Headache/migraine 339.0-.8, 346.0-.9 
Suicide  E950 – E959 
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Table D.2: Comparison of Prevalence (%) for Select Comorbidities by Opioid Type 
 Heroin 
n = 1,410 
Methadone 
n = 1,699 
Prescription 
Opioid 
n = 6,783 
Unspecified 
n = 3,770 
p-value 
Sedative/hypnotic/ 
anxiolytic involvement 
 
17.3 35.6 30.7 43.5 < 0.0001 
Alcohol involvement 26.7 15.9 14.9 17.6 < 0.0001 
Involvement of other 
drugs of abuse 
36.2 27.6 22.6 30.5 < 0.0001 
Endocarditis 0.3 0.1 0.1 0.1 0.1650 
Skin infections 4.0 2.2 2.3 2.1 0.0003 
Gastrointestinal bleed  1.1 1.2 1.2 1.0 0.7783 
Pancreatitis 0.6 2.0 1.5 1.4 0.0149 
Sexually transmitted 
infection 
0.1 0.1 0.2 0.1 0.2971 
Herpes simplex 0.1    0.1254 
Burns 0.07 0.12 0.19 0.21 0.7799 
Trauma 5.4 4.1 5.9 5.6 0.0471 
Motor vehicle accidents 0.5 0.2 0.3 0.3 0.4461 
Back/neck pain 3.6 15.3 16.6 14.1 < 0.0001 
Acute pain NOS 0.0 0.2 0.3 0.1 0.0829 
Chronic pain NOS 2.3 15.9 13.2 15.9 < 0.0001 
Neuropathic pain 1.0 1.1 1.8 1.6 0.0444 
Headache/migraine 0.5 1.8 3.3 3.0 < 0.0001 
Suicide 19.6 20.2 33.9 28.1 < 0.0001 
Pearson’s χ2 was used to test differences in frequency. 
 
 
 
 
 
 
 
 
 
 189 
Appendix D, continued 
Table D.3: Costs by Presence of Select Comorbidities 
 Present, $ (SD) Not Present, $ (SD) p-value 
Sedative/hypnotic/anxiolytic 
involvement 
 
8,744 (12,108) 10,316 (15,598) < 0.0001 
Alcohol involvement 9,779 (13,048) 8,797 (14,840) 0.9582 
Involvement of other drugs 
of abuse 
8,906 (13,213) 10,112 (14,982) < 0.0001 
Skin infections 16,334 (23,467) 9,629 (14,215) < 0.0001 
Pancreatitis 15,803 (23,075) 9,698 (14,353) < 0.0001 
Trauma 15,491 (27,020) 9,456 (13,386) < 0.0001 
Back/neck pain 8,427 (10,718) 10,022 (15,086) < 0.0001 
Chronic pain NOS 8,733 (11,506) 9,958 (14,963) 0.0009 
Neuropathic pain 11,296 (14,678) 9,762 (14,533) 0.1285 
Headache and Migraine 8,239 (11,885) 9,836 (14,612) 0.0411 
Suicide 7,824 (11,550) 10,593 (15,526) < 0.0001 
Under the central limit theorem (t-tests are robust in large sample sizes) Student’s t-test was used 
to compare costs (present vs. not present) 
 
 
Table D.4: LOS by Presence of Select Comorbidities 
 Present Not Present p-value 
Sedative/hypnotic/anxiolytic 
involvement 
 
3.5 (5.4) 4.1 (4.2) < 0.0001 
Alcohol involvement 4.1 (6.0) 4.0 (6.3) 0.4062 
Involvement of other drugs 
of abuse 
3.5 (4.7) 4.0 (5.1) < 0.0001 
Skin infections 7.2 (9.2) 3.8 (4.9) < 0.0001 
Pancreatitis 6.1 (7.6) 3.9 (5.0) < 0.0001 
Trauma 5.5 (6.9) 3.8 (4.9) < 0.0001 
Back/neck pain 3.5 (4.0) 4.0 (5.2) 0.0005 
Chronic pain  3.6 (4.3) 3.9 (5.1) 0.0029 
Neuropathic pain 5.1 (6.3) 3.9 (5.0) 0.0004 
Headache and Migraine 3.7 (4.6) 3.9 (5.0) 0.3476 
Suicide 3.6 (4.3) 4.0 (5.3) < 0.0001 
Under the central limit theorem, Student’s t-test was used to compare LOS (present vs. not 
present) 
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Table D.5: Mortality by Presence of Select Comorbidities 
 Present Not Present p-value 
Sedative/hypnotic/anxiolytic 
involvement 
 
111 (2.4) 269 (3.0) 0.0764 
Alcohol involvement 66 (17.4) 2,249 (17.0) 0.8316 
Involvement of other drugs 
of abuse 
95 (2.6) 285 (2.9) 0.4294 
Skin infections 12 (3.7) 368 (2.8) 0.3248 
Pancreatitis 5 (2.5) 375 (2.8) 0.8322 
Trauma 20 (2.7) 360 (2.8) 0.8594 
Back/neck pain 32 (1.6) 348 (3.0) 0.0008 
Chronic pain  26 (1.4) 354 (3.0) 0.0001 
Neuropathic pain 3 (1.4) 377 (2.8) 0.1995 
Headache and Migraine 1 (0.3) 379 (2.9) 0.0027 
Suicide 376 (1.9) 304 (3.1) < 0.0001 
Pearson’s χ2 test was used to compare mortality 
 
 
Table D.6:  Included Conditions for Each Model Among Select Comorbidities 
 Cost Model LOS Model Mortality Model 
Sedative/hypnotic/anxiolytic 
involvement 
X X  
Involvement of other drugs 
of abuse 
X X  
Skin infections X X  
Pancreatitis X X  
Trauma X X  
Back/neck pain X X X 
Chronic pain NOS X X X 
Neuropathic pain  X  
Headache/migraine X  * 
Suicide X X X 
Only select shown to be significantly different according to opioid type are shown. X 
indicates inclusion. 
*Though significant, headache and migraine was excluded due to the very small cell 
size 
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Table D.7: Parameter Estimates for Select Comorbidities in Costs Model 
Parameter β SE Exp(β) (95% CI)  Z p-value 
Sedative/hypnotic 
involvement 
-0.006 0.023 0.99 (0.95 to 1.04) -0.24 0.8105 
Other drug abuse -0.027 0.025 0.97 (0.93 to 1.02) -1.05 0.292 
Skin and soft tissue 
infection 
0.245 0.076 1.28 (1.10 to 1.48) 3.21 0.0013 
Pancreatitis 0.365 0.100 1.44 (1.19 to 1.75) 3.67 0.0002 
Trauma 0.360 0.056 1.43 (1.28 to 1.60) 6.45 < 0.0001 
Suicide -0.119 0.023 0.89 (0.85 to 0.93) -5.18 < 0.0001 
Headache/migraine 0.052 0.059 1.05 (0.94 to 1.18) 0.87 0.3827 
Chronic pain -0.071 0.028 0.93 (0.88 to 0.98) -2.51 0.0119 
Back and neck pain -0.053 0.028 0.95 (0.90 to 1.00) -1.86 0.0628 
 
 
Table D.8: Parameter Estimates for Select Comorbidities in LOS Model 
Parameter β SE Exp(β) (95% CI)  Z p-value 
Sedative/hypnotic 
involvement 
-0.051 0.025 0.95 (0.91 to 1.00) -2.09 0.037 
Other drug abuse -0.080 0.028 0.92 (0.87 to 0.97) -2.88 0.0039 
Skin and soft tissue 
infection 
0.384 0.066 1.47 (1.29 to 1.67) 5.84 < 0.0001 
Pancreatitis 0.336 0.090 1.40 (1.17 to 1.67) 3.72 0.0002 
Trauma 0.281 0.042 1.32 (1.22 to 1.44) 6.69 < 0.0001 
Suicide 0.063 0.028 1.07 (1.01 to 1.13) 2.23 0.026 
Chronic pain -0.069 0.033 0.93 (0.88 to 1.00) -2.11 0.0345 
Back and neck pain -0.069 0.033 0.96 (0.91 to 1.02) -1.25 0.2124 
Neuropathic pain 0.140 0.085 1.15 (0.97 to 1.36) 1.65 0.0997 
 
 
Table D.9: Parameter Estimates for Select Comorbidities in Mortality Model 
Parameter OR SE 95% CI χ2 p-value 
Suicide 1.10 0.172 0.81 to 1.49 0.36 0.5471 
Chronic pain 1.62 0.379 1.02 to 2.56 4.20 0.0403 
Back and neck pain 1.20 0.238 0.81 to 1.77 0.81 0.3667 
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